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Hydrogen sulfide (H2S), is a gasotransmitter with several key roles in metabolism and 
vascular function. The effects of H2S are dependent on concentration and target organ. For 
example, increased H2S concentrations impair liver metabolic function but protect against 
vascular dysfunction and atherosclerosis. Thiosulfate sulfurtransferase (TST), a nuclear 
encoded mitochondrial matrix enzyme, is proposed to be a component of the sulfide 
oxidising unit (SOU) which metabolises H2S. Preliminary data has shown that Tst deletion in 
mice (Tst–/–) increases circulating H2S levels measured in whole blood. Therefore, it was 
hypothesised that Tst–/– mice would exhibit worsened metabolic function in the liver but also 
protection of vascular function under conditions of vascular stress e.g. atherosclerosis. Liver 
metabolism was assessed by extensive metabolic phenotyping of Tst–/–mice fed control diet 
and in conditions of metabolic dysfunction induced by a high fat diet (HFD). Tst deletion 
altered glucose metabolism in mice; gluconeogenesis was increased in liver from Tst–/–mice 
fed control diet. Glucose intolerance in HFD-fed Tst–/–mice was also more severe than HFD-
fed C57BL/6 controls. In vitro metabolic investigations in primary hepatocytes isolated from 
Tst–/–mice demonstrated that mitochondrial ATP-linked and leak respiration were increased 
compared to controls. The effect of Tst deletion on vascular function was investigated in Tst–
/–mice fed control or HFD using myography. Tst deletion did not alter vessel function when 
mice were maintained on a normal diet. HFD feeding (20 weeks) reduced maximal vessel 
constriction in the presence of endothelial nitric oxide synthase and cyclooxygenase 
inhibitors in C57BL/6 aorta. However, in Tst–/–mice fed HFD there was no reduction in 
maximal constriction suggesting a protective action of Tst deletion. The effects of Tst 
deletion on atherosclerotic lesions was investigated by generating double knock-out (DKO) 
mice by deletion of the Tst gene in ApoE–/– mice and (ApoE–/–Tst–/–). Atherosclerotic lesion 
formation was accelerated by feeding mice a western diet. Within the brachiocephalic branch 
lesion volume and total vessel volume were reduced in DKO mice fed western diet for 12 
weeks, indicating that Tst deletion reduced lesion formation. Plasma cholesterol was reduced 
in DKO mice compared to ApoE–/– controls and a trend towards reduced systolic blood 
pressure was also noted. Overall this work supported the hypothesis that Tst deletion 
engenders metabolic dysfunction but vascular protection. The findings are consistent with 
the reported effects of increased H2S signalling. Overall inhibition of TST represents a novel 
target for treatment of atherosclerosis, with the caveat that glycaemia may be worsened due 




Hydrogen sulfide (H2S) is a toxic gas with a characteristic smell of rotten eggs. It has 
recently been discovered that H2S is produced within the cells of mammals. High levels of 
H2S can impair the liver’s ability to regulate glucose, leading to diabetes. However, in blood 
vessels high H2S can be beneficial and has been found to protect vessels from developing the 
fatty plaques (atherosclerosis) that cause heart disease. Cells have mechanisms to eliminate 
H2S and prevent it rising to toxic levels. Thiosulfate sulfurtransferase (TST) is a protein 
thought to be involved in elimination of H2S. In mice genetically altered to remove TST (Tst 
knockout mice) increased levels of H2S were found in the blood. Therefore, it was 
hypothesised that Tst knockout mice would have impaired liver function (resulting in 
diabetes) but be protected from atherosclerosis in the blood vessels. The liver function of Tst 
knockout mice was evaluated extensively. It was found that loss of the TST enzyme led to 
higher blood glucose levels in mice fed a normal diet (ND). It was also found that feeding 
mice a high fat diet (HFD) led to more severe diabetes in mice lacking TST. The blood 
vessels of Tst knockout mice were investigated by measuring the response of the aortic 
artery to drugs which cause vessels to contract or relax. On ND, there were no differences in 
arterial function between Tst knockout and control mice. In control mice fed HFD arteries 
were less able to contract in response to compounds that blocked natural relaxation 
processes. In Tst knockout mice fed HFD however, this reduction in contraction was not 
seen. These results suggest that the absence of TST from the artery protected mice from the 
effects of the HFD. The effect of TST removal on atherosclerosis was investigated by 
removing the TST protein from a mouse which is at risk of developing atherosclerosis (ApoE 
knockout mice) resulting in a ‘double knock-out’ (DKO) mouse (ApoE & Tst knockout). In 
these mice, atherosclerosis was accelerated by feeding with a high fat, high cholesterol 
western diet for 12 weeks. Following this, the size of atherosclerotic growths was measured 
in a susceptible artery. Plaque size was reduced in DKO mice indicating that the removal of 
TST led to protection from atherosclerosis. This may have been the result of reduced blood 
cholesterol which was seen in DKO mice or a reduction in blood pressure which was 
suggested by the data. Overall this work has confirmed the hypothesis. The effects that have 
been observed are consistent with the reported effect of increased H2S in these organs. In the 
future, the inhibition of the TST enzyme may be useful in preventing atherosclerosis, with 
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1.1 Metabolic syndrome 
Metabolic reactions include the full range of biochemical processes occurring in cells which, 
in concert, act to maintain cellular and organism homeostasis and function despite extreme 
fluctuations in the external environment. Many metabolic diseases arise from defects in a 
key enzyme in a certain pathway, often called inborn errors of metabolism. These diseases 
are usually monogenic and manifest early in life as life-threatening disorders if treatment is 
not begun immediately. However, more complex disorders of metabolic function exist that 
impact upon multiple enzymatic pathways and nutrient homeostasis, the most prominent of 
which has now been termed the metabolic syndrome (MetS, historically known as ‘syndrome 
x’) (1–3). 
1.1.1 History and definition 
Contrary to rare monogenic metabolic diseases (which are driven by clear defects in a 
specific enzyme and metabolic pathway,), metabolic syndrome is not clearly defined. The 
concept of an identifiable syndrome was first identified as early as 1920 when a Swedish 
physician noted the association linking hypertension, hyperglycaemia and gout (1). Over the 
following generations associations between metabolic disorders (such as hyperglycaemia, 
hypertriglyceridaemia, hypertension and obesity) in type II diabetes and cardiovascular 
disease were frequently noted (4). In 1988 Reaven described hyperglycaemia, 
hypertriglyceridaemia and hypertension as ‘a cluster of risk factors for diabetes and 
cardiovascular disease’ which he termed ‘Syndrome X’ (5). A year later the addition of 
obesity, or more specifically upper body ‘visceral’ obesity, by Kaplan to this ‘cluster of risk 
factors’ led to his definition of ‘The deadly quartet’ (6).   
Further efforts to establish a clear definition of the syndrome for clinical diagnosis were 
undertaken by the World Health Organisation (WHO) (7), the European Group for the study 
of Insulin Resistance (EGIR) (8), the National Cholesterol Education Program Adult 
Treatment Panel (NCEP/ATP) (9), the American Association of Clinical Endocrinologists 
(AACE) (10) and the International Diabetes Federation (IDF) (11). The definitions provided 
by each organisation are summarised in Table 1.1 Despite the range of definitions, it is now 
generally agreed that MetS represents a clustering of related metabolic conditions including 
visceral obesity, insulin resistance, atherogenic dyslipidaemia, hypertension, glucose 




Table 1.1 Diagnostic criteria proposed for the clinical diagnosis of metabolic syndrome. Subscript notes: a) 
Insulin sensitivity measured under hyperinsulinemic, euglycemic conditions, glucose uptake below lowest 
quartile for background population under investigation. b) In 2003, the American Diabetes Association (ADA) 
changed the criteria for IFG tolerance from >110 mg/dl to >100 mg/dl. c) Includes family history of type 2 
diabetes mellitus, polycystic ovary syndrome, sedentary lifestyle, advancing age, and ethnic groups susceptible to 
type 2 diabetes mellitus. BMI: body mass index; HDL-C: high density lipoprotein cholesterol; IFG: impaired 
fasting glucose; IGT: impaired glucose tolerance; Rx: receiving treatment; TGs: triglycerides; T2DM: type 2 
diabetes mellitus; WC: waist circumference. Table reproduced from Kaur (2014) (1). Study Abbreviations: WHO 
1998: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1… (7); EGIR: 
Comment on the provisional report from the WHO consultation (8); ATPIII: Executive Summary of The Third 
Report of The National Cholesterol Education Program… (9), AACE: American College of Endocrinology 
Position Statement on the Insulin Resistance Syndrome (10), IDF: Metabolic syndrome-a new world-wide 
definition. A Consensus Statement from the International Diabetes Federation (11). 
Clinical 
measures 
WHO (1998) EGIR (1999) ATPIII (2001) AACE (2003) IDF (2005) 
Insulin 
resistance 
IGT, IFG, T2DM, 
or lowered insulin 
sensitivitya   





plus, any 2 of 
the following 
None, but any 3 




IGT or IFG 
plus, any of the 
following based 









hip ratio >0.85 
and/or BMI > 
30 kg/m2 
WC ≥94 cm in 
men or ≥80 cm 
in women 
WC ≥102 cm in 
















<35 mg/dL in men 































in men or 
<50 mg/dL 





















IGT, IFG, or 
T2DM 


























Strikingly, recent IDF estimates predict that around 25% of the world adult population could 
currently be diagnosed with MetS (1). The proportion of people affected is highly variable 
between populations. Depending on the region, whether it is an urban or rural environment, 
and the composition of the population (sex, age and ethnicity), the rate of MetS can vary 
from <10% to ~84% of individuals affected (12–14). Higher incidence of MetS was 
associated with increased body mass index (BMI), with over 60% of obese individuals found 
to have MetS compared with 5% in normal weight individuals (15). The prevalence of MetS 
also increases with age in both men and women, with post-menopausal women being 
particularly affected (16,17).  
Epidemiological evidence also indicates that the individual conditions that comprise MetS 
(visceral obesity, insulin resistance, atherogenic dyslipidaemia, hypertension, glucose 
intolerance, systemic inflammation) share a common aetiology. The metabolic alterations 
were found to occur simultaneously more frequently than would be expected by chance, 
suggesting that they share a pathology (18).  In terms of increased future disease risk, the 
number of simultaneous symptoms associated with MetS increases CVD risk is increased to 
a greater extent than the risk associated with each individual condition (19). 
1.1.3 Pathophysiology 
1.1.3.1 Visceral obesity 
Visceral obesity defines an excess of adipose accumulation in the abdominal cavity. This is 
mainly due to fat accumulation in the mesenteric, omental, epididymal (or gonadal) and 
perirenal white adipose depots (20). This type of fat distribution is more commonly 
associated with the male gender and is, therefore, sometimes referred to as an android pattern 
of fat distribution as opposed to gynoid (female gender-associated) wherein fat is deposited 
predominantly on the thighs and buttocks (21). Compared to gynoid or subcutaneous fat 
distribution, an excess of visceral fat (measured using waist circumference or, more 
accurately, using computed tomography (CT), dual energy X-ray absorptiometry (DEXA) or 
magnetic resonance imaging (MRI) scanning), has a strong correlation with CVD risk and 
insulin resistance (22). The reason for the correlation of excess visceral fat with CVD risk 
and insulin resistance is not clear. Two key features of visceral adipose tissue depots 
compared to subcutaneous fat storage are; a direct connection to the portal vein for release of 
metabolic products such as free fatty acids, and that the depot plays an active role as an 
endocrine organ. One hypothesis (the portal hypothesis) suggests that an increased release of 
metabolites and adipokines from visceral adipose depots affects hepatic function and leads to 
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a loss of metabolic control (23).  This may occur particularly in conditions of localised 
adipose hypoxia which can result when angiogenesis fails to compensate for hypertrophy of 
the adipose depots (1,24). Localised inflammation resulting from adipose hypoxia has been 
linked to increased free fatty acid release in addition to the release of many adipocytokines, 
which can act systemically to impair insulin sensitivity and precipitate diabetes. The release 
of adipocytokines by the adipose tissue has been linked to many of the features of MetS, 
including insulin resistance and systemic inflammation (1,25).  
The exact cause of increased android fat accumulation is also unknown although, as 
mentioned, it is most prevalent in males and in post-menopausal females, giving a clear 
indication of the impact of sex steroids on the risk of visceral adiposity. Other genetic factors 
have been identified which appear to predispose patients to visceral fat accumulation over 
other depots (26,27). Some studies have even suggested that visceral obesity is the sole cause 
of MetS with the other diseases being secondary to its accumulation (28). 
1.1.3.2 Insulin resistance 
Insulin is a key regulatory hormone of metabolic function and it is unsurprising that 
resistance to its actions leads to metabolic dysfunction (29). Insulin is the most potent 
anabolic hormone known and its actions promote synthesis and storage of carbohydrates 
(mainly liver glycogen), lipids and proteins and suppresses their degradation (Figure 1.1, 
30). These actions are stimulated through activation of the insulin receptor which is an auto-
phosphorylating tyrosine kinase. Within the liver insulin receptor activation then leads to 
binding and phosphorylation of many insulin receptor substrates (IRS) proteins as well as 
other Src-homology-2 (SH2) domain containing proteins. These proteins then activate 
downstream signalling protein kinases including phosphoinositide 3-kinase (PI3K) and 
mitogen activated protein kinase (MAPK). Through these pathways insulin signalling is able 
to cause widespread changes in protein activation and gene transcription which overall lead 
to suppression of carbohydrate, lipid and protein degradation, suppression of 










Figure 1.1 Insulin signalling general actions and cellular cascade. a) Insulin is a potent anabolic hormone. Its 
actions promote the uptake of glucose, amino acids and free fatty acids from the circulation and the synthesis of 
glycogen, proteins and triglycerides from them. In addition, downstream mediators suppress degradation of these 
molecules. b) The cellular processes by which insulin mediates its anabolic actions. Following receptor binding 
to insulin autophosphorylation occurs at the insulin receptor. This facilitates binding and activation of numerous 
proteins which contain ‘SH2’ domains including the insulin receptor substrate family. Activation of downstream 
protein kinases such as phosphoinositide-3-kinase and mitogen activated protein kinase then further propagates 
insulins actions leading to specific protein activation/inhibition and regulation of gene transcription. 
Abbreviations: Akt; Protein kinase B, aPKC; atypical protein kinase C, C3G; Cyanidin 3-glucoside, CAP; Cbl 
associated protein, Cbl; E3 ubiquitin protein ligase, Crk; adaptor molecule Crk, Gab-1; Grb-associated binder-1, 
Grb2; growth factor receptor-bound protein-2, GSK3; glycogen synthase kinase-3, IGF-1; insulin-like growth 
factor-1, IRS; insulin receptor substrate, MAP; mitogen activated protein, Mek; mitogen activated protein kinase 
kinase, p70rsk; 70 KDa S6 kinase, PI(3)K; phosphoinositide-3 kinase, PP1; protein phosphatase-1, PTEN; 





triphosphatases, Shc; SHC-transforming protein 1, SHP2; protein tyrosine phosphatase-1D, SHIP2; SH2 domain 
containing inositol phosphatase-2, SOS; Son of sevenless protein, TC10; Ras homolog family member Q. 
Reproduced from Saltiel and Kahn (2001) (30). 
Insulin is produced by β-cells within the islets of Langerhans of the pancreas and released in 
response to increasing blood glucose concentrations (31,32). Destruction of the pancreatic β-
cells is well known as a cause of type I diabetes mellitus (T1DM) in which patients suffer 
from a total lack of insulin action resulting in extreme hyperglycaemia and eventual death if 
insulin is not replaced through exogenous administration (29). 
Insulin resistance represents the converse where insulin is still produced by the pancreas but 
the target peripheral tissues are resistant to its signalling actions (33). As expected this often, 
but not always, results in hyperglycaemia and glucose intolerance due to a lack of glucose 
uptake by the peripheral tissues and a failure to suppress gluconeogenesis within the liver 
(5,34). This can progress to full type II diabetes mellitus (T2DM) if symptoms worsen. In 
many insulin-resistant patients who exhibit hyperglycaemia, insulin levels may be 
unchanged or increased confirming that a lack of sensitivity to insulin is the underlying 
problem (35). 
The exact cause of insulin resistance is not yet established, although it is most simply 
explained by desensitisation of the insulin signalling cascade in cells because of constant 
insulin over production and exposure (36,37). Due to the complex nature of insulin 
signalling desensitisation can occur at many points throughout the pathway and can include a 
reduction in the number and autophosphorylation activity of insulin cell membrane 
receptors, decreased IRS concentrations and activities and a decrease in PI(3)K or other 
intracellular proteins activity (30,38). This effect may especially be stimulated in patients 
who have a diet which is high in sugars (39,40). Ingestion of these foods requires increased 
insulin production to compensate for their high glycaemic index and this increase in 
production can lead to eventual desensitisation of organs due to a decrease in function of the 
insulin signalling cascade. However, it is likely that beyond this simple mechanism more 
complex regulation of insulin sensitivity exists as there is evidence that adipokines, such as 
adiponectin and leptin, can also regulate insulin sensitivity within tissues (41,42). 
1.1.3.3 Dyslipidaemia 
Dyslipidaemia results from altered, usually increased, levels of triglyceride and/or 
cholesterol concentrations within the circulation (1,43). When triglyceride or cholesterol 
content is outside set limits (>2.3 mmol/L for total fasting triglyceride, >5.2 mmol/L total 
cholesterol, set by the National Cholesterol Education Program (9)) this is considered a 
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disease because increased triglyceride concentrations, increased cholesterol in low density 
lipoproteins (LDL, >2.6 mmol/L) and decreased cholesterol in high density lipoproteins (<1 
mmol/L) can contribute to increased atherosclerotic lesion formation in the blood vessels 
(9,44,45). Increased plasma triglyceride concentrations are also linked with non-alcoholic 
fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) two related 
conditions which are frequently observed in MetS patients (46,47). 
Paradoxically, lipid synthesis is normally stimulated by insulin as a response to excess 
glucose. The synthesised lipid can then be stored for use in fasting conditions (48). This 
suggests that post-receptor insulin signalling may be differentially affected during the 
development of insulin-resistance and depends upon the distinct cellular signalling pathways 
downstream. As described (section 1.1.2) MetS patients are usually considered to be insulin-
resistant and often have hyperglycaemia as a result of this defect. However, increased plasma 
and liver triglyceride is a common observation in MetS and T2DM patients (1,48). This may 
be because lipid synthesis is stimulated by an unaffected, insulin-sensitive pathway or is 
simply due to high levels of excess substrates for lipid synthesis present in patients who have 
a high sugar and fat diet (1,34,49). 
1.1.3.4 Hypertension 
Hypertension or high blood pressure is an increase in blood pressure (>140 mmHg systolic 
and >90 mmHg diastolic in patients <60 years old (50)) which is reproducibly observed in 
patients (29). It is primarily a concern as increased blood pressure is a risk factor for serious 
cardiovascular events such as stroke and myocardial infarction (51,52).  
The cause of hypertension in MetS is unclear. It has been suggested that hyperinsulinemia 
and hyperglycaemia, which can occur in MetS due to insulin-resistance, can stimulate the 
renin-angiotensin system (RAS) (by stimulating expression of angiotensinogen, angiotensin 
II (AT II), and the AT1 receptor) which can act to increase blood pressure (53,54). Leptin, 
which is often increased in MetS and obesity, has also been linked to the central control of 
blood pressure (55,56). Increased leptin can lead to activation of the sympathetic nervous 
system (SNS) through activation of receptors in the arcuate nucleus (57) resulting in 
alterations to kidney function, including increased reabsorption of sodium leading to 
hypervolemia and increased blood pressure (55,56).  
Finally, MetS is also frequently associated with vascular endothelial cell dysfunction (58). 
This is thought to be the result of increased circulating metabolites, such as glucose and 
oxidised LDL particles, which can damage the endothelium due to increased reactive oxygen 
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species (ROS) production within the cells (59–61). Endothelial dysfunction can result in the 
endothelium being unable to correctly modulate vascular function due to reduced production 
of vasodilator molecules such as nitric oxide (NO) (62). Through this mechanism endothelial 
dysfunction may also contribute to the pathogenesis of hypertension (63).  
1.1.3.5 Proinflammatory state 
In recent years MetS has been linked to the development of a systemic ‘proinflammatory 
state’ (1). Also known as chronic low-grade inflammation, this type of inflammation relates 
to the activation state of the immune cells (i.e. whether they are ‘primed’ for inflammatory 
activity) systemically rather than in one focal region, as well as to the concentrations of 
cytokines such as tissue necrosis factor α (TNFα) and interleukin-6 (IL-6) within the 
circulation (64). Systemic inflammation is linked to a patient’s future risk of CVD events 
(65). One possible mechanism for this is interaction with atherosclerotic lesion formation. 
Immune cell infiltration is a key component of lesion formation (45) (section 1.3.2) and, 
therefore, systemic inflammation could increase immune cell infiltration (due to increased 
activity) and worsen lesion formation. This would naturally increase the risk of CVD events 
(64). 
The exact cause of the proinflammatory state is currently unknown. Increased adiposity, 
which is typically observed in MetS patients, leads to an overproduction of certain cytokines 
by the adipose tissue. Examples include IL-6 which can systemically affect the immune 
system (1,64). One suggestion is that the generation of a pro-inflammatory state by 
overproduction of these cytokines may be the fundamental defect in MetS. Evidence for this 
includes the fact that many cytokines which are altered in the pro-inflammatory state can 
decrease insulin sensitivity and increase triglyceride levels (1). However, it is unlikely that 
the emergence of systemic low-grade inflammation precedes the other changes in MetS in all 
human patients (66). 
1.1.3.6 Genetics 
The cause of MetS is heavily debated and, as referenced, many suspected causes (such as 
obesity) do not always induce MetS in all patients. Therefore, it has become increasingly 
accepted that an individual’s genetic background can greatly influence their susceptibility to 
development of MetS (67). Moreover, adiposity is highly heritable, clearly linking genetic 
factors to an individual’s susceptibility to fat mass accumulation, including its anatomical 
distribution (68,69). The metabolic effects of excess fat accumulation are also genetically 
influenced. One example is ethnicity; people of South Asian ethnicity, for example, are far 
more likely to develop T2DM at smaller waist circumference measurements than European 
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or American populations (1,70). This has necessitated the development of individual 
diagnosis criteria for certain populations (11).  
As well as these examples, variation exists within similar populations in almost all the 
symptoms associated with MetS. For example, many studies have shown that patients fed 
identical calorie controlled diets exhibit different levels of weight gain and propensity to 
obesity (71,72).  As discussed (section 1.1.3) the deposition of adipose within the visceral or 
other depots is also influenced by genetic background. Several polymorphisms within genes 
which control lipoprotein metabolism have also been identified and these can contribute to a 
worsening of lipid profile in affected obese patients (73). Glucose intolerance and T2DM 
have also been linked to genetic factors. Genome wide associated studies (GWAS) of T2DM 
identified a predominance of genes that predispose patients to worsened insulin secretion. 
This led to the hypothesis that insulin resistance, accompanied by a defect in insulin 
secretion, is the reason some insulin resistant patients go on to develop T2DM whereas 
others increase insulin secretion to compensate for resistance and experience milder glucose 
intolerance (1,74).  
Further to variation within the genome, hypotheses have emerged which suggest that 
epigenetic mechanisms associated with in utero nutrient and stress hormone exposure may 
explain an individual’s susceptibility to MetS development. Barker et al. proposed that 
malnutrition of foetuses during development (for example due to famine as in the Dutch 
Famine Cohort) meant they were metabolically primed through epigenetic modification to 
store energy by reducing energy expenditure and optimising absorption and storage (75). 
This phenotype would be useful in conditions of low food availability but could lead to 
excessive energy storage and increased risk of MetS development when plentiful high 
calorie food became readily available in the modern environment. Support for the role of 
epigenetic mechanisms in the control of MetS susceptibility comes from a number of studies 
which demonstrate the correlation between low-birth weight (often due to malnutrition 




1.2 Diabetes Mellitus 
As discussed in the previous section, one of the main concerns for patients with MetS is the 
increased risk of developing T2DM. Development of T2DM can often be considered a 
worsening of the insulin-resistance and hyperglycaemia commonly observed in people with 
MetS and, therefore, it is a frequent complication of MetS. In addition to the complications 
of T2DM which can include blindness, poor wound healing, nerve damage, and renal 
damage (77), T2DM is a major risk factor for development other diseases, including CVD 
(78). 
1.2.1 Epidemiology 
The World Health Organisation estimated that 422 million adults were living with diabetes 
in 2014. Compared to 1980 when 108 million adults suffered from diabetes the percentage of 
the world population affected by this condition has nearly doubled from 4.7% in 1980 to 
8.5% in 2014. Due to the relative complexity of determining whether diabetes is T2DM or 
type I diabetes mellitus (T1DM) an exact figure for T2DM cannot be generated. However, 
based on the evidence available, it is highly likely that the increase is mainly due to new 
cases of T2DM rather than T1DM. General estimates of prevalence suggest that 90% of 
diabetes cases are T2DM (79). 
The increase in the prevalence of T2DM is believed to be mainly due to an increase in risk 
factors associated with T2DM.  Obesity rates in adult men and women have risen from 3% 
and 6%, respectively, in 1975 to 11% and 13% in 2014 (79,80). Over the same period the 
percentage of overweight adult men and women has risen from 21% and 23%, respectively, 
to 39% and 40% (79,80). This increase is seen as the primary driver behind increasing rates 
of T2DM. Consistent with this belief, rates of both diabetes and obesity have risen to a 
greater extent in middle and low-income countries and both diseases can now truly be 
considered a global concern.  
T2DM was estimated to be independently responsible for 1.5 million deaths in 2012. As 
T2DM is a major risk factor for CVD it was also estimated the sub-optimal blood glucose 
concentrations contributed to a further 2.2 million deaths (79). By 2030 the WHO predicts 
that diabetes will be the 7th leading cause of death worldwide (79,81). Diabetes was 
estimated to cost the global economy $825 billion dollars in 2014 in the cost of treatment for 
T2DM and its associated complications. This calculation does not, however, include the cost 




T2DM can be considered a failure of the pancreas to compensate for insulin resistance 
(section 1.1.3) (77). While insulin resistance is a major feature of T2DM, the pancreas is able 
in many patients to increase (at least temporarily) insulin secretion to compensate for this 
resistance. Consequently,  glucose levels are maintained at normal, or only mildly elevated, 
levels (35,43,77). Hyperglycaemia is often associated with inappropriately increased glucose 
production by the liver (gluconeogenesis) which can be up to 2-fold higher in fasted T2DM 
patients compared to those with normal insulin function (1,82). Insulin is a suppressor of key 
gluconeogenic enzymes, including phosphoenolpyruvate carboxykinase (PEPCK) (83,84). 
Therefore, liver insulin-resistance is also the cause of increased gluconeogenesis (85). In 
addition to alterations of glucose metabolism, T2DM is often linked with increased 
triglyceride synthesis and increased VLDL triglyceride concentrations (48). This is 
paradoxical as triglyceride synthesis and packaging into VLDL is stimulated by insulin 
action (48). Suggested causes for this include that the insulin signalling pathway has two 
signalling arms and some evidence indicates that while resistance in one leads to the effects 
on glucose metabolism the second, which controls triglyceride synthesis amongst other 
processes, remains active leading to VLDL triglyceride production (48,49,86).  
Why some patients can compensate for insulin-resistance and do not go on to develop the 
symptoms of T2DM is unclear. However, certain genetic polymorphisms can contribute to 
this and predispose certain individuals to diabetes development whereas others can maintain 
glucose homeostasis (87). These polymorphisms primarily appear to affect genes involved in 
the function of pancreatic β-cells; for example, cyclin-dependent kinase inhibitor 2A which 
has a role in pancreatic islet regeneration (88). However, as diabetes is a complex disease it 
is not surprising that polymorphisms in genes affecting the other major metabolic tissues 
such as glucokinase regulatory protein in the liver (87) and adiponectin within the adipose 
tissue may also predispose patients to diabetes (89). 
The pathologies of T2DM that a patient may experience are associated with the 
hyperglycaemia which results from the loss of metabolic control by insulin. Hyperglycaemia 
is well known to cause vascular damage through increased ROS production in endothelial 
cells (90) and this explains a number of symptoms experienced by people with 
T2DM,including microvascular damage in retinal vessels for example (91). Damage of the 
vessels within the retina followed by compensatory angiogenesis to repair this can lead to 
micro haemorrhages within the retina leading to eventual blindness. The microvasculature of 
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the kidney is also frequently affected by chronically hyperglycaemia resulting in destruction 
of nephrons and eventual kidney failure (92).  
Micro- and macro-vascular damage also contributes to poor wound healing responses in 
diabetic patients and an increased risk of peripheral vascular disease where blood supply to 
the periphery (mainly the lower limbs) is inadequate leading to ischaemia of the tissue (93). 
These symptoms can be especially troublesome as an additional defect is diabetic 
neuropathy, which is the result of damage to the peripheral nervous system caused by 
hyperglycaemia (94). Due to the loss of sensation a common occurrence in T2DM patients is 
severe ulcer formation on the extremities (93). This can happen when patients fail to realise 
that they have a wound (due to neuropathy) and, combined with the poor wound healing 
response, leads to a delay in treatment until the ulcer is serious. In these cases, amputation is 
often the only remaining treatment available and complications associated with amputation 
of limbs is a common cause of death in T2DM patients (93). 
1.2.3 Treatment 
During initial stages of the disease T2DM may be successfully managed through changes in 
diet and increased exercise. Both of these have been shown to reduce the hyperglycaemia 
experienced by patients and improve insulin sensitivity (95,96). However, in cases where 
there is poor compliance with these methods or a continued worsening of symptoms 
pharmacological treatments are available. These include compounds in the biguanide, 
sulfonylurea and thiazolidinedione classes. In addition to these compounds insulin analogues 
may be added to further control blood glucose concentrations (97). 
1.2.3.1 Biguanides 
The prototypical biguanide compound and first line treatment for T2DM is metformin (98). 
metformin is listed on the WHO list of essential medicines underlining its usefulness in 
treating T2DM (99). metformin acts to reduce blood glucose and improve insulin sensitivity 
in tissues (98). The reduction in blood glucose is thought to be partly caused by a 
suppression of hepatic gluconeogenesis which is often increased in T2DM patients due to a 
lack of suppression by insulin. The exact mechanism behind these effects is unknown 
although activation of AMP kinase (AMPK) by metformin is thought to be involved (100).  
AMPK, in addition to other roles, is a downstream mediator of insulin signalling and, 
therefore, activation of AMPK by metformin may be able to partially restore insulin 
signalling, resulting in suppression of hepatic gluconeogenesis and increased glucose uptake 
through the insulin responsive GLUT-4 glucose uptake channel in peripheral tissues such as 
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muscle (100,101). In addition to its actions on AMPK metformin also has actions which are 
AMPK-independent, demonstrated by mouse models in which AMPK function is eliminated 
but metformin remains active (102). These actions may include improved binding of insulin 
to its receptor, an effect for which the mechanism is not understood (103).  
1.2.3.2 Sulfonylureas 
If metformin treatment alone is not sufficient to control a patient’s hyperglycaemia then a 
second compound or insulin analogue may also be used in treatment (97). An example of a 
second line therapy such as this is the sulfonylurea class of compounds, such as 
glibencamide. These compounds act to increase insulin secretion from the pancreatic β-cells, 
essentially sensitising the cells to increases in blood glucose (104). They have a relatively 
simple mechanism of action to explain these effects. Sulfonylureas inhibit the function of 
ATP-sensitive potassium channels (KATP channels) (104). Within pancreatic β-cells these 
channels maintain the polarisation of the cells and prevent action potentials (32). During 
normal function of pancreatic β-cells as glucose concentrations increase there is an increase 
in the production of ATP which inhibits the KATP channels and allows the cells to depolarise. 
Depolarisation of the cell results in voltage gated calcium channel activation. The influx of 
calcium permitted by these channels is coupled to the binding of insulin secretary vesicles 
within the plasma membrane and the release of insulin to the circulation (32). By inhibiting 
these channels independently of ATP concentrations sulfonylureas can cause depolarisation 
of the β-cells or sensitise them (due to a partial inhibition for example) to increasing glucose 
concentrations (104). 
1.2.3.3 Thiazolidinediones 
Thiazolidinediones or glitazones are another second line therapy which can be considered if 
metformin fails to control blood glucose concentrations alone. An example of these 
compounds is the commonly used rosiglitazone (105). Glitazones decrease the plasma 
concentrations of free fatty acids (FFA) and blood glucose. The proposed mechanism for 
these effects is complex but mainly relies on the activation of peroxisome proliferator-
activated receptors (PPAR), particularly PPARγ (105,106). The endogenous ligands for these 
receptors are FFA and eicosanoids. PPAR activation results in a wide variety of 
transcriptional changes, including increased lipoprotein lipase and fatty acyl CoA synthase 
within adipose cells (106). These transcriptional changes lead to increased storage of FFA in 
adipocytes. This is suggested to increase the body’s reliance on carbohydrate metabolism for 
energy production and, hence, also results in decreased blood glucose. In addition, a variety 
of endocrine signals released from the adipose tissue may have beneficial effects on insulin 
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sensitivity within muscle and liver tissues (105,106). While glitazones are still currently in 
use, recent evidence has suggested that their use may contribute to increased risk of CVD 
events such as myocardial infarction and lead to heart failure (107). These findings have led 
to decreased clinical use of glitazones. 
1.2.3.4 Insulin analogues 
Insulin can be used as an individual therapy or in combination with one or more of the above 
compounds when good glycaemic control is not attained with them alone (87,108). As 
covered in section 1.2.2, the emergence of full T2DM as opposed to milder glucose 
intolerance has been linked to a reduced ability of pancreatic β-cells to secrete insulin (77). 
In addition to this the sulfonylurea compounds are also primarily designed to increase insulin 
secretion and this is shown to be effective in T2DM (104). Therefore, increasing insulin 
concentrations in T2DM using exogenously administered insulins is an obvious approach to 
therapy. Most commonly long acting analogues of human insulin are administered once daily 
to provide increased concentrations over the course of a day. Doses can be increased until 
blood glucose concentrations are within acceptable ranges or an additional dose of insulin 





In addition to development of T2DM, MetS also leads to increased risk of CVD defined by 
increased rates of coronary artery disease, MI, and stroke (1). This increased risk is 
associated with an increased prevalence of atherosclerotic lesion formation. These fatty 
plaques form within the vessel walls over time and can be either relatively stable and 
asymptomatic or unstable and vulnerable to rupture. Formation of complex, vulnerable 
atherosclerotic plaques inherently predisposes a patient to possible cardiovascular events 
such as MI and stroke because rupture of an atherosclerotic plaque followed by thrombosis 
and vascular occlusion is the most common cause of these events (45). The increased 
development of atherosclerotic lesions in MetS patients can be linked to a number of risk 
factors, including atherogenic dyslipidaemia, hypertension, hyperglycaemia, and the 
proinflammatory state (1,45). 
1.3.1 Epidemiology of CVD and atherosclerosis  
Cardiovascular disease (CVD) is a catch-all term for diseases of the heart and blood vessels. 
CVD is the leading cause of non-communicable disease (NCD) death worldwide. It was 
responsible for 17.5 million deaths in 2012(109); 31% of all global deaths. Refuting the idea 
that it is a ‘Western’ disease 80% of CVD deaths occur in low and middle-income countries. 
The World Health Organisation (WHO) also suggests that NCDs including CVD ‘are major 
barriers to poverty alleviation and sustainable development (109).  
Atherosclerosis is recognised as the cause of several important CVDs including MI and 
stroke, two of the most acute manifestations of CVD. Atherosclerotic lesions are highly 
prevalent throughout the population. Fatty streaks which are a first step in their formation 
have previously been found in childhood autopsies, suggesting very rapid development 
(110). Autopsies of 300 US soldiers killed in the Korean conflict revealed that 77.3% had 
gross evidence of coronary atherosclerosis. Again, this study reflects a high degree of 
prevalence amongst the population as well as early formation as the mean age of the men in 
the study was only 22.1 years (111). However, despite the extremely high prevalence of 
coronary atherosclerosis, the observed rate of acute event caused by lesion rupture is not as 
high. Therefore, these studies also suggest that processes which control the stability of 





Atherosclerosis represents a precursor to CVD. Atherosclerotic lesion development is a 
complex and chronic process involving numerous cell types and pathological processes. A 
general scheme has been proposed (Figure 1.2) and is widely accepted (112,113). This 
process begins with accumulation of lipid-containing lipoprotein particles within the vessel 
wall primarily in the form of low density lipoprotein (LDL). This can be exacerbated in 
certain areas of the vasculature due to actions of haemodynamic forces on the endothelium 
leading to altered cell function such as decreased nitric oxide (NO) synthesis, increased 
permeability and increased adhesiveness for immune cells of the endothelium (113,114). 
Worsening of endothelial function in areas of high haemodynamic stress due to can occur in 
hypertension and may explain why it is a risk factor for atherosclerosis development (115). 
Continuing development of the lesion is caused by recruitment of monocytes (which then 
become macrophages) in the cell wall due to increased adhesion molecule expression on the 
endothelial cells. These macrophages uptake and accrue free oxidised LDL via cell surface 
LDL receptors becoming “foam cells”. Uptake of large amounts of lipid eventually leads to 
cell death by apoptosis and/or necrosis. Consequently, lipids and cellular debris are released 
back into the lesion, aggravating the immune response further (113).  
In complex lesions, smooth muscle cells from the medial vessel wall infiltrate the lesion area 
forming a cap of cells above a ‘necrotic core’ of extracellular lipid and cellular debris 
released from dying foam cells. These cells deposit fibrous tissue, such as collagen, leading 
to a ‘fibrous cap’. In some cases, the ‘cap’ of lesions may also be actively calcified by 
smooth muscle cells or vascular pericytes which have taken on osteoblast characteristics 
(116). This can lead to a brittle, unstable cap structure. In an unstable plaque undergoing 
these remodelling processes tissue proteinases can degrade the fibrous cap structure leading 
to rupture of the plaque and exposure of the underlying thrombogenic tissues (113). This can 
lead to thrombus formation, which, if not effectively cleared, leads to vessel occlusion and 




Figure 1.2 A basic scheme of atherosclerotic lesion development. a) In early stages of atherosclerotic disease 
there is internalisation of low density lipoprotein (LDL) lipid particles into the intimal space. Alterations in 
endothelial cell function, sometimes caused by altered haemodynamic forces, allow LDL lipoproteins to be taken 
up into the vessel wall leading to lipid deposition and ‘fatty streak’ type lesions. b) Oxidisation of the LDL 
particles can lead to adhesion molecule expression on endothelial cells and recruitment of immune cells to the 
lesion including monocytes which can transmigrate into the intimal layer and become macrophages. These 
macrophages take-up ox-LDL particles producing ‘foam cells’ c) Uptake of ox-LDL can lead to cell death, 
releasing lipid and cellular debris into the extracellular environment further aggravating the immune response. 
This, along with the presence of other risk factors such as high circulating homocysteine, can cause smooth 
muscle cell proliferation and migration into the intimal layer forming a ‘fibrotic cap’ above a necrotic core of 
extracellular lipid and cell debris. d) Complex remodelling processes including calcification and proteinase 
function can cause plaques to become unstable and rupture exposing thrombogenic material to the vessel lumen 
and leading to thrombus formation and vessel occlusion. Without removal of the thrombus, tissue supplied by the 
vessel will become ischaemic. Abbreviations: ox-LDL; oxidised low-density lipoprotein, LDL; low density 
lipoprotein, SMC; smooth muscle cell. Reproduced from Libby et al. 2011 (112). 
1.3.2.1 Plasma lipoproteins and cholesterol 
As described, atherosclerosis is initially driven through accumulation of lipoprotein particles, 
in the form of LDL, in the vessel wall (45,112). Lipoproteins consist of a core of lipid and 
cholesterol surrounded by a phospholipid monolayer membrane allowing the hydrophobic 
fats to be emulsified for transport in the aqueous plasma (117,118). Lipoproteins contain 
transmembrane proteins, called apolipoproteins, which act to target the lipoprotein to 
specific tissues. Lipoproteins are classified by density and usually divided into very low 
density lipoprotein (VLDL), low density (LDL) and high density lipoproteins (HDL) and 





(also known as chylomicrons) particles (119,120). The density of the particles is broadly 
reflective of triglyceride content with lower densities containing the most triglyceride and 
HDL the least (119). However, the different classes of lipoprotein also contain different 
types and ratios of the transmembrane proteins which act to direct the particles to certain 
tissues (120).   
The lipid transport process begins with the ‘exogenous pathway’ in the intestine (Figure 1.3, 
121). Following absorption, dietary lipids and cholesterol are packaged into nascent 
chylomicrons for transport to the liver and, to a lesser extent, to other tissues such as muscle 
and fat. These particles contain high levels of ApoB48 which permits their release into the 
lymphatic system (120,121). Through interaction with HDL particles present in the 
bloodstream chylomicrons receive ApoC-II and E proteins. ApoC-II can interact with the 
endothelial cell membrane-bound lipoprotein lipase (LPL) which hydrolyses the triglycerides 
and transfers lipid, in the form of free fatty acids and glycerol, into tissues such as muscle or 
adipose. ApoE allows interaction of the particle with the remnant reuptake receptor at the 
liver resulting in absorption of the lipoprotein and intracellular hydrolysis in lysosomes 
(120,121).  
The liver forms the main regulator of what is termed the ‘endogenous pathway’ for 
lipoproteins (48,117,118,120,122). It hydrolyses triglycerides from absorbed chylomicron 
particles and can either use them for energy generation or store them for later use (117). It is 
also able to synthesise triglycerides and cholesterol de novo from excess nutrients. These 
nutrients are then packaged into VLDL particles for transport to peripheral tissues, such as 
muscle or adipose, for storage or energy generation. Nascent VLDL synthesised in liver 
contains ApoB100 which controls export into the bloodstream (117). Similar to 
chylomicrons, interaction of these nascent particles with HDL allows the donation of ApoC-
II and ApoE to the VLDL particles (120). Depletion of the lipid content of VLDL particles 
through interaction of ApoC-II with LPL in target tissues results in the formation of IDL 
(also termed VLDL remnants). IDL particles are either reabsorbed by the liver through 
interaction of ApoE with the remnant receptor or further hydrolysed by hepatic lipase. 
Hydrolysis by hepatic lipase results in LDL particles which are increasingly cholesterol rich 
due to removal of triglycerides (122,123). LDL particles are absorbed by the liver, or some 
peripheral tissues, through an interaction of the LDL receptor and ApoB100 protein on the 
LDL membrane transferring their cholesterol contents to the tissue. LDL can also be 




The final pathway associated with lipid homeostasis is the ‘reverse transport pathway’ 
mediated through HDL (118,120). HDL particles are synthesised by the liver and usually 
contain apolipoproteins from the ‘A’ family e.g. ApoA-I or II. However, they also contain 
some ApoC-II and ApoE to allow them to perform their role in maturation of chylomicron 
and VLDL particles (118,120). The other role of HDL is to transport cholesterol (and some 
other lipids) from peripheral tissues either back to the liver or to tissues requiring cholesterol 
for steroid synthesis e.g. the adrenal glands. HDL particles acquire cholesterol and lipids 
from tissues through interaction with membrane bound proteins such as ABCG1 and PLTP. 
This content can then be transferred to tissues either directly through uptake of HDL by 
scavenger receptors or indirectly through interactions with VLDL. The indirect process 
predominates in mammals and is mediated by cholesterol ester transfer protein (CETP). This 
protein exchanges triglycerides from VLDL particles for the cholesterol contained in HDL. 
This forms a cholesterol rich LDL particle and a triglyceride rich HDL particle. While LDL 
can then be absorbed by tissues, releasing its cholesterol content (discussed above), the HDL 
is unstable in this form and is hydrolysed by hepatic lipase removing the triglycerides and 
recycling the HDL particle for reuse (49,118,120).  
Given that the accumulation of cholesterol rich LDL within the vessel wall is the initiating 
step in atherosclerosis, blood lipoprotein levels have long been considered a risk factor for 
this disease (45). Indeed, increased plasma cholesterol in both human and animal models has 
been shown to independently cause lesion development in the absence of other known risk 
factors (124). The atherosclerotic risk of increased cholesterol is also demonstrated by a 
number of genetic models of elevated circulating cholesterol in mice such as ApoE–/– and 
Ldlr–/– which develop lesions in aortic vessels unlike wild type animals (125). Similar effects 
have also been found in human patients with familial hypercholestaemia in whom 
development of severe atherosclerotic lesions can occur in childhood leading to mortality 










Figure 1.3 Mammalian exogenous and endogenous lipoprotein metabolism. Lipoprotein metabolism begins 
with lipid absorption from the intestine and transfer to the liver in chylomicron particles (exogenous pathway). 
The liver regulates secretion of VLDL particles containing cholesterol and triglyceride for transport to peripheral 
tissues. When VLDL interacts with LPL triglyceride is progressively removed resulting in the generation of 
cholesterol rich IDL and LDL particles. These can be reabsorbed by the liver or can transfer their contents to 
other tissues (such as the adrenal glands). The cholesterol can also be absorbed by circulating macrophages. 
Nascent HDL particles synthesised by the liver or intestine can then interact with cholesterol containing 
macrophages or tissues to take up cholesterol. These HDL particles can then transport the cholesterol back to the 
liver or to cholesterol-requiring tissues. A-I; ApoA-I, ABC1; ATP-binding cassette transporter 1, B; ApoB, C-II; 
ApoC-II, CETP; cholesterylester binding protein, E; ApoE, HDL; high-density lipoprotein, HL; hepatic lipase, 
IDL; intermediate-density lipoprotein, LCAT; lecithin-cholesterol acyl transferase, LDL; low-density lipoprotein, 
LDLr; low-density lipoprotein receptor, LPL; lipoprotein lipase, LRP; lipoprotein receptor related proteins; SR-
A; scavenger receptor A, SR-BI; scavenger receptor B-I, VLDL; very low-density lipoprotein. Reproduced from 
Kwiterovich (2000) (120). 
1.3.2.2 Hypertension 
Hypertension increases the risk of atherosclerosis in patients who already have the additional 
high risk factor of increased cholesterol (115). The exact mechanisms of this increased risk 
have not been well elucidated. However, the effects of hypertension on the vascular 
endothelium may play a key role. A number of groups have hypothesised that atherosclerosis 
is primarily an unresolved inflammatory response within the vascular wall. The immune 
response may be triggered by either damage to the endothelium or endothelial cell 
dysfunction induced through other mechanisms such as hyperglycaemia (61,114). 
Endothelial dysfunction has classically been defined as a reduction in nitric oxide production 
by the endothelium in response to acetylcholine stimulation and occurs in areas prone to 
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formation of atherosclerotic lesions (114,115,127). However, in addition to a reduction in 
NO formation endothelial cell dysfunction is associated with increased expression of 
immune cell adhesion molecules, such as vascular cell adhesion molecule 1 (VCAM-1). 
Increased expression of these molecules leads to greater immune cell attachment and 
infiltration into the vascular wall, an initiating process in atherosclerosis formation (45,128).  
The cause of endothelial cell dysfunction is unclear. However, increased reactive oxygen 
species (ROS) production in endothelial cells is linked to dysfunction (127,129). Increased 
ROS production in endothelial cells has been demonstrated with both increased circulating 
cholesterol concentrations and hypertension (129). The increase in vascular shear stress 
resulting in increased turbulent blood flow experienced in patients with hypertension can 
result in altered endothelial cell function and increased ROS production (130). Under normal 
conditions vascular shear stress (caused by laminar flow of blood through the vessels) 
initiates signalling processes in endothelial cells through mechanotransduction mechanisms 
at the cell membrane (131). This can include the stimulated release of vasodilator molecules 
including NO. In conditions of hypertension not only is shear stress generally increased but 
more complex changes also occur in certain complex areas of the vascular system such as 
bifurcations (131). This results in turbulent flow in these regions and alterations to the local 
shear stress forces experienced by the endothelium in these regions including reversal of 
flow, oscillatory stress and turbulent flow (131). The altered shear stress experienced by 
these cells induces transcriptional changes which make them susceptible to focal 
development of atherosclerosis including downregulation of NO producing eNOS protein 
(131). This further supports the idea that dysfunction or damage to the endothelium by 
hypertension is the reason for its effect on atherosclerosis, as these areas are also the most 
vulnerable to lesion formation (130). 
1.3.2.3 Hyperglycaemia 
T2DM is recognised as an important risk factor for CVD and atherosclerosis. This is linked 
to the effect of hyperglycaemia on the vasculature. As discussed in section 1.2.2, 
hyperglycaemia can lead to vessel damage in both the micro- and macro-vasculature (90). In 
a similar fashion to hypercholesterolaemia and hypertension this most likely occurs due to 
stimulation of ROS production in endothelial and other vascular cells by high glucose 
concentrations. Increased ROS production due to hyperglycaemia has again been linked to 
endothelial cell dysfunction which is commonly observed in diabetic patients (132). As 
previously mentioned, endothelial cell dysfunction leading to increased immune cell 
infiltration has been linked to atherosclerosis and, therefore, this mechanism explains how 
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hyperglycaemia may contribute to increased atherosclerotic risk (45,114). Insulin-resistance 
associated with T2DM may be involved in this process as insulin can also stimulate NO 
production (133). Resistance of the endothelium to insulin has been linked to an early state 
of endothelial cell dysfunction in T2DM patients that may precede hyperglycaemia. 
Therefore, endothelial cell resistance to insulin may also be partly responsible for the 
endothelial dysfunction observed in diabetic patients which contributes to increased 
atherosclerosis risk (133,134). 
1.3.2.4 Pro-inflammatory state 
A low-grade systemic inflammation, similar to that observed in MetS, can worsen a person’s 
risk of atherosclerosis (112,135). This is logical as atherogenesis involves an inflammatory 
response within the blood vessel wall. Increased inflammatory, as opposed to resolution 
activity of the immune system leads to a worsening of this process as more immune cells are 
recruited to the lesion and pro-inflammatory cytokines are released (135). Immune cells 
induce the increased remodelling of lesions through release of a vast array of pro-
inflammatory cytokines and proteases (136). Not only can this increase lesion formation but 
increased inflammatory activity within a lesion is linked to plaque vulnerability and risk of 
rupture (135,136). Therefore, systemic inflammation which leads to pro-inflammatory 
priming of the immune system is an inherent risk factor for atherosclerosis.  
1.3.3 Treatment of Atherosclerosis  
Treatments for atherosclerosis mainly rely on a prophylactic approach: i.e. reducing risk 
factors associated with lesion development before substantial disease progression has taken 
place or reducing the risk of plaque rupture leading to a serious cardiovascular event 
(52,109). These can initially include encouraging lifestyle alterations such as smoking 
cessation, dietary changes and increasing exercise (109). Therapeutically, using medications 
to lower blood cholesterol and blood pressure has been shown to be effective in reducing risk 
of serious cardiovascular events (137). Treatment for hyperglycaemia or T2DM can also 
reduce risk as covered in section 1.2.3. Finally anti-thrombogenic therapies can be used in 
conjunction with other therapies to reduce the risk of thrombus formation in the event of 
plaque rupture (138). 
Unfortunately, while current therapies can decrease risk of a serious cardiovascular event 
they do not lead to lesion resolution and repair as desired, especially for patients with 
substantial lesion formation prior to initiation of therapy. There is some evidence that 
chronic (139) or intensive (45) statin therapy can reduce lipid content of lesions and stabilise 
them, reducing the risk of rupture. These studies require further validation. New therapies 
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that can complement the current approach are still a high priority for the scientific and 
clinical community.  Suggested avenues for development of new treatments include directly 
combatting the two key processes which lead to lesion formation; endothelial cell 
dysfunction (113,114) and the unfavourable immune/inflammatory response which fails to 
resolve within the vessel wall (45).  
1.3.3.1 Statins 
Cholesterol for packaging into VLDL lipoproteins is synthesised by the liver from acetyl 
CoA (29). This synthetic pathway has many steps. The rate-limiting step is catalysed by the 
enzyme 3-hydroxy-3-methylglutaryl (HMG) reductase which converts a molecule of 3-
hydroxy-3-methylglutaryl CoA (HMG-CoA) to mevalonate (45,140). This enzymatic step 
can be inhibited by statin compounds resulting in a decrease in cholesterol concentrations 
within the circulation. In addition to this action the inhibition of cholesterol synthesis also 
results in increased concentration of the LDL receptor (LDLR) in the cell membranes of 
peripheral tissues increasing their uptake of LDL from the circulation. The mechanism of 
action for all statins is the inhibition of HMG-CoA reductase. However, they differ in how 
well individual patients can tolerate the drugs without the occurrence of side effects. Statin 
therapy has been shown in a number of studies to reduce the occurrence of cardiovascular 
events and this reduction in risk is positively correlated to the drop in plasma cholesterol 
cause by statin administration (140,141). Statins are typically well tolerated by patients and 
are enormously important in reducing the rate of CVD events such as MI on a population 
level (141,142). 
1.3.3.2 Anti-hypertensives 
Several classes of anti-hypertensive agents exist. The main classes of drugs used in most 
patients are diuretics, compounds which reduce the effect of the renin-angiotensin system 
(RAS) and Ca2+ channel blockers (143). The exact regimen of compound administration will 
depend on an individual’s unique circumstances accounting for their tolerance of certain 
compounds and comorbidities. Diuretic compounds reduce blood volume by increasing urine 
excretion. Subclasses of diuretic differ in how this is achieved and with regard to where in 
the nephron they exert their action. Diuretics are recommended as first line therapies for 
hypertension (144).  Diuretics are often combined with compounds that affect the RAS and 
reduce the stimulation of vascular tone by angiotensin which leads to increased blood 
pressure (145,146). The two main classes of drugs acting on the RAS are angiotensin 
converting enzyme (ACE) inhibitors (147), which prevent the production of the hypertensive 
angiotensin II, and angiotensin II AT1 receptor antagonists (148). The mechanism of action 
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for both of these classes is to reduce the hypertensive effect of angiotensin II on blood 
pressure.  
Finally, Ca2+ channel blockers, such as nifedipine and verapamil, are also intended to reduce 
the tone of the vasculature and hence reduce pressure (143,149). These compounds are often 
used in combination with diuretics and ACE or angiotensin II inhibitors. As expected, Ca2+ 
channel blockers exert their effects by inhibiting the function of Ca2+ channels within 
vascular smooth muscle cells. By blocking Ca2+ entry into the cells they reduce the 
constriction of the muscle and therefore reduce vascular tone and overall blood pressure 
(149). While the individual mechanisms of action for the first line anti-hypertensives differ 
the end goal of therapy using these compounds is a reduction in a patient’s blood pressure, 
ideally to normotensive levels, in order to reduce the risk of serious cardiovascular events. 
Evidence indicates that a reduction in blood pressure of 5 mmHg diastolic reduces the risk of 
stroke by 34% and MI by 21%, regardless of the starting value (150). Therefore, control of 
blood pressure using these agents is an important and useful treatment to mediate the effects 
of atherosclerosis. 
1.3.3.3 Anti-thrombotic agents 
Used in addition to agents which reduce plasma cholesterol and blood pressure, anti-
thrombotic drugs have been shown to reduce the occurrence of serious cardiovascular events 
such as stroke and MI (151). Plaque rupture and thrombosis are two key events which cause 
MI and stroke. Therefore, agents which can prevent clot formation or allow for more rapid 
thrombolysis before occlusion of a vessel takes place can be useful in preventing MI and 
stroke. For patients with atherosclerotic disease long term anti-thrombotics, such as aspirin 
and warfarin, can be useful either individually or in combination (152,153). These treatments 
can reduce the risk of serious cardiovascular events especially in high risk patients who have 
previously experienced thrombotic events such as MI or ischaemic stroke (153). Aspirin and 
warfarin have independent mechanisms of action. Aspirin inhibits platelet aggregation, an 
early stage of clot formation. This is achieved by inhibition of cyclooxygenase (COX). 
Inhibition of COX prevents thromboxane A2 production which is a key stimulator of platelet 
aggregation. Daily low dose aspirin therapy can prevent most thromboxane A2 production 
while avoiding the gastrointestinal side effects of conventional aspirin therapy (154).  
Warfarin inhibits the production of a number of active clotting factors used in the 
coagulation cascade (155). This endogenous cascade leads to activated fibrin formation 
which is required alongside activated platelets for thrombus formation. Warfarin reduces the 
availability of vitamin K which is required for carboxylation of clotting factors at certain key 
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residues. This affects clotting factors II, VII, IX and X and removes their ability to bind to 
the vessel wall, preventing them from acting in the clotting cascade. Therefore, warfarin 
reduces clotting and, hence, cardiovascular events in patients with atherosclerosis. However, 
its administration must be carefully controlled and monitored as it is an irreversible inhibitor 
and increased accumulation of inactive clotting factors can lead to excessive bleeding (155). 





1.4 Hydrogen sulfide 
Hydrogen sulfide (H2S) is an endogenously produced gasotransmitter that may reduce 
atherosclerotic lesion development (156). H2S is known for its potent toxicity at high 
concentrations, which can result from exposure to exogenous sources such as oil/gas 
production and sewerage. At high concentrations H2S inhibits ATP generation by the 
mitochondria by binding with the iron in the mitochondrial cytochrome enzymes resulting in 
inhibition of the electron transport chain (157). Despite this toxicity, H2S has recently been 
found to be produced in physiological quantities by mammalian cells and, therefore, joins 
nitric oxide (NO) and carbon monoxide (CO) in the family of ‘gasotransmitters’ (158,159). 
Recent evidence has shown that H2S signalling can have effects both on metabolic function 
and diabetes and on cardiovascular disease, including atherosclerosis, making it a highly 
interesting target for investigation. 
1.4.1 Production of H2S 
H2S is actively produced by the enzymes cystathionine γ lyase (CSE) and cystathionine β 
synthase (CBS) from the amino acid cysteine and there is evidence that a third enzyme, 3-
mercaptopyruvate sulfurtransferase (MPST) may be able to catalyse H2S production from 3-
mercaptopyruvate (160).  Measurement of H2S concentrations within tissues is technically 
challenging and is complicated by compounds such as polysulfides which may be formed 
from H2S and detected by a number of the methods used for H2S measurement, thus giving 
artificially high values (161). Current best estimates of the maximum endogenous H2S 
concentration are <500 nM (162) consistent with the signalling range hypothesised for NO. 
Cbs or Cse knockout has been demonstrated to reduce tissue and plasma H2S levels in 
comparison to wild type mice (162). 
1.4.2 H2S signalling 
The biology of H2S is typically investigated by measuring secondary responses to reduced 
endogenous (as in the case of Cse–/– and Cbs–/– mice) H2S production or following exogenous 
administration of an H2S donor compound.  Increased concentrations could be considered as 
>500 nM however, donor compounds are often used at much higher concentrations 
experimentally. While several effects of altered H2S concentrations have been found 
(detailed below) the mechanisms which cause them are typically less well defined. However, 
a general principle adopted within the community is that H2S signals by reacting with 
cysteine residues of proteins resulting in -SSH persulfide ‘tag’ formation on proteins (163–
165). Direct persulfidation by H2S on unreacted cysteines is unlikely to occur as it is an 
unfavourable reaction (165) however, a number of possible reactions have been identified 
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either between H2S and cysteine residues which have already been modified or through the 
formation of polysulfides which can donate sulfur atoms for persulfidation (165). The 
formation of persulfide tags on proteins is then thought to cause either direct changes to the 
active site or changes in protein folding altering activity (figure 1.4) (163,164). Mustafa et 
al. (163) demonstrated that increasing or decreasing the concentration of H2S (either through 
H2S donors or modifying endogenous levels) increases or decreases the number of 
persulfidated proteins, respectively thereby increasing or decreasing H2S signalling. 
 
Figure 1.4 Proposed mechanisms for persulfide formation. A number of reaction mechanisms have been 
proposed by which H2S, or reaction products of H2S, may mediate persulfidation of protein cysteine residues. a) 
No reaction will occur with H2S and unreacted cysteine as this is thermodynamically unfavourable. b) H2S can 
react with sulfenic acids formed on cysteine residues. c) Reaction of H2S with nitrosylated cysteines can result in 
HSNO formation or, depending on the protein environment, HNO and persulfidated protein. d) H2S reaction with 
existing intra or inter protein disulfide bridges. e) Polysulfides can react with unmodified cysteine residues 
resulting in persulfide formation. f) Metal ions (e.g. contained within protein active sites) could act as oxidants 
for formation of persulfides in combination with H2S. g) Existing persulfides could react in ‘transulfuration’ 




This mechanism is similar to that of NO which nitrosylates proteins leading to altered 
activity (163). Compared to nitrosylation persulfidation appears to be even more prevalent 
within the cell and usually acts to increase a proteins activity (164). In a particularly elegant 
example Mustafa et al. identified that persulfidation of cys150 within glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) led to increased activity whereas nitrosylation of the 
same residue abolished activity (163). Persulfidation of key proteins is thought to be the 
mechanism by which H2S signals and produces the physiological changes observed in vitro 
and in vivo. As techniques for investigating persulfidation of proteins have developed some 
mechanisms have now been identified involving persulfidation of specific proteins (sections 
1.4-6) lending support to this hypothesis (163,166,167). 
1.4.3 Breakdown of H2S  
A working hypothesis for the intracellular breakdown of H2S was recently proposed by 
Libiad et al. (Figure 1.5, 166) iterating on previous work (169) by altering the suggested 
chemical reactions occurring at each step. However, both pathways involved the same 3 key 
mitochondrial enzymes; sulfide:quinone oxidoreductase (SQR), sulfur dioxygenase (SDO) 
also known as ethylmalonic encephalopathy protein 1 (ETHE1) and thiosulfate 
sulfurtransferase (TST) (168,169). The coordinated actions of these enzymes result in a final 
product of thiosulfate which is excreted in the urine. Additionally, conversion of thiosulfate 
to sulfate can be metabolised by sulfite oxidase (SO) and this occurs in some tissues 
resulting in a mixture of sulfate and thiosulfate in the urine (168,169). 
The pathway established by Libiad et al. begins with the oxidation of H2S to sulfur, which is 
transferred to an acceptor molecule, such as glutathione (GSH), forming glutathione 
persulfide (GSSH). This molecule can then donate its persulfide (-SH) to ETHE1 which uses 
oxygen to form sulfite (SO32-) and water. Sulfite is then processed by TST which combines 
sulfite with persulfide to form thiosulfate (S2O32-). Alternatively, SO can use sulfite to 
generate sulfate (SO42-) which is excreted along with thiosulfate. The production ratio of 
these molecules varies between tissues and potentially reflects differences in expression of 
















Figure 1.5 A working model of intracellular H2S breakdown in the mitochondria. Oxidation of H2S begins 
with the transfer of sulfur at the sulfide:quinone oxidoreductase (SQOR) to the acceptor molecule glutathione 
(GSH) which becomes glutathione persulfide (GSSH). Sulfur dioxygenase (SDO) can then generate sulfite (SO32-
) by combining this persulfide with O2. Sulfite can be further processed either by thiosulfate (S2O32-) sulfur 
transferase (TST) to thiosulfate or by sulfite oxidase to sulfate (SO42-). Both of these compounds represent 
excretion products. Reproduced from Libiad et al. (2014) (the ‘rhodanese’ label in the original figure has been 
replaced with ‘TST’ and the ‘SQR’ label with SQOR) (168). 
During investigations of the disease ethylmalonic encephalopathy by Tiranti et al. it was 
demonstrated that loss of function of the SDO enzyme led to increased H2S concentrations 
(170). H2S was measured by taking a gas sample for analysis following tissue 
homogenisation in a sealed vessel. Compared to control mice SDO knockout mice had 
approximately 10-fold higher H2S concentrations in liver and muscle tissue with a smaller 
increase (approximately 4-5 times) also observed in brain tissue. Tiranti et al. showed that 
the increase in H2S in this case eventually resulted in toxicity due to inhibition of COX and 
short-chain acyl-CoA dehydrogenase (SCAD) leading to a range of tissue damage 
predominately in brain and muscle tissue. Whilst SDO knockout led to growth arrest and 
eventual death it also provided the first evidence that inhibition of the H2S breakdown 
pathway is sufficient to increase endogenous H2S concentrations (170).  
1.4.4 Metabolic actions of hydrogen sulfide 
Many of the physiological actions of H2S have either been inferred from Cse–/– and Cbs–/– 
mice (which lack the enzymes associated with production of H2S and, hence, have decreased 
H2S concentrations) or investigated using exogenously-administrated H2S made from either 
NaHS or Na2S salts. The concentrations of H2S administered in vitro or in vivo are often 





therefore the physiological relevance of the findings must be questioned. However, from a 
number of studies have shown that hepatic carbohydrate and lipid metabolism are altered in 
response to changes in H2S levels either directly through H2S mediated signalling or as a 
result of changes to insulin signalling. 
1.4.4.1 Glucose metabolism 
H2S has been linked to diabetic-like phenotypes in the liver (171) and pancreas (172) 
resulting in increased plasma glucose concentrations. Cse overexpression or exogenous 
administration of NaHS in mouse primary hepatocytes increased glucose production via 
gluconeogenesis (171,173). Initially this was linked to increased PEPCK activity which 
catalyses the first committed step towards gluconeogenesis. However, recent evidence has 
suggested that it may in fact be the result of increased pyruvate carboxylase (PC) activity 
(166) which catalyses the preceding step in gluconeogenesis and has been suggested to exert 
some control over the flux through the gluconeogenic pathway (174,175). Exogenous NaHS 
increased PC activity through the formation of a persulfide protein modification at an active 
cystine residue (166). Therefore, this represents a direct mechanism by which H2S is able to 
increase gluconeogenesis.   
Glycogen production was also decreased by Cse over-expression or exogenous NaHS 
administration (173). Both increased gluconeogenesis and decreased glycogen production 
occur physiologically during fasting conditions when insulin concentrations are low (29). 
Further to this, increased gluconeogenesis and decreased glycogen storage persisted in 
primary hepatocytes despite insulin stimulation. A dose-dependent inhibition of Akt 
phosphorylation (a key signalling reaction of the insulin signalling pathway) was also 
observed in NaHS-treated HepG2 cells (a hepatic cell line) (173). Taken together these 
findings suggest that H2S can drive hepatic insulin resistance, a common feature of diabetes. 
Finally, increases in CBS or CSE expression have also been found in the livers of 
streptozocin-induced diabetic rats (176) and insulin resistant HepG2 cells (173), 
respectively. Along with this suggestive evidence, changes in CBS or CSE expression have 
also been demonstrated in people with T2DM (177) lending support to the involvement of 
these enzymes in the pathogenesis of this condition. 
In addition to the changes observed in hepatic metabolism, NaHS and the amino acid 
cysteine (which is a precursor for H2S generation by CSE or CBS) inhibit the release of 
insulin from pancreatic β-cell lines (172,178,179). The most obvious cause of this is the 
known interaction of H2S with KATP channels (180,181). In contrast to sulfonylurea 
compounds (section 1.2.3.2) which inhibit the function of KATP channels, H2S can 
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persulfidate KATP channels leading to increased activity (181). Increased activity of these 
channels within pancreatic β-cells leads to a suppression of the action potentials required for 
insulin release (32). In addition to this  effect, H2S has also been linked to inhibition of L-
type Ca2+ channels within pancreatic β-cells (178). These channels are required for Ca2+ 
influx which is coupled to insulin release (32). Therefore, inhibition of the channels can 
suppress insulin release.  
Finally, H2S has also been linked to death of pancreatic β-cells.  Exogenous NaHS caused 
apoptosis of an insulin-secreting INS-1E cell line, suggesting that it may inhibit insulin 
release through destruction of the β-cells (182). However, it should be noted that, as in many 
tissues, this appears to be dependent on the concentration and environment as several groups 
have linked to the protection of β-cells in toxic conditions (183,184). Overall these findings 
suggest that H2S signalling acts to decrease insulin release; an effect which will naturally 
result in diabetic-like function. Therefore, H2S appears to exhibit negative effects on glucose 
metabolism resulting in hyperglycaemia. 
1.4.4.2 Lipid metabolism 
The proposed effects of H2S on lipid metabolism have not been as clearly defined as those on 
glucose metabolism. Clinical studies have identified a positive correlation between plasma 
H2S levels and HDL cholesterol, and a negative correlation with LDL/HDL cholesterol ratio 
(185). In Cbs–/– mice, which are suggested to have decreased endogenous H2S 
concentrations, this relationship was mainly supported as serum triglycerides, non-esterified 
cholesterol and non-esterified fatty acids were increased in concentration. This finding was 
associated with a decrease in liver VLDL secretion (186). However, it should be noted that a 
decrease in H2S concentrations within the liver was not confirmed in these mice and so these 
effects may reflect changes elsewhere (171). In Cse–/– mice similar changes in lipid profile 
were noted; including an increase in total, LDL and HDL cholesterol when mice were fed an 
atherogenic diet (187). However, in contrast to the effects in Cbs–/– mice, a decrease in total 
triglyceride content was observed on both control and high fat diets compared to C57BL/6 
controls (187). Treatment of Cse–/– mice with the H2S donor NaHS abolished these changes, 
suggesting that the lack of H2S in these mice could be responsible for the changes in lipid 
profile (187).  
Given the importance of the liver in controlling lipid synthesis and release of lipoproteins it 
is not surprising that changes in lipid metabolism can lead to diseases of the liver, including 
steatosis (the accumulation of triglyceride within the tissue) (46). Consistent with this in, 
Cbs–/– mice (in which plasma cholesterol and triglyceride were increased) steatosis of the 
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liver has been identified even when mice were fed a control chow diet (186). This has led to 
the suggestion that H2S signalling prevents hepatic steatosis although this has not yet been 
tested through exogenous H2S administration or endogenous enzyme overexpression 
(171,186). It is also worth noting that Cbs–/– mice also suffer from hyperhomocysteinaemia 
due to decreased function of the trans sulfuration pathway (171). Increased homocysteine has 
itself been linked to hepatic steatosis and, therefore, this effect may be independent of 
decreased H2S signalling (188). Hepatic steatosis has not been thoroughly investigated in 
Cse–/– mice. However, Mani et al. report that no obvious steatosis was evident in these 
animals (171). Cse–/– mice also exhibit hyperhomocysteinaemia showing that the influence of 
H2S on hepatic steatosis is not clear cut. However, overall the evidence suggests that H2S 
signalling engenders protective changes with regard to lipid metabolism and that decreased 
endogenous H2S signalling results in increased plasma cholesterol and hepatic steatosis but 
with unknown effects on plasma triglycerides. 
1.4.5 Cardiovascular actions of hydrogen sulfide 
H2S was initially investigated primarily as an endogenous vasodilator similar to NO. 
Therefore, it is of obvious interest in CVD in which  impaired activity of  vasodilators, such 
as NO, has been linked to vascular pathologies (129,189). H2S has been found to influence 
vascular function, myocardial ischaemia/reperfusion injury and atherosclerogenesis. 
1.4.5.1 H2S and vascular function 
H2S signalling has been linked to activation of potassium channels, including KATP, 
intermediate conductance and small conductance potassium channels (159,180,181). The 
coordinated action of these K+ channels within the smooth muscle of the vasculature results 
in hyperpolarisation of smooth muscle cells resulting in fewer action potentials and 
relaxation of the vessel (190,191). Therefore, H2S has now been defined as an endothelium-
derived hyperpolarising factor (EDHF) (181). H2S, given exogenously as NaHS,  induces 
vasodilation (measured using myography) in isolated aortic and mesenteric vessels (192). It 
should be noted that, as seen in metabolic investigations, vasodilator responses have 
typically been recorded following administration of H2S concentrations far above the normal 
physiological concentrations (<500 nM) in the µM or mM range. This evidence questions the 
direct effect of H2S on vasodilation physiologically however, it does not rule out that it may 
modulate the response of the vessels to other vasodilators and hence indirectly stimulate 
vasodilation. Indeed, as has been extensively reported in the ischaemia field (section 1.4.5.2) 
H2S signalling has been demonstrated to increase production and decrease breakdown of 
NO, a well-known vasodilator (167). Mustafa et al. have also reported that ACh-mediated 
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vasodilation in mesenteric arteries is impaired in Cse–/– mice and this is supported by 
intermediate effects observed in Cse+/– mice compared to C57BL/6 controls (192). 
Consistent with this evidence, it has also been reported that Cse–/– mice exhibit hypertension 
on both control and high fat diet (187). There are few reported data on the effects of 
increased or decreased H2S signalling on other aspects of vascular function, such as 
vasoconstriction. 
1.4.5.2 H2S and ischaemia/reperfusion injury 
Elrod et al. showed that in C57BL/6 mice with induced myocardial ischaemia and 
reperfusion (I/R) exogenous Na2S  administration directly into the left ventricle during 
reperfusion results in decreased injury exemplified by a 72% reduction in infarct size (193). 
They also demonstrated that mice with myocardial (α-myosin heavy chain driven 
expression)-specific overexpression of Cse had decreased infarct size following myocardial 
I/R injury. Data from this study suggested that administration of Na2S led to a conservation 
of mitochondrial function that was responsible for the reduction of infarct size and the 
protection of left ventricular function (193).  
Later evidence from King et al. showed that the protective effects of Na2S administration on 
myocardial and hepatic I/R injury were in fact reliant on functional endothelial nitric oxide 
synthase (eNOS) expression (167). The protective effect of H2S donor administration was 
abolished in eNOS–/– mice or eNOS–/– mice expressing a form of eNOS which lacked the 
Ser1177 residue. Phosphorylation of this residue is stimulatory, leading to increased NO 
synthesis, and its phosphorylation was found to be induced by Na2S administration. When 
mice did not express a form of eNOS that could be phosphorylated in this way, the protective 
effect of Na2S was lost (167). These data show that the H2S and NO signalling pathways 
have significant and important cross-talk which is important for the beneficial cardiovascular 
effects of exogenously administered H2S donors (194). Supporting this idea Cse–/– mice, 
which suffered worsened responses to myocardial I/R injury, also exhibited decreased NO 
production and impaired eNOS function, suggesting that cross-talk between the H2S and NO 
systems is key in cardiovascular function (167). 
1.4.5.3 H2S and atherosclerosis 
Cse–/– mice fed an atherogenic diet for 12 weeks developed fatty streaks within the 
brachiocephalic branch of the aorta which was not observed in C57BL/6 control mice (187). 
Treatment with the H2S donor NaHS significantly reduced the size of the streaks in Cse–/– 
providing evidence that a lack of H2S signalling was responsible for the increased 
development of lesions. However, as in other fields, the concentration of H2S donor 
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administered to mice (39 µmol/kg) was far higher than predicted endogenous concentrations 
in wild type mice. Strikingly, streak development occurred in Cse–/– without requiring 
breeding with the atherosclerosis susceptible ApoE–/– or Ldlr–/– models. This is unusual 
within atherosclerotic research as the lipid profile of wild type mice is shifted to HDL and, 
therefore, is not conducive to formation of atherosclerosis (125). Cse–/– mice exhibited 
abnormal lipid profiles, including increased cholesterol, and hypertension; both of which are 
risk factors for atherosclerosis. However, these were normalised using ezetimibe, a 
cholesterol absorption inhibitor, and hydralazine, an anti-hypertensive, treatment and this did 
not alter the size of the streaks showing that these risk factors were not responsible for the 
increased streak volumes. Instead endothelial expression of intercellular adhesion molecule 1 
(ICAM-1) was increased in Cse–/– mice and this was suggested as the explanation for 
increased lesion development (187). 
In addition to these findings, Cse–/– mice crossed with a well-established atherosclerosis 
model; apolipoprotein E knock-out mice (ApoE–/–) also exhibited more extensive lesion 
development than identically treated ApoE–/– mice. Excluding an increase in HDL content in 
the DKO mice (which would usually be considered protective from atherosclerosis 
formation), lipid profiles were not altered suggesting that altered lipid metabolism was not 
the cause of increased atherosclerosis. ApoE–/–Cse–/– double knockout mice treated with 
NaHS (39µmol/kg) also had decreased lesion formation without any effect on lipid profiles 
(187). Overall increased H2S is beneficial in the vasculature and can mitigate atherosclerotic 





1.5 Thiosulfate sulfurtransferase 
Thiosulphate sulfurtransferase (EC.2.8.1.1) is a type 1 class detoxification enzyme encoded 
by the nuclear Tst gene and expressed predominantly in the mitochondrial matrix (195). 
Historically known as ‘Rhodanese’, it was initially linked to cyanide detoxification through 
conversion of thiosulfate (S2O32-) and cyanide (CN) to thiocyanate (SCN-), for excretion 
(196). This reaction illustrates the general mechanism of TST action, which is the acceptance 
of a sulfur atom from a donor compound (in this case S2O32-) leading to formation of a 
persulfide at the active site cysteine residue. This sulfur is then cleaved from TST and 
transferred to an acceptor molecule (in this case CN) (196). TST exists within a superfamily 
of sulfur transferase proteins which contain ‘rhodanese’ domains (197,198). Many have not 
been thoroughly investigated however, from initial investigations they do appear to have 
similar reaction mechanisms to TST (197,198). Whether these enzymes provide 
physiological roles similar to those of TST is unknown however, from preliminary 
investigation in our mice 3 other sulfur transferases (TSTD1, D2 and D3) are all minimally 
expressed in mouse liver (data not shown).   
Given the general nature of the sulfur transfer mechanism it is not surprising that TST is 
promiscuous in its interaction with a variety of sulfur donor and acceptor compounds 
including H2S, SO32-, S2O3- and persulfides such as glutathione (169). In addition to 
involvement in the H2S breakdown pathway (section 1.4.3) TST has also been linked to iron-
sulfur cluster regeneration (199,200). . Iron-sulfur clusters are essential components within 
the active sites of many enzymes including complexes I, II and III of the mitochondrial 
electron transport chain (201) which are located in close vicinity to TST within the 
mitochondrial matrix. It has been suggested that TST may play a role in the regeneration of 
these clusters when they are consumed in enzymatic reactions. In cell free systems TST can 
incorporate sulfur donated from thiosulfate into succinate dehydrogenase (200) (complex II 
of the respiratory chain) however, this has not been demonstrated under physiological 
conditions. Kinetic analysis of TST by Hildebrandt and Grieshaber has shown that the Km for 
thiosulfate is far higher than sulfite and persulfides leading them to suggest that its proposed 
role in H2S breakdown is its most likely physiological role (169).  
1.5.1 Thiosulfate sulfurtransferase and metabolic dysfunction 
Work by Morton et al. independently led to identification of Tst as a potential adipose tissue-
specific ‘healthy lean gene’ (202–204). As discussed in section 1.1.9, there are a large 
number of genetic factors which may affect a person’s propensity for development of obesity 
and MetS (87). Most studies have investigated genes or polymorphisms which predispose 
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people to weight gain leading to obesity (205,206). However, the converse approach, i.e. 
investigating genes which reduce weight gain and promote a lean phenotype, has not been 
extensively followed (204). Overexpression of Tst in the adipose tissue protected mice 
(Adipoq-Tst mice) from weight gain and the negative metabolic consequences of a high fat 
diet (HFD). Adipoq-Tst mice fed HFD had decreased hyperglycaemia, increased insulin 















Figure 1.6 The effects of adipose Tst overexpression on metabolic function following high fat diet feeding 
(HFD). C57BL/6N are displayed in black lines, Adipoq-Tst in purple. A) Body weight measured over 6 weeks of 
HFD feeding. B) A glucose tolerance test performed in mice fed HFD for 6 weeks. C) The glucose infusion rate 
measured in a euglycaemic hyperinsulinaemic clamp performed in C57BL/6N and adipoq-Tst mice fed HFD for 
2 weeks. D) The mean adipocyte area measured in sections of adipose tissue from C57Bl/6N or Adipoq-Tst mice 





In addition to these findings, global deletion of Tst (Tst–/–) mice was found to be associated 
with mild hyperglycaemia following HFD and decreased suppression of non-esterified fatty 
acids (NEFA) although body weight in HFD-fed mice was unchanged compared to 
C57BL/6N controls (Figure 1.7) (204). Control-fed Tst–/– mice also had increased 
gluconeogenesis following a pyruvate bolus (Figure 1.7) (207). Increased gluconeogenesis is 
a common phenotype in people with T2DM (section 1.2) and is, therefore, consistent with 
the hyperglycaemia observed in Tst–/– mice fed HFD. Plasma insulin concentrations were 
unchanged in HFD-fed Tst–/–mice, demonstrating that insulin deficiency is not responsible 
for these effects (204). Instead the finding of increased gluconeogenesis, which occurs only 
in liver and kidney, suggests that Tst deletion within the liver may be mechanistically linked 
with the whole-body changes in glucose homeostasis. In the mouse Tst is also most highly 
expressed within the liver (208) lending further support to this hypothesis.   
 
 
Figure 1.7 Metabolic dysfunction in Tst–/– mice. A) A glucose tolerance test in C57BL/6N or Tst–/– mice fed 





beginning the test. Following an initial blood glucose measurement (time 0), mice were given a glucose bolus (2 
mg/g body weight) and glucose disposal was measured at the indicated time points. B) Plasma insulin 
concentration in C57BL/6N or Tst–/– mice fed HFD for 6 weeks measured over the course of the glucose tolerance 
test. C) Plasma non-esterified fatty acids concentration in C57BL/6N or Tst–/– mice fed HFD for 6 weeks 
measured over the course of the glucose tolerance test. D) A pyruvate tolerance test in C57BL/6N or Tst–/– 
maintained on control chow diet. A-C) reproduced from Morton et al. (2016) (204), D) Gibbins et al. Masters 
project (207). 
Many of the phenotypes observed in Adipoq-Tst and Tst–/–mice may be explained by 
increased or decreased H2S breakdown, respectively. Increased H2S has been linked to 
various symptoms associated with MetS, including worsened glucose tolerance, increased 
gluconeogenesis and insulin resistance; all of these symptoms have been observed in Tst–/–
mice along with reciprocal phenotypes in Adipoq-Tst mice. As previously demonstrated in 
Ethe1–/– mice, deletion of genes within the H2S breakdown pathway can lead to increased 
H2S concentrations. Morton et al. recently demonstrated similar findings in Tst–/–mice 
showing that  H2S and related species, including HS-, S2- and biologically bound forms of 
these molecules (such as those associated with human serum albumin and haemoglobin), 
referred to as ‘total sulfide’ measured in whole blood by HPLC were significantly increased 
in Tst–/– compared to C57BL/6 mice (Figure 1.8, 200). Therefore, increased or decreased H2S 
signalling represents a plausible mechanistic explanation for the current metabolic 
phenotypes observed in Adipoq-Tst and Tst–/– mice. Investigations directed at the effects of 
H2S on lipid homeostasis and cellular metabolism may lead to greater understanding of Tst 



































Figure 1.8 Total sulfide and thiosulfate (S2O3) detected in whole blood of C57BL/6 and Tst–/– mice. A) Total 
sulfide detected in whole blood of C57BL/6 and Tst–/– mice. B) Thiosulfate detected in whole blood of C57BL/6 
and Tst–/– mice. Thiosulfate was undetectable in C57BL/6 mice therefore it was not possible to test the data using 
unpaired t-test. Whole blood reacted with monobromobimane to derivatise -SH containing compounds to sulfide 
dibimane. Peak identities were assigned using pure chromatography standards. 4 independent biological repeats 
are shown for each genotype. *** indicates p < 0.0001 unpaired Student’s t test. Data was prepared by Martin 
Barrios-Llorena and provided by Dr Roderick Carter/Prof Nik Morton (personal communication). 
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1.5.2 Thiosulfate sulfurtransferase in the vasculature 
Little work has been reported investigating the effect of Tst deletion in the vessels of Tst–/– 
mice, although expression of TST in cardiac vessels has been confirmed by Emerson et al. 
(Figure 1.9, Unpublished observations). As shown by previous work in Cse–/– mice, 
however, decreased H2S signalling within the vasculature can lead to hypertension, a loss of 
endothelium-mediated vasorelaxation and a worsening of atherosclerosis (187,192). Given 
the clear findings of elevated H2S in Tst–/– mice detected in whole blood  (above, 200) the 
vascular function of Tst–/– mice represents a target for further investigation. In addition, the 
effect of Tst deletion on atherosclerotic lesion development in an appropriate model (e.g. 
ApoE–/– mice fed western diet) would be a useful test of the function of Tst in chronic 
vascular disease. 
 
Figure 1.9 TST is expressed in the smooth muscle of cardiac vessels. Fluorescence microscopy of heart 
sections using a nuclear dye (DAPI; blue), and antibodies against CSE (green, upper panel) and TST (green, 
lower panel) enzymes co-localised with smooth muscle marker alpha-SMA (red). The far-right panel shows 




1.6 Hypotheses and aims 
Based on the evidence described above, 2 major hypotheses were proposed in this Thesis. 
1. Deletion of Tst engenders hepatic metabolic dysfunction. 




To test these hypothesis, the following aims were pursued  
 
1. To undertake extensive metabolic phenotyping of Tst–/– and C57BL/6 mice in control 
or high fat diet-fed conditions with a focus on aspects of hepatic metabolism, where 
Tst is most highly expressed. 
2. To investigate vascular function in control and high fat diet-fed Tst–/– and C57BL/6 
mice using isolated arteries to determine whether Tst deletion alters contraction or 
relaxation of the arterial wall. 
3. To determine atherosclerotic lesion formation in an inter-cross of Tst–/– with ApoE–/– 








2.0 Materials and methods 
Unless otherwise stated all reagents were obtained from Sigma-Aldrich, St. Louis, US. 
2.1 Experimental Animals 
2.1.1 Colony maintenance  
Mice were bred, and group housed in a controlled environment at the Biological 
Research Resources department of the University of Edinburgh. Temperature and 
humidity were maintained at 21-22oC and 50%, respectively with a 12-hour diurnal 
light/dark cycle (7am to 7pm). Mice were given ad-libitum access to water and standard 
mouse CRM ‘chow’ (Special Diet Services, Essex, UK) except during fasting or high fat 
feeding experiments (section 2.1.2.) All animal procedures were performed in 
accordance with the animals (scientific procedures) act 1986 and received local ethical 
approval. 
2.1.2 Alteration of diet 
During high fat feeding experiments (details given within results chapters) mice were 
given ad libitum access to either ‘Surwit’ 58% fat, high sucrose diet referred to as ‘high 
fat diet’ (HFD, Research Diets, New Brunswick, US) or ‘Western’ 42% fat, 0.15% 
cholesterol diet (829100, Special Diet Services, Essex, UK).  Within HFD experiments 
standard chow (RM1 diet) was used for control groups. For Western diet fed 
experiments AIN93M 9.4% fat control diet (Special Diet Services, UK) was used for 
control groups. 
2.1.3 Generation of ApoE–/–Tst–/– double knock-out 
Throughout the breeding process genotyping for Tst and ApoE was performed by 
Transnetyx, Cordova, US. B6.129P2-Apoetm1Unc/J mice (ApoE–/–) were initially purchased 
from Charles River, Tranent, UK. These mice are on a C57BL/6J background. Tst–/– mice, 
previously generated (204) as a full Tst deletion (Tsttm1(KOMP)Vlcg) by the University of 
California at Davis knockout mouse project and kindly donated by Prof. Nicholas Morton, 
were initially on a C57BL/6N background (204). To generate double knock-out and ApoE–/–
controls on a uniform C57BL/6J background a speed congenics backcrossing approach was 
undertaken in collaboration with Prof. Simon Horvat.  Initially sex chromosomes were fixed 
to J by crossing ApoE–/– with Tst–/– and selecting obligate heterozygotic Males (Y(6N), 
X(6J)) for a second breeding round with ApoE–/–females. Selection of Tst+/–ApoE–/–female 




Figure 2.1 Breeding strategy for ApoE–/–
Tst–/– double knockout breeding. During the 
initial crosses the sex chromosomes were 
fixed to J subtype through selection of 
specific sexes from litters. Following this 
selection of mice for backcrossing was 
guided using a speed congenics panel 
performed by Prof. Simon Horvat designed to 
identify key differences between N and J 
subtypes and genotyping for Tst and ApoE 
performed by Transnetyx. Once mice were 
found to be J subtype at all genotyped regions 
mice were crossed and double knockouts 
selected. 
During the following rounds of 
breeding a so-called "speed 
congenics" protocol (209) was used. 
The starting population was of ApoE–
/–-; Tst+/– genotype on a mixed 
C57BL/6J/C57BL/6N (N/J) genetic 
background. Though strains N/J are 
genetically very closely related, 
detailed genome sequencing project 
(210) and especially a comprehensive 
genomic and phenotypic comparison 
of the N/J strains (211) identified 
several SNP and copy number variant 
differences as well as significant 
phenotypic differences. In five 
consecutive backcross generations 
parents of the next generations were selected based on their proportion of the N/J genome – 
pairs with the highest proportion of the J genome were chosen for further breeding. Primers 
(Appendix, table 1) for genotype screening were designed in the Primer 3 software 
(http://bioinfo.ut.ee/primer3/) based on the information on polymorphisms found between the 
N/J strains (211). Point mutation loci were screened either by restriction fragment length 
polymorphism assay in agarose gels or Sanger sequencing, while some structural length 
variants by resolving PCR products in high resolution 4% agarose gel electrophoresis. 
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Following completion of the breeding cycles animals were determined as being J substrain at 
all tested mutation loci. Heterozygous mice were then crossed to generate ApoE–/–Tst+/+ and 





2.2 In vivo techniques 
2.2.1 Fasting glucose and insulin 
Mice were fasted for a short period (4-6 hours) with free access to water. A blood sample 
was taken from the tail vein to measure glucose using a OneTouch Ultra glucometer 
(LifeScan, Milpitas, US) and disposable OneTouch testing strips (LifeScan, Milpitas, 
US). Further blood was taken from the tail using a Sarstedt EGTA blood collection tube 
and kept on ice. Following manufacturer’s guidance these samples were then centrifuged 
at 20oC at 10000 g for 5 minutes to isolate plasma. Plasma samples were stored at -80oC 
before insulin was measured following using an Ultra-Sensitive Mouse Insulin ELISA 
kit (Crystal Chem, Zaandam, Netherlands) following manufacturer’s guidance. 
2.2.2 Glucose tolerance test 
Animals were fasted for 4-6 hours with free access to water. A tail nick was made for 
blood sampling and an initial baseline blood glucose taken using disposable glucose 
testing strips and a glucometer. If insulin measurements were being recorded, then a 
blood sample was also taken into a Sarstedt EGTA blood collection tubes and kept on 
ice before later centrifugation and collection/storage of blood plasma. This time point 
was referred to as time 0. Immediately following this 25% glucose dissolved in 0.9% 
saline (0.9 g NaCl/100 ml 18 Ω H2O) was administered via intra peritoneal bolus at a 
dose of 2 mg/g body weight using a 0.3 or 0.5 ml BD Micro-Fine Insulin syringe (BD, 
Madrid, Spain). The disposal of the glucose bolus was measured by taking blood glucose 
concentrations at 15, 30, 60 and 120 minutes post injection. Larger samples for plasma 
collection and insulin measurement were taken as required. 
2.2.3 Insulin tolerance test 
As above animals were fasted for 4-6 hours with free access to water. A tail nick was 
made for blood sampling and an initial baseline blood glucose taken using a glucometer 
and disposable glucose test strips. This sample was referred to as time 0. Immediately 
following this insulin (Humulin, Eli Lilly, Indianapolis, USA) was administered via intra 
peritoneal bolus at a dose of 1mU/g body weight. Further blood glucose measurements 
were performed at 15, 30, 45 and 60 minutes following the bolus to record the effect of 
insulin administration.  
2.2.4 Tail plethysmography  
Systolic blood pressure was recorded in conscious mice using a tail cuff system along with 
automatic recording software (Harvard Apparatus, Cambourne, UK). Briefly, an inflatable 
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cuff and measurement device capable of detecting the reduction of a luminosity signal 
caused by blood flow in the tail vein was passed over the tail. Once a blood flow signal was 
clearly identifiable the measurement program was started. This involved 4 inflation and 
deflation cycles. As the pressure of the cuff became equal to the systolic pressure of the 
mouse this was detected as a reduction and finally cessation of the signal oscillation. 
Deflation was the more accurate measurement (reappearance of the signal was more easily 
visible) and so the 4 measures of systolic pressure during the deflation cycle were used to 
calculate the average systolic pressure for the mouse. Details of the number of measurements 




2.3 Ex vivo techniques 
2.3.1 Plasma lipid profiling 
Mice were fasted with free access to water for 4 hours prior to cull. During this process, 
a terminal blood sample was taken by one of two methods. Primarily blood was 
collected directly into Sarstedt Microvette CB 300 K2E EGTA containing plasma 
sample tubes (Sarstedt, Nümbrecht, Germany) following cull by decapitation. When 
other techniques did not allow for this (e.g. perfusion fixation section 2.7.1.1) mice were 
instead euthanised with an overdose of sodium pentobarbital (Euthatal, Scientific 
Laboratory Supplies, Wilford, UK) given as an intraperitoneal (i.p.) bolus. Following 
cessation of respiration, the abdominal cavity was rapidly opened, and blood sampled 
into a BD Plastipak 1 ml syringe (BD, Madrid, Spain) from the abdominal vena cava. 
This was then transferred to Sarstedt EGTA containing sample tubes for centrifugation. 
Blood samples obtained by either method were centrifuged at 20oC and 10000 g for 5 
minutes according to manufacturer’s guidance to obtain plasma samples. 
Plasma samples were analysed for cholesterol and triglyceride content by Prof. Bart 
Staels and Dr. Anne Muhr-Tailleux as previously described (212). Briefly, samples were 
subjected to gel filtration chromatography using an integrated Alliance HPLC 
separations module (e2695, Waters, Milford, US) to separate lipoproteins based on size. 
Effluent was immediately and continuously mixed with either triglyceride (Infinity 
Triglyceride, Thermo Scientific, Loughborough, UK) or cholesterol (Infinity 
Cholesterol, Thermo Scientific, Loughborough, UK) enzymatic colourmetric detection 
kits at the correct conditions for reaction (as specified in manufacturer’s guidance). The 
optical density was then recorded using a spectrophotometer at the appropriate 
wavelength and the signal turned into a continuous trace i.e. a lipid profile. By 
identification of the lipoprotein peaks (based on their time of emergence from the 
chromatograph) the concentration for each could be calculated. 
2.3.2 Myography 
2.3.2.1 Vessel isolation and mounting 
Mice were euthanised by CO2 asphyxiation and the descending heart and thoracic aorta were 
isolated and removed down to the diaphragmatic insertion. The heart and vessel were 
immediately placed in ice cold physiological salt solution (PSS; 120 mM NaCl, 5 mM KCl, 
1.2 mM MgSO4.7H2O, 25 mM NaHCO3, 1.2 mM KH2PO4, 0.034 mM EDTA, 6 mM glucose 
and 2.5 mM CaCl2.2H2O) and then transferred to a dissection plate coated with matrigel 
allowing the vessel to be securely stretched out and pinned down. Using a dissecting 
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microscope, the adventitial fat was then removed from the aorta using fine forceps and 
spring scissors (Fine Science Tools, Heidelberg, Germany) and the aorta was detached from 
the heart. 2 mm long vascular rings for myography were taken from the region of the aorta 
immediately following the aortic arch. These rings were mounted in the organ baths of a 
multi myography model 610 M wire myograph (Danish Myo Technology, Aarhus, 
Denmark). Briefly, vessels were threaded onto 40 µm tungsten wire (Danish Myo 
Technology, Aarhus, Denmark) and secured between the jaws of the myography supports. A 
second wire was then passed through the lumen of the vessel and secured to the opposing 
support.  
2.3.2.2 Concentration response measurements 
Following mounting the vessels were returned to the myograph which maintained the 
temperature of the baths at 37oC and continuously perfused with 95%O2/5%CO2 (BOC, 
Guildford, UK). A resting tension of 7.38 mN was applied to aortic vessels for 30 minutes by 
adjustment of the micrometer. This has been previously determined as the optimal resting 
force for mouse aorta. Data were recorded by connecting the myography output to a bridge 
amplifier (AD Instruments Powerlab 8/30, AD Instruments, Oxford, UK) and subsequently 
into a computer running LabChart 8 software (AD Instruments, Oxford, UK). Following the 
establishment of a stable resting tension in vessels the myography was zeroed and 3 
measurements were recorded following the addition of high K+ PSS (KPSS; 125 mM KCl, 
1.2 mM MgSO4.7H2O, 25 mM NaHCO3, 1.2 mM KH2PO4, 0.034 mM EDTA, 6 mM glucose 
and 2.5 mM CaCl2.2H2O, aerated continuously with 95% O2/5% CO2). Between each 
stimulation the organ bath was washed with PSS until the vessel had returned to its resting 
tension. The maximal tension after 2 minutes of constriction with KPSS represented the 
vessels ‘baseline constriction’ for normalisation of data. 
Following KPSS stimulation vessels were returned to resting tension and then cumulative 
concentration-response curves to a number of compounds were recorded. If inhibitor 
compounds such as 10-4 M L-NAME and 10-5 M indomethacin were used these were 
incubated for a minimum of 20 minutes before cumulative concentration-response curves 
were recorded. Vasoconstriction responses to 5-hydroxytryptamine (5-HT) and α1-
adrenoreceptor agonist phenylephrine (PE) were recorded in half log steps from 10-9 to 10-4 
M and 10-9 to 10-5 M, respectively. Vessels were washed with PSS and left to return to 
resting tension between responses. For vasodilation responses vessels were preconstricted 
using a concentration of 5-HT to achieve approximately 80% of maximal tension. 5-HT was 
used for this as opposed to PE because it was found in aorta that 5-HT produced larger more 
stable constrictions. Following a stable preconstriction of 5-10 minutes a cumulative 
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concentration-response to vasodilators such as acetylcholine and sodium nitroprusside was 
recorded in half log steps from 10-9 to 10-4 M. Exact protocols are recorded in the relevant 
results section. 
2.3.2.3 Normalisation 
For vasoconstriction agents, the recorded tension of each vessel in response to administration 
of the compounds was normalised to the baseline constriction of that vessel and expressed as 
a percentage. For vasodilation, the response of the vessel was expressed as a percentage of 
the initial tension of the vessel. These data were plotted using GraphPad Prism 5 software 
(Graph Pad Software, La Jolla, US) and 3 variable non-linear regression curve fitting 
performed. From these curves summary data such as EMax (maximal constriction) and EC50 
(concentration eliciting 50% of EMax, also converted to –log(EC50) i.e. pD2 or -Log(IC50) for 
constrictors or dilators, respectively) were calculated automatically. Where responses were 
recorded with and without L-NAME (10-4 M) and indomethacin (10-5 M) the difference 





2.4 Biochemical assays 
2.4.1 Liver triglyceride measurement 
Frozen liver samples (approximately 50 mg) were accurately weighed before transfer to 
a borosilicate glass culture tube (Thermo Scientific, Loughborough, UK). The sample 
was then homogenised in 10 volumes (W/V) isopropanol (20 volumes W/V was used for 
20-week HFD samples) using a mechanical homogeniser (T8.10, IKA Labortechnik, 
Staufen im Breisgau, Germany). Throughout the remainder of the procedure tubes were 
covered with Parafilm (Bemis, Neenah, US) to avoid evaporation of samples. Tubes 
were agitated for 45 minutes on a shaker and vortexed every 10 minutes.  Following this 
samples were centrifuged at 4oC at 835 g for 10 minutes in an Eppendorf 5415 R 
centrifuge (Eppendorf, Stevenage, UK). The supernatant was removed to a fresh glass 
sample tube with a stopper to prevent evaporation. Triglyceride content of the samples 
was detected using Thermo infinity triglyceride reagent (Thermo Scientific, 
Loughborough, UK). The reaction scheme of this enzymatic reagent is shown below:  
1. 𝑇𝑟𝑖𝑔𝑙𝑦𝑐𝑒𝑟𝑖𝑑𝑒𝑠 +  𝐻 𝑂 ⎯⎯⎯  𝐺𝑙𝑦𝑐𝑒𝑟𝑜𝑙 + 𝐹𝑟𝑒𝑒 𝑓𝑎𝑡𝑡𝑦 𝑎𝑐𝑖𝑑𝑠 
2. 𝐺𝑙𝑦𝑐𝑒𝑟𝑜𝑙 + 𝐴𝑇𝑃 
 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯ 𝐺𝑙𝑦𝑐𝑒𝑟𝑜𝑙 3 𝑝ℎ𝑜𝑠𝑝ℎ𝑎𝑡𝑒 + 𝐴𝐷𝑃 
3. 𝐺𝑙𝑦𝑐𝑒𝑟𝑜𝑙 3 𝑝ℎ𝑜𝑠𝑝ℎ𝑎𝑡𝑒 +  𝑂
 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯ 𝐷𝐴𝑃 + 2𝐻 𝑂  
4. 𝐻 𝑂 + 4𝐴𝐴𝑃 + 3,5 𝐷𝐻𝐵𝑆 ⎯⎯⎯⎯⎯⎯⎯ 𝑄𝑢𝑖𝑛𝑜𝑛𝑒𝑖𝑚𝑖𝑛𝑒 𝑑𝑦𝑒 + 2𝐻 𝑂 
Reaction 2.1 Triglyceride assay reaction scheme. 
Following manufacturer’s instructions 7 glycerol standards between 0.25-8 mmol/L were 
made up in isopropanol. 2 µl of standard, sample or isopropanol blank was added to a 96 
well assay plate (Corning Life Sciences, Amsterdam, The Netherlands) before adding 198 
µl of reagent. Samples typically had to be diluted 5-20 times to ensure they were within 
the standard curve. The reaction was left at 37oC for between 20-40 minutes and then 
absorbance measured using a plate spectrophotometer (Molecular Devices OPTImax 
microplate reader and software, Molecular Devices, Wokingham, UK) at 500 nm. All 
standards, samples or blanks were performed in duplicate. Duplicates were analysed for 
%CV values and the mean only included in further statistical analysis if <15%. 
Unknown samples were interpolated from the standard curve and multiplied by their 
dilution factor giving final units of µmol/g liver.  
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2.4.2 Liver glycogen measurement 
2.4.2.1 Glycogen extraction and breakdown 
Frozen liver samples (between 30-90 mg) were accurately weighed and recorded. The 
sample was added to a 1.5 ml Eppendorf tube (Eppendorf, Stevenage, UK) along with 
0.3 ml 30% KOH. Samples were heated to 100oC on a Techne Dri-Block DB-2A 
(Techne, Stone, UK) for 30 minutes with vigorous shaking at 10-minute intervals to aid 
dissociation. Following this 0.1 ml 1M Na2SO4 and 0.8 ml ethanol were added, and 
samples were heated for a further 2-3 minutes. Samples were then centrifuged at 4oC at 
1011 g in an Eppendorf 5415 R centrifuge for 5 minutes. The supernatant was removed, 
and the pellet resuspended in distilled H2O before 0.1 ml 1M Na2SO4 and 0.8 ml ethanol 
were again added, and samples boiled at 100oC for 5 minutes before centrifugation. This 
was repeated a final time to wash the sample. Following removal of the supernatant after 
the final wash the pellet was resuspended in a 10 mg/ml (~1200 U/ml) amyloglucosidase 
enzyme solution dissolved in 0.3 M sodium acetate adjusted to pH 4.8 with HCl. 
Samples were then incubated at 50oC for 2 hours to allow for glycogen breakdown into 
glucose. Quantification of samples was then performed using a standard hexokinase-
based glucose assay. 
2.4.2.2 Hexokinase glucose assay 
The assay was performed following manufacturer’s instructions. Briefly, 7 glucose 
standards were made up between 0.25-5 mg/ml in distilled 18 Ω H2O. Samples were 
diluted in H2O to be within the linear range of the assay. All assays were performed in 
duplicate with the mean taken for further analysis. 2 µl of standard, sample or H2O blank 
were added to the wells of a 96 well plate. A non-enzyme control was included for each 
sample to check for any absorbance caused by the sample itself by replacing the reagent 
mix with distilled water. 198 µl of glucose reagent or H2O was added to each sample and 
left to react for approximately 15 minutes at 20-25oC. Absorbance was then measured 
using a plate spectrophotometer (Molecular Devices OPTImax microplate reader and 
software, Molecular Devices, Wokingham, UK). A samples final absorbance was 
calculated by taking the absorbance of the sample (ASample) – absorbance of its H2O 
control (ASample Blank) – absorbance of the 0 mg/ml glucose control (ABlank) (Absorbance = 




2.4.4 Phosphoenol pyruvate carboxykinase (PEPCK) enzyme activity 
Cytosol samples were obtained from 100 mg unfrozen fresh liver samples by the following 
method. All steps were performed on ice or at 4oC. Liver samples were homogenised in 1.2 
ml SH buffer (250 mM sucrose, 5 mM HEPES, pH 7.4) using a glass Potter Elvehjem 
homogeniser and centrifuged for 15 minutes at 4oC at 13362 g in an Eppendorf 5415R 
centrifuge (Eppendorf, Stevenage, UK). Supernatants were then transferred to a Beckmann 
polycarbonate ultracentrifuge tube (Beckman Coulter, High Wycombe, UK) and centrifuged 
at 195028 g for 30 minutes at 4oC in a Beckman Optima TLX ultracentrifuge (Beckman 
Coulter, High Wycombe, UK). Supernatants were diluted 1:10 and measured for protein 
concentration using Bio-Rad DC protein reagent (Bio-rad, Watford, UK) and following 
manufacturer’s guidance (described in section 2.9). 
  
For the activity assay reactions were prepared on a 96 well plate. All solutions were kept on 
ice throughout preparation. The activity of PEPCK was inferred in this assay from the 
measure of NADH extinction. The reaction scheme is outlined in reaction 2.2. All assays 
were performed in duplicate with the mean taken for further analysis. Fresh 5 mM 
NADH, 3 mM dGDP and 5 mM PEP were prepared along with a CO2 buffer (66 mM 
NaHCO3-, 66 mM HEPES, 1.5 mM MnCl2) and a 1:308 dilution of malate dehydrogenase 
which was diluted in CO2 buffer. 200 μg protein from the cytosol sample (between 10-20 μl), 
10 μl MdeH and 10 μl NADH were added to a variable volume of CO2 buffer up to a final 
volume of 182 μl prior to be being placed in a Tecan infinite M1000 spectrophotometer 
(Script software, Tecan, Reading, UK) which was heated to 37oC. Measurements were set to 
be taken every 30 seconds at 340 nm for 60 minutes to allow for equilibration of the reaction 
and establishment of a baseline rate of extinction. The plate was then removed and placed on 
ice for 30 seconds to slow the reaction before adding 8 μl PEP and 10 μl dGDP and replacing 
the plate. The reaction was followed using the same settings for a further 60 minutes to 
record both a linear rate of decrease and the final plateau. For analysis, the rate for each 
sample was calculated from a linear portion of the curve. 
 
1. 𝑃ℎ𝑜𝑠𝑝ℎ𝑜𝑒𝑛𝑜𝑙 𝑝𝑦𝑟𝑢𝑣𝑎𝑡𝑒 + 𝑑𝐺𝐷𝑃 + 𝐶𝑂  ⎯⎯⎯  𝑂𝑥𝑎𝑙𝑜𝑎𝑐𝑒𝑡𝑎𝑡𝑒 + 𝐺𝑇𝑃 
2. 𝑂𝑥𝑎𝑙𝑜𝑎𝑐𝑒𝑡𝑎𝑡𝑒 + 𝑁𝐴𝐷𝐻 ⎯⎯  𝑀𝑎𝑙𝑎𝑡𝑒 + 𝑁𝐴𝐷  
Reaction 2.2 Phosphoenolpyruvate carboxykinase activity assay reactions. 
2.4.5 TST activity assay 
Reactions were performed in a 96 well plate. 50 µg of protein (collected from tissues as 
described in 2.9) was used in each reaction and a negative reaction containing no protein was 
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also prepared. 50 mM KPO4 and 50 mM NaS2O3 were added to the reaction along with a 
variable volume of 18 Ω H2O to adjust for volume. The reaction (shown below) was started 
with the addition of 50 mM KCN.  
 
1. S2O32- + CN-  SO32- + SCN  
2. SCN + Fe(NO3)3  Fe(SCN)2+ 
Reaction 2.3 Reaction scheme for TST activity assay. 
All assays were performed in duplicate with the mean taken for further analysis. 7 
standards of KSCN were prepared from 0.25-25 mM along with a zero and added to the 
reaction plate. The reaction was incubated at 30oC for a length of time relative to the tissue 
expression of TST. Liver protein reactions were left for 30 minutes whereas aortic protein 
reactions were left for 4 hours. The reaction was stopped with the addition of 10% formalin 
solution (38% formaldehyde) to all wells. An equal volume of acidified iron nitrate (250 mM 
Fe(NO3)/26 % nitric acid) was then added to form the iron complex leading to a colour 
change. Absorbance was then measured at 460 nm using a plate spectrophotometer. The 0 
standard was subtracted from all values and a linear standard curve generated. Following 
further subtraction of the no protein control from the unknown samples the concentrations 
were interpolated from the standard curve.  
2.4.6 Insulin ELISA 
Blood samples were collected in Sarstedt Microvette CB 300 K2E EGTA containing 
plasma sample tubes (Sarstedt, Nümbrecht, Germany) and centrifuged at 20oC at 10000 
g for 5 minutes following manufacturer’s guidance to collect plasma samples. Insulin 
concentration was assayed in plasma samples using an Ultra-Sensitive Mouse Insulin 
ELISA kit (Crystal Chem, Downers Grove, USA) following manufacturer’s instructions. 
All assays were performed in duplicate with the mean taken for further analysis. Briefly, 
5 µl of plasma or provided mouse insulin standards was mixed with 95 µl of sample 
diluent in an antibody coated well of the plate. Plates were then incubated for 2 hours at 
4oC before being washed 5 times using provided wash buffer. 100 µl of anti-insulin 
enzyme conjugate solution was added to wells and left for 30 minutes at 20-25oC to 
react. Following this; plates were washed 7 times using wash buffer before 100 µl of 
enzyme substrate was added to wells. Plates were incubated for 40 minutes at 20-25oC 
avoiding exposure to light before the reaction was stopped through addition of 100 µl of 




spectrophotometer. Following manufacturer’s instructions A630 was subtracted from A450 





2.5 Molecular Biology 
2.5.1 Protein collection 
For tissue homogenisation, fresh tissues were collected and stored on ice or at -80oC for long 
term storage. The required amount of tissue was transferred to either a PeqLab Precellys 2 
ml homogenisation tube (VWR, Lutterworth, UK) or a 2 ml Eppendorf safety lock tube 
(Eppendorf, Stevenage, UK). Depending on expected protein yield a variable amount of 
protein lysis buffer (50 mM Tris, 270 mM sucrose, 50 mM NaF, 1 mM EDTA, 1 mM 
EGTA, 1% Triton-X) with added cOmplete ULTRA protease inhibitor tablets (Roche, 
Mannheim, Germany) and phosphatase inhibitors (10 mM β-glycerophosphate, 1 mM Na 
Orthovanadate, 5 mM Na pyrophosphate, 0.1% β-mercaptoethanol, all added fresh on day of 
use) was used. PeqLab Precellys tubes were used in conjunction with a PeqLab Precellys 24 
tissue homogeniser (VWR, Lutterworth, UK). The standard protocol for mechanical 
homogenisation was 2 x 20 seconds at 6500 RPM.  
For homogenisation of samples using Eppendorf tubes a ball bearing was transferred to the 
tube before placing the tube into a Retch Mixer Mill MM301 tissue homogeniser (Retsch, 
Haan, Germany) for 30 seconds at 30 Hz. This process was repeated as required until the 
tissue was completely homogenised. Following either homogenisation technique samples 
were centrifuged for 10 minutes at 16168 g at 4oC. The supernatant was then collected as the 
protein sample. If necessary (due to contamination with lipid content for example) samples 
were centrifuged again to aid removal.  
For cells either 0.1 ml or 3 ml of protein lysis buffer was added to 6 well cell plates (Corning 
Life Sciences, Amsterdam, The Netherlands) or 75 ml culture flasks (Corning Life Sciences, 
Amsterdam, The Netherlands), respectively. Cells were then physically lysed by scraping 
with either pipette tips or a cell scraper (Corning Life Sciences, Amsterdam, The 
Netherlands). The solution was collected and centrifuged for 10 minutes at 16168 g at 4oC to 
remove any crude cell debris.  
2.5.2 Protein quantification  
Briefly, samples were diluted to ensure absorption was within the linear standard curve (0-
1.2 mg/ml, made up using Bovine Serum Albumin). All assays were performed in 
duplicate with the mean taken for further analysis. 5 µl of standard or sample was added to 
a 96 well plate (96 well ELISA Microplates, Greiner bio-one). 25 µl of solution A was then 
added to each sample which were then briefly mixed. 200 µl of solution B was then added to 
all wells and the plate was incubated for a minimum of 15 minutes at room temperature. 
Absorption at 750 nm was then measured using a plate spectrophotometer (Molecular 
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Devices OPTImax microplate reader and software, Molecular Devices, Wokingham, UK). 
Sample concentrations were interpolated from the standard and adjusted for dilution factors. 
Following quantification cytosol samples were used immediately in the PEPCK activity 
assay. 
2.5.3 mRNA quantification 
2.5.3.1 mRNA isolation 
RNA was collected from tissue or cells using Qiazol reagent (Qiagen, Hilden, Germany). All 
steps were performed on ice or at 4oC unless otherwise stated. For tissues, the sample was 
placed in 500 µl Qiazol in a PeqLab Precellys homogenisation tube or a 2 ml Eppendorf with 
a ball bearing. The tissue was then physically homogenised using either a PeqLab Precellys 
24 homogeniser (for Precellys tubes) or a Retch Mixer Mill MM301 tissue homogeniser. For 
cells, a minimal volume of Qiazol was used (approximately 300 µl) to ensure well coverage 
and cells were physically lysed by scraping. Following this samples from tissue or cells were 
treated identically.  
Samples were centrifuged at 16168 g for 10 minutes at 4oC to remove any crude debris. The 
supernatant was transferred to a fresh 1.5 ml Eppendorf tube and 1:5 volume of chloroform 
was added. The sample was thoroughly mixed through inversion and then left for 5 minutes 
at room temperature to separate. The samples were centrifuged at 16168 g for 5 minutes at 
4oC and then the aqueous (top) layer was carefully transferred to a new Eppendorf tube. An 
equal volume of isopropanol was added and mixed thoroughly with the sample. Samples 
were then centrifuged to collect the precipitated RNA for 10 minutes at 16168 g at 4oC. The 
pellet of RNA was washed twice by removing the supernatant and resuspending the pellet in 
70% ethanol made with DEPC treated distilled water. Finally, the ethanol was removed, and 
the pellet allowed to air dry briefly. The pellet was then dissolved in 50 µl DEPC treated 
distilled water and the solution was quantified for RNA content using a ND-1000 Nanodrop 
spectrophotometer (Nanodrop, Thermo Scientific, Loughborough, UK). 
2.5.3.2 Reverse transcription 
RNA samples were used for reverse transcription and quantitative real-time polymerase 
chain reaction (qRT-PCR) for mRNA quantification. Initial RNA samples were diluted to an 
appropriate concentration and reverse transcribed using Qiagen QuantiTect Reverse 
Transcription Kit (Qiagen, Hilden, Germany) following manufacturer’s guidance. Briefly, 
for each sample a known amount of RNA (300 – 1000 ng) was added to a fresh 1.5 ml 
Eppendorf. A control sample which would not receive the reverse transcription enzyme was 
also prepared using RNA from a mixture of random samples. The samples were then 
incubated with genomic DNA Wipeout buffer and a variable volume of RNase free water at 
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42oC for 2 minutes before being placed on ice. A master mix containing Quantiscript 
Reverse Transcriptase enzyme, Quantiscript RT Buffer and RT Primer Mix was prepared 
and the appropriate volume added to each sample. The reaction was then incubated for 30 
minutes at 42oC. To terminate the reaction, the temperature was increased to 95oC for 3 
minutes at the end of the reaction. Finally, samples were centrifuged briefly (<20 seconds) to 
collect them. This sample represented the ‘neat’ cDNA samples. To generate a standard for 
RT-PCR analysis approximately 4-5 µl was taken from each cDNA sample and added to a 
pooled standard. This standard was diluted 1:4 for use in RT-PCR. The first standard was 
assigned the value 256 and then serially diluted 1:2 to generate standards: 256, 128, 64, 32, 
16, 8, 4. The remaining cDNA in the samples was diluted 1:10 for use in RT-PCR. All 
standards and samples were stored at 4oC. 
2.5.3.3 Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
For RT-PCR 2 µl of standard, sample or reverse transcription control was pipetted onto a 
384 well RT-PCR compliant wellplate (384 well lightcycler plate, Sarstedt, Nümbrecht, 
Germany). A no template control (RNAase free water) was also included as a final standard. 
All reactions were run in triplicate and the mean used for further analysis. Tst 
(Mm01195231_m1), Tbp (Mm01277042_m1) and Gapdh (Mm99999915_g1) Taqman assay 
probes were obtained from Applied Biosystems (Thermo Scientific, Loughborough, UK). A 
master mix for each gene was made up using the Taqman probe, DEPC treated H2O and 
qRT-PCR master mix (PerfeCTa FastMix, Quantabio, Beverly, USA) per reaction. 8 µl of 
gene specific master mix was added to each sample. The plate was then sealed using a plastic 
cover (Sarstedt, Nümbrecht, Germany) and centrifuged using a plate centrifuge (LMC-
3000, Grant-Bio, Shepreth, UK) at 560 g for 2 minutes at 20-25oC. The wellplate was added 
to a Roche Lightcycler (Lightcycler 480, Roche, Mannheim, Germany) RT-PCR machine 
and a standard FAM hydrolysis protocol run. The quantification segment of the protocol 
consisted of a repeated amplification cycle where temperature was cycled to 95oC for 
denaturing (to a single strand), to 60oC for primer annealing, and finally to 72oC for 
elongation by Taq polymerase. This was repeated for 50 cycles. Based on the standard curve 
which was recorded and calculated the Roche Lightcycler software the expression value for 
unknown samples was automatically interpolated. Accuracy of the triplicates Ct values 





2.6 In vitro techniques 
2.6.1 Primary hepatocyte isolation and culture 
Primary hepatocytes were isolated from mouse liver using a modified protocol from the 
University of Santa Cruz. Briefly, mice were euthanised using CO2 before rapid dissection to 
expose the portal vein and thoracic inferior vena cava. The portal vein was then cut followed 
immediately by cannulation of the vena cava. Perfusion with Liver Perfusion Media (LPM, 
140 mM NaCl, 2.6 mM KCl, 0.28 mM Na2HPO4, 5 mM glucose, 10 mM HEPES, 0.5 mM 
EGTA) was driven by a peristaltic pump (Minipuls 2, Gilson, Dunstable, UK) for 10 
minutes. During this time, the liver visibly cleared of blood. Following this the perfusion was 
switched to Liver Digestion Media (LDM, 140 mM NaCl, 2.6 mM KCl, 0.28 mM Na2HPO4, 
5 mM glucose, 10 mM HEPES, 5 mM CaCl2) containing 100 U/ml type I collagenase 
(Worthington Biochemical corporation, Lakewood, US) for between 5-7 minutes depending 
on the response of the liver to the collagenase. Once the liver was sufficiently digested the 
perfusion was returned to LPM for 10 minutes to flush the liver of collagenase. The liver was 
then excised and transferred to DMEM D5546 media containing 10% Hyclone fetal calf 
serum, 1% Penicillin streptomycin and 8 mM L-glutamine (all Invitrogen, Carlsbad, USA).  
Isolation of the cells was then performed in sterile conditions using a BioMAT2 cell culture 
flow hood (Contained Air Solutions, Manchester, UK) and aseptic technique. The liver was 
transferred to a petri dish and physically manipulated with forceps to encourage cells to 
dissociate into the media. This media was then filtered using a Fischerbrand 100 µm sterile 
cell strainer filter (Thermo Scientific, Loughborough, UK) to remove any crude tissue and 
transferred to a clean 50 ml CellStar tubes (Greiner bio-one, Kremsmünster, Austria). 
Following this, cells were collected by centrifugation at 216 g at 20-25oC in a Heraeus 
Megafuge 1.0 R (Thermo Scientific, Loughborough, UK) for 5 minutes. The supernatant was 
removed, and the cells were resuspended in 10 ml DMEM before repeated centrifugation to 
wash the preparation. Cells were again resuspended in 10 ml DMEM media. A 50% Percoll 
solution was prepared from 100% commercially available Percoll equalised with DMEM by 
addition of 11 ml 10x DMEM media and mixed 1:1 with 1x DMEM. 50% Percoll was added 
underneath the cell containing suspension creating a 2-layered solution. This was centrifuged 
at 723 g for 15 minutes at 20-25oC. Pelleted cells represented viable primary hepatocytes. 
The layer of cells contained at the border of the Percoll and DMEM were dead or not 
hepatocytes and these were removed and disposed of with the rest of the supernatant.  Any 
remaining Percoll was removed by twice washing the cells through centrifugation collection 
resuspension in DMEM media. The final cell pellet was resuspended in 5 or 10 ml DMEM 
media depending on size. A sample was taken from the suspension and mixed 1:1 with 
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Trypan blue stain for dead cells. The number and viability (live cells/total cells x 100) of the 
preparation was then counted using an Improved NeuBuyer chamber BS.748 (Hawksley, 
Lancing, Sussex) in preparation for cell seeding. Typical preparations resulted in 20-30 
million viable cells with a viable percentage > 85%. 
2.6.2 Seahorse extracellular flux analysis 
Primary hepatocytes were seeded in Seahorse XFe24 V7 cell culture microplates 
(SeahorseBio, Copenhagen, Denmark). Optimisation experiments determined the optimal 
seeding density which was then standardised at 10,000/well. The microplates used for 
primary hepatocyte experiments were pre-coated with rat tail collagen at a concentration of 
10 µg collagen/well diluted from a stock solution with 0.1 M sterile acetic acid. Following 
coating (a minimum of overnight) any remaining acid was removed by washing with sterile 
Dulbecco’s Phosphate Buffered Saline (DPBS) before the plates were used for cell culture.  
Based on manufacturer’s guidance cells were seeded initially in 200 µl DMEM media 
containing 10% FCS, 1% P/S and L-Glutamine. This was then topped up to 500 µl after 
approximately 4 hours and the plates were then left overnight in a 37oC cell culture 
incubator. On the day of the experiment Seahorse mitochondrial stress test media (Seahorse 
assay media, 10 mM glucose, 2 mM Na pyruvate) media was prepared and pH adjusted to 
7.35 ± 0.5. Compounds from Seahorse mitochondrial stress test kits (SeahorseBio, 
Copenhagen, Denmark) were prepared using the appropriate volume of media according to 
manufacturer’s instructions. Cells were washed 3 times with Seahorse media before a final 
500 µl of Seahorse media was added to wells. Plates were then incubated for a minimum of 
30 minutes at 37oC in a Techne Hybridiser HB-1D oven (Techne, Stone, UK) to allow for 
CO2 depletion.  
Tests were performed using standard measurement and injection protocols. An initial 12-
minute equilibration period was followed by a series of measurement cycles consisting of 3 
minutes mixing, 2 minutes waiting and 3 minutes measuring. This measurement cycle was 
repeated 3 times for basal respiration and then 3 times following the addition of each 
compound. The mitochondrial stress tests injections were oligomycin, FCCP and 
antimycin/rotenone. The concentrations used for the compounds are given in results 
chapters. Raw data responses from each well were normalised to relative protein 
concentration measured using the sulforhodamine B assay (SRB, described in section 2.6.3) 
using Wave desktop software. Following this data were collected and averaged (typically 10 
wells/genotype) to produce a single value at each measurement time for each biological 











Figure 2.2 Standard Seahorse Mitochondrial stress test with calculated parameters. A standard 
mitochondrial stress test protocol with example data. The marked columns show the metabolic variables which 
can be calculated from the test. 
Respiration parameter Description 
Basal Initial mitochondrial respiration. Calculated by subtracting ‘non-
mitochondrial respiration’ from the first measurements. 
ATP production Mitochondrial respiration which is coupled to H+ flow through ATP synthase 
(complex V). Calculated by subtracting respiration after oligomycin (a 
complex V inhibitor) addition from basal respiration. 
Proton leak Respiration which is not coupled to ATP synthesis and occurs despite 
inhibition of complex V and therefore represents ‘leak’ of protons back across 
the mitochondrial membrane. Calculated by subtracting non-mitochondrial 
respiration from respiration occurring following oligomycin addition. 
Maximal respiration The maximal capacity for respiration within the samples wells. Established by 
allowing unlimited leak of protons across the mitochondrial membrane 
following FCCP addition. Calculated by subtracting non-mitochondrial 
respiration from the respiration achieved following FCCP addition. 
Spare capacity The additional respiration above basal that can be achieved through FCCP 
addition. Calculated by subtraction of basal from maximal respiration 
Non-mitochondrial 
respiration 
Consumption of oxygen which is not as a result of mitochondrial respiration. 
Calculated following the addition of antimycin A (complex III) and rotenone 
(complex I) inhibitors to completely inhibit mitochondrial electron transport 
chain activity. 
Table 2.1 A description of mitochondrial respiratory parameters determined through Seahorse 
extracellular flux analysis. 
2.6.3 Sulforhodamine B relative protein assay 
Following completion of Seahorse tests cells were fixed using 50% trichloroacetic acid 




minutes at 4oC cells were washed 10 times using tap water. Plates were dried in a 37oC oven. 
50 µl of SRB reagent (0.4% SRB dissolved in 1% acetic acid) was then added to bottom of 
wells and mixed to ensure coverage. Plates were incubated at room temperature for 30 
minutes. Plates were then washed 4 times with 1% acetic acid to remove any excess SRB. 
Finally, bound SRB was released by adding 200 µl 10 mM Tris buffer (pH adjusted to 10.5). 
Samples were left for a minimum of 30 minutes to allow release of the SRB stain. The 
solution within the well was mixed using a pipette before a 100 µl sample was taken and 
transferred to a Costar 96 well assay plate (Corning Life Sciences, Amsterdam, The 
Netherlands) for measurement. Absorbance readings were measured using a plate 
spectrophotometer at 540 nm. Absorbance readings were used for a relative normalisation 
(i.e. no quantification was performed as this was not practical for the experimental design) 
however, an optimisation experiment showed that absorption at 540 nm was linear between 





2.7.1 Optical projection tomography 
2.7.1.1 Perfusion fixation and dissection 
Mice were euthanised with an overdose of sodium pentobarbital (Euthatal) given as an i.p. 
bolus. Once toe pinch and corneal reflexes were absent the heart was rapidly exposed, and a 
cannula placed into the left ventricle. The right atrium was cut, and perfusion begun with 
PBS containing 20 units Heparin. Perfusion was driven by a peristaltic pump at a rate of 5 
ml/min for approximately 2 minutes to clear the vessels and tissues of blood. Once this had 
been completed the perfusion was switched to 4% formalin solution (38% formaldehyde). 
Perfusion was continued for approximately 30 seconds after movement was seen in the 
extremities (a signature of muscle fixation).  The aortic arch along with the brachiocephalic, 
left common carotid and left subclavian artery was cleaned of fat and dissected before being 
transferred and stored in 4% formalin solution.  
2.7.1.2 Embedding and scanning 
Arches were embedded in 1.5% agar (Ultrapure LMP agarose, Invitrogen, Carlsbad, UK) for 
scanning. The agar solution was heated to liquid form and drawn up into 1 ml syringes with 
the tapered end removed. The aortic arch was then placed into the liquid agar and positioned 
in the centre. Syringes were chilled for approximately 5 minutes until the agar had become 
solid. The block of agar was then extruded from the syringe and placed into 50 ml 100% 
ethanol for dehydration. Following a minimum of 2-days dehydration agar blocks were 
transferred to benzyl alcohol/benzyl benzoate solution (BABB; 1:2 benzyl alcohol/benzyl 
benzoate) to increase the tissues transparency. Tissues remained in BABB for several weeks 
to allow for bubbles within the arches to escape. Once this process had been completed the 
agar blocks were mounted onto a magnetic stage for placement into a Bioptonics 3001 
optical projection tomography scanner (Bioptonics, Edinburgh, UK). Using SkyScan 
software (Bruker MicroCT, Kontich, Belgium) tissues were positioned within the field of 
view, focussed and exposure in the GFP channel was adjusted to reduce areas of signal 
above maximum. A 360o scan was then performed in the GFP channel in increments of 0.9o. 
360o TIFF files were reconstructed using NRecon GPU (Bruker MicroCT, Kontich, 
Belgium) software into 2D slices. CTan software (Bruker MicroCT, Kontich, Belgium) was 
then used to quantify the 3D volume of atherosclerotic lesions in the brachiocephalic branch 
between the emergence of the vessel and the bifurcation into the right common carotid and 
right subclavian arteries. This was performed by defining a region of interest (the slices of 
the area within the brachiocephalic branch) and then drawing areas of interest around the 
lumen of the vessel onto these slices. Through adjustment of the signal threshold the 
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software could detect the lesion within this area. Following assignment of areas of interest 
along the length of the region of interest the software was then able to calculate the volume 
of the vessel (total volume of interest) and the volume of the lesion (total object volume) 




2.8 Statistical analysis 
Detailed statistical methods are described in the results chapters. Statistical tests were 
performed using GraphPad Prism 5 software except for MANOVA analysis (glucose, insulin 
tolerance tests) which was performed using MiniTab 18 software (Minitab, Coventry, UK).  








3.0 The effects of Tst deletion on hepatic energy metabolism 
3.1 Introduction 
Dysfunction of metabolic tissues such as liver, adipose tissue and skeletal muscle is linked to 
the development of a number of diseases including diabetes, dyslipidaemia and steatosis of 
the liver (35,213). Many of these disorders occur collectively in what is termed the 
‘metabolic syndrome’ (3). Metabolic syndrome is commonly associated with obesity (2). 
The rate of obesity is rising in both developed and developing nations (109) and, therefore, 
research aimed at reducing obesity rates or combatting the metabolic syndrome is of great 
importance.  
3.1.1 Genetic leanness and Tst 
Recent research undertaken by Morton et al. investigated the contrasting phenotype of 
‘leanness’, based upon the idea that some individuals remain intrinsically (genetically) leaner 
than others despite modern calorie-dense diets (214). Genetic investigations in polygenic 
lean and fat mice, which were bred over many generations for divergent fat mass, led to the 
identification of thiosulfate sulfurtransferase (Tst) as a candidate adipose tissue-specific ‘lean 
gene’. Adipose Tst mRNA and protein levels were inversely correlated with adiposity across 
a large number of rodent strains and in several human populations (204). Overexpression of 
Tst in the adipose tissue of C57BL/6N mice (Adipoq-Tst mice) led to obesity-resistance in 
the face of high fat diet (HFD) exposure. This was associated with improved glucose 
homeostasis and insulin sensitisation in adipose tissue and  muscle, as well as increased fat 
oxidation in liver compared to C57BL/6N littermates (204). 
3.1.2 The metabolic consequences of Tst deletion 
In further experiments using mice with global Tst deletion (Tst–/–) Morton et al. found that 
while weight gain on control or HFD appeared to be unchanged Tst–/– mice fed HFD for 6 
weeks exhibited worsened glucose tolerance and failure to suppress non-esterified fatty acids 
(NEFA) across the glucose tolerance period, indicative of peripheral insulin resistance (204). 
This finding was consistent with the idea that TST maintains normal metabolic function in 
conditions of nutrient excess, such as obesity induced through HFD. However, TST 
expression is >20-fold higher in liver than in adipose tissues (208) suggesting that hepatic 
TST also contributes to metabolic homeostasis. Consistent with this, chow-fed Tst–/– mice 
fasted for 16 hours exhibited increased blood glucose concentrations in response to a 
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pyruvate bolus, suggesting increased hepatic gluconeogenesis in Tst–/– mice (Figure 3.1) 
(207)).  
Figure 3.1 Increased gluconeogenesis in control fed Tst–/– mice. A pyruvate tolerance test in C57BL/6N or Tst–
/– maintained on control chow diet. Mice were fasted for 16 hours prior to beginning the test. Following an initial 
blood glucose measurement (time 0) mice were given a pyruvate bolus (1.5 mg/g body weight) and glucose 
concentration was measured repeatedly at the indicated time points. Data are presented as Mean ± SEM. n = 9 
(C57Bl/6N), 8 (Tst–/–). Data were tested using Repeated Measures ANOVA with Bonferroni post-hoc testing. ** 
indicates p < 0.01 compared to C57BL/6N mice (207).  
3.1.3 Tst–/– mice exhibit elevated blood sulfide levels.  
The cause of altered metabolic function in Tst–/– mice is currently unknown. However, TST 
has recently been linked to the oxidative breakdown of the gasotransmitter hydrogen sulfide 
(H2S) (168,169). Consistent with this suggestion initial studies in Tst–/– mice have found that 
H2S, detected in whole blood samples by high performance liquid chromatography, is 
increased in Tst–/–  compared to C57BL/6 mice ((204) section 1.5.1). Elevated H2S signalling 
within the liver is linked to diabetes and increased gluconeogenesis but, perhaps 
counterintuitively, reduces liver steatosis through improved lipid metabolism (171,173). 
Elevated H2S therefore represents an intriguing possible mechanism for the metabolic 































3.1.4 Hypothesis and Aims 
In this chapter, it was hypothesised that: The diabetogenic phenotype in Tst–/– mice is 
driven by major defects in hepatic glucose metabolism and lipid metabolism. 
Aims 
 To determine whether Tst deletion negatively impacts hepatic glucose metabolism 
including, gluconeogenesis, glycogen storage and whole-body glucose homeostasis 
in short (6 week) and long (20 week) term HFD fed Tst–/–and C57BL/6 mice. 
 To determine whether Tst deletion induces mitochondrial dysfunction of cellular 
metabolism in C57BL/6 and Tst–/– hepatocytes. 
 To determine whether Tst deletion negatively impacts hepatic lipid metabolism 
including any effects on lipoprotein secretion in short (6 week) and long (20 week) 




3.2 Experimental Design 
3.2.1 Assessment of metabolic function in Tst–/– mice fed control or high fat diet 
Body weight recording, glucose and insulin tolerance tests and blood collection at 
termination were performed with Prof. Nicholas Morton, Dr Rod Carter and Ms. Clare Mc 
Fadden. Quantification of plasma cholesterol and triglyceride content was performed by 
Prof. Bart Staels and Dr Anne Muhr-Tailleux. PEPCK activity quantification, liver glycogen 
and triglyceride measurement, and all data analysis (including glucose and insulin tolerance 
test, plasma cholesterol and triglyceride data) was undertaken independently. C57BL/6 or 
Tst–/– mice maintained in controlled conditions by the Central Biological Services 
department (section 2.1) of the University of Edinburgh were given ad libitum access to 
either CRM ‘chow’ diet or 58% fat (kcal) ‘Surwit’ sucrose diet (HFD) for 6 or 20 weeks 
(Figure 3.2). The number of biological replicates is reported in results figure legends. 
Figure 3.2 Experimental design of investigations into the metabolic consequences of Tst deletion in mice fed 
control and high fat diet. Two independent dietary intervention studies were conducted. Firstly, a 6-week 
feeding study matched to the previous work performed by Morton et al., was performed to investigate hepatic 
glucose metabolism in greater detail and examine any changes in lipid metabolism. Secondly, a longer-term 20-
week study was performed to test the effects of Tst deletion in severe obesity. During both studies mice were 
given ad libitum access to control CRM ‘chow’ diet or 58% fat (kcal) ‘Surwit’ sucrose HFD (215). The 
experimental outcomes are highlighted in bold, details of the methods can be found in section 2. All data except 
glucose and insulin tolerance tests were tested statistically within study groups (i.e. independently within the 6 
and 20-week studies) using 2-way ANOVA with Bonferroni post-hoc testing. Glucose and insulin tolerance test 
data were tested with a General Linear Model due to the number of factors required for testing (genotype, diet, 
time). CD; control diet, HFD; high fat diet. Biological replicates (n numbers) are reported in the relevant figure 
legends within section 3.3. 
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3.2.2 Assessment of mitochondrial respiration in Tst–/– hepatocytes 
Nutrient metabolism is fundamentally regulated by the cellular energy status of the cell. This 
is comprised of two major components, mitochondrial respiration (largely linked to ATP 
generation) and glycolysis. These processes are disturbed in diabetes (216,217) and, as such, 
represent plausible candidates for the diabetogenic phenotype of Tst–/– mice. To assess 
mitochondrial function in Tst–/– mice compared to C57BL/6 controls, we isolated primary 
hepatocytes (described in 2.6.1) from control diet fed C57BL/6 and Tst–/– mice and 
performed a mitochondrial stress test using the Seahorse Extracellular Flux analyser (Figure 
3.3). Glycolysis stress tests were not performed, as a pilot study showed that glycolysis was 
extremely low in the cultured hepatocytes and thus could not be accurately measured (data 








































Figure 3.3 Experimental design of investigations into mitochondrial respiration in C57BL/6 and Tst–/– 
primary hepatocytes. The outcome of the experiment was O2 consumption during the Seahorse extracellular 
flux mitochondrial stress test. All details of methods can be found in the relevant materials and methods sections 
(section 2). Experiments were performed in a pairwise fashion i.e. 1 C57BL/6 and 1 Tst–/– mouse were processed 
and analysed together. Following normalisation mitochondrial stress test summary data were calculated as 





3.3.1 Tst deletion results in decreased body weight on control diet 
Weekly body weight recording revealed that final body weights were lower in 6-week 
control diet-fed Tst–/– mice than in C57BL/6 controls (Figure 3.4A, Bonferroni post-hoc 
p<0.05). No significant difference was noted in 20-week control diet fed Tst–/– mice. 6 or 20-
week HFD feeding caused an increase in body weight in C57BL/6 mice. There was no 
difference in the response of Tst–/– mice to HFD at either time point; both genotypes gained 
similar weight with the HFD intervention (Figure 3.4A&B, 6-week diet). 
6 weeks of HFD feeding led to an increase in liver/body weight indicating a larger liver 
compared to the animal’s body weight. Tst–/– mice appeared to have greater liver/body 
weight ratio under control diet-fed conditions, leading to a significant interaction of diet and 
genotype (Figure 3.4C) however, this increase was not significant by post-hoc testing.  No 






































Diet p = 0.005





























































































































Interaction p = 0.04

























Figure 3.4 Body weight and liver/body weight ratio in C57BL/6 and Tst–/– mice fed chow or 58% high fat 
diet (HFD) for 6 or 20 weeks. This work was performed with Dr Roderick Carter and Ms. Clare Mc Fadden. 
Analysis by MG. A) Final body weights for C57BL/6 and Tst–/– mice fed control or HFD for 6 weeks. B) Final 
body weights for C57BL/6 and Tst–/– mice fed control or HFD for 20 weeks. C) Liver weight normalised to body 
weight (Liver/body weight) in C57BL/6 and Tst–/– mice fed control or HFD for 6 weeks. D) Liver/body weight in 
C57BL/6 and Tst–/– mice fed control or HFD for 20 weeks. Data are presented as Mean ± SEM. n = for 6 
(C57BL/6 CD), 6 (Tst–/– CD), 10 (C57BL/6 HFD), 11 (Tst–/– HFD) for 6-week data, n = 8 (C57BL/6 CD), 8 (Tst–
/– CD), 7 (C57BL/6 HFD), 8 (Tst–/– HFD) for 20-week data. Data were compared using 2-way ANOVA and 




3.3.2 Tst deletion exacerbates the effect of long term HFD feeding on glucose 
intolerance 
To test for changes in glucose homeostasis in Tst–/– mice, a glucose tolerance test (GTT) was 
performed near the end of long term dietary exposure to HFD (18 weeks of feeding).  No 
difference was found in glucose tolerance between control diet fed C57BL/6 and Tst–/– mice 
(Figure 3.5A). HFD feeding led to worsened glucose tolerance (blood glucose concentrations 
reached higher peaks and took longer to normalise) in both C57BL/6 and Tst–/– mice (Figure 
3.5A). However, it was also noted that Tst deletion exacerbated this effect overall i.e. the 
worsening of glucose tolerance was greater in Tst–/– mice than in C57BL/6 controls as 
demonstrated by the significant interaction of genotype and diet (p=0.04) although no 
specific time point was different by post-hoc testing (Figure 3.5A). 
Blood insulin concentrations were also measured in samples taken over the time course of 
the glucose tolerance test to give insight into the endogenous insulin secretory response 
(early phase 0-15 minutes) and insulin clearance/resistance (15-120 minutes) in HFD-
induced metabolic dysfunction. HFD feeding led to an increase in blood insulin 
concentrations over the entire time course of the GTT in both C57BL/6 and Tst–/– mice. 
However, on both chow diet and HFD Tst–/– mice demonstrated an overall reduction in blood 
insulin concentration (General linear model ANOVA genotype p < 0.0001) although no 
specific time points was different by post-hoc testing (Figure 3.5B).  
 
 
Figure 3.5 Glucose tolerance test along with blood insulin concentrations in C57BL/6 and Tst–/– mice fed 
control or HFD for 20 weeks. This work was performed with Prof. Nicholas Morton, Dr. Roderick Carter, Ms. 
Rhona Aird and Ms. Clare Mc Fadden. Intraperitoneal injection was performed by NM, blood sampling was 
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tolerance test (GTT) performed in C57BL/6 and Tst–/– mice fed control or HFD for 18 weeks. Mice were fasted 
(with free access to water) for 6 hours prior to the test. Following an initial blood glucose measurement mice 
were given a glucose bolus (2 mg/g body weight) at time 0 and glucose disposal was monitored through repeated 
blood glucose measurement at times 15, 30, 60 and 120 minutes. B) Blood insulin concentrations measured over 
the time course of the GTT. Data are presented as Mean ± SEM. n = 6 (C57BL/6 CD), 8 (Tst–/– CD), 6 (C57BL/6 
HFD), 8 (Tst–/– HFD). Data were tested using General Linear Model ANOVA (diet, mouse number, genotype and 




3.3.3 Tst deletion accentuates the blood glucose decrement in response to insulin 
bolus  
To assess the effect of Tst deletion on changes to whole body insulin sensitivity, an insulin 
tolerance test (ITT) was performed following 19 weeks of feeding with control or HFD. No 
differences were found in the response of control fed C57Bl/6 and Tst–/– to the insulin bolus. 
Consistent with the changes observed in the glucose tolerance test, HFD feeding led to an 
increase in blood glucose concentrations over the time course of the ITT in C57BL/6 mice 
(Figure 3.6). This effect was exacerbated by Tst deletion over the time course of the ITT; i.e. 
the increase in blood glucose concentrations was greater in Tst–/– mice fed HFD compared to 
C57BL/6 mice as shown by the significant interaction of genotype and diet (General linear 
model ANOVA genotype diet interaction p =0.001). However, no specific time point was 
different between HFD fed C57BL/6 and Tst–/– mice by post-hoc testing (Figure 3.6).  
Further to this, the decrease in blood glucose (decrement) induced by the insulin bolus was 
calculated at 15 and 30 minutes (concentrations mostly plateaued after this time) to assess 
the response to insulin (Table 3.1). In both C57BL/6 and Tst–/– mice, HFD feeding resulted in 
an attenuated decrement at 15-minutes compared to control diet-fed mice. There were no 
differences between the genotypes in the response at the 15-minute point (Table 3.1).  
HFD feeding did not result in an altered 30-minute blood glucose decrement in either 
C57BL/6 or Tst–/– mice. However, overall in Tst–/– mice the blood glucose decrement at 30 
minutes was found be greater compared to C57BL/6 mice (2-way ANOVA genotype p = 
0.01) although neither diet group was individually different from C57BL/6 mice by post-hoc 






















Figure 3.6 An insulin tolerance test performed in C57BL/6 and Tst–/– mice fed control or HFD for 19 
weeks. This work was performed with Prof. Nicholas Morton, Dr. Roderick Carter and Ms. Clare Mc Fadden. 
Intraperitoneal injection was performed by NM, blood sampling was performed equally by MG, RC and CM. All 
analysis was done by MG. Mice were fasted (with free access to water) for 6 hours prior to the test. Following an 
initial blood glucose measurement, mice were given an insulin bolus (1 mU/g body weight) at time 0 and the 
suppression of blood glucose monitored through repeated blood glucose measurement at times 15, 30, 45 and 60 
minutes. n = 8 (C57BL/6 CD), 7 (Tst–/– CD), 7 (C57BL/6 HFD), 8 (Tst–/– HFD). Data were tested using General 
Linear Model ANOVA (diet, mouse number, genotype and time factors). CD; Control diet, HFD; High fat diet. 
 
Table 3.1 Blood glucose decrements during an insulin tolerance test in C57BL/6 and Tst–/– mice fed control 
or HFD for 19 weeks. This work was performed with Prof. Nicholas Morton, Dr. Roderick Carter, Ms. Rhona 
Aird and Ms. Clare Mc Fadden. Intraperitoneal injection was performed by NM, blood sampling was performed 
equally by MG, RC and CM. All analysis was done by MG. Blood glucose decrements at the indicated times 
were calculated by subtraction of blood glucose concentration at that time-point from the Time 0 concentration. n 
= 8 (C57BL/6 CD), 7 (Tst–/– CD), 7 (C57BL/6 HFD), 8 (Tst–/– HFD). Data were tested using 2-way ANOVA with 
Bonferroni post-hoc testing. CD; Control diet, HFD; High fat diet.  
Time 
(minutes) 









15 3.20 ± 0.6 4.59 ± 0.7 
1.46 ± 
0.8 
1.78 ± 0.8 0.004, 0.25, 0.47 
30 3.50 ± 0.4 5.04 ± 0.4 
2.89 ± 
0.5 
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3.3.4 Tst deletion increases liver phosphoenolpyruvate carboxykinase activity in 
control diet-fed mice 
To test whether phosphoenolpyruvate carboxykinase (PEPCK), a key regulatory enzyme of 
gluconeogenesis, was affected by Tst deletion, activity was measured in 6-week control and 
HFD fed mice (Figure 3.7A). There was no overall effect of HFD feeding on PEPCK activity 
in C57BL/6 or Tst–/– mice. However, overall Tst–/– mice exhibited significantly increased 
PEPCK activity compared to C57BL/6 controls (genotype p = 0.01) although no specific 





Figure 3.7 Liver phosphoenolpyruvate carboxykinase (PEPCK) activity in C57BL/6 and Tst–/– mice fed 
control or HFD for 6 weeks. A) An example trace of PEPCK activity measured in C57BL/6 and Tst–/– mice fed 
control diet for 6 weeks. The addition of PEP and dGDP to the reaction mixture is indicated by the arrow. B) 
Quantification of PEPCK activity in 6-week control and HFD fed C57BL/6 and Tst–/– mice. NADH extinction 
was calculated from the linear portion of the reaction curve following PEP and dGDP addition. Data are 
presented as Mean (figure A) or Mean ± SEM (figure B). n = 6 (C57BL/6 CD), 6 (Tst–/– CD), 11 (C57BL/6 
HFD), 11 (Tst–/– HFD). Data were tested using 2-way ANOVA and Bonferroni post hoc testing. CD; Control diet, 









































































3.3.5 Tst deletion does not alter liver glycogen content in chow- and high fat diet-fed 
mice 
To test whether glycogen storage, a process sensitive to insulin signalling, was altered in Tst–
/– mice, glycogen content of the liver ((mg/ml)/mg of liver tissue) was analysed in 6 and 20-
week HFD fed mice. No change in liver glycogen content was found in mice fed chow or 
HFD for 6 weeks (Figure 3.8A). There were also no changes in liver glycogen content 
between C57BL/6 and Tst–/– mice fed either diet for 6 weeks. Following 20 weeks of diet 
mice fed HFD did exhibit decreased liver glycogen content overall compared to chow fed 
mice (2-way ANOVA p < 0.01) (Figure 3.8B). However, there were no differences between 




Figure 3.8 Liver glycogen content in C57BL/6 and Tst–/– mice fed control or HFD for 6 or 20 weeks. A) 
Liver glycogen content following 6 weeks of control or HFD feeding. B) Liver glycogen content following 20 
weeks of control or HFD feeding. Data are presented as Mean ± SEM. n = 5 (C57BL/6 CD), 5 (Tst–/– CD), 6 
(C57BL/6 HFD), 6 (Tst–/– HFD) for 6-week data, n = 8/8/7/8 for 8 (C57BL/6 CD), 8 (Tst–/– CD), 7 (C57BL/6 
HFD), 8 (Tst–/– HFD) for 20-week data. Data were tested using 2-way ANOVA and Bonferroni post hoc testing. 
































































































3.3.6 Tst deletion in Hepatocytes increases ATP-linked and leak mitochondrial 
respiration 
Evaluation of mitochondrial metabolism was performed on C57BL/6 and Tst–/– primary 
hepatocytes isolated from control diet fed mice at 12-14 weeks of age. An initial observation 
from these experiments showed that wells seeded with Tst–/– hepatocytes contained more 
protein than wells containing hepatocytes from C57BL/6 liver, despite seeding at the same 
cell density (Figure 3.9C). Mitochondrial stress test results showed that Tst–/– hepatocytes 
displayed increased basal respiration (Figure 3.10A). Examination of the components of 
basal metabolism (ATP-linked and leak respiration) showed that both parameters were 
increased in Tst–/– hepatocytes compared to C57BL/6 (Figure 3.10B). No changes were 
observed in non-mitochondrial O2 consumption, maximum respiration or spare capacity 
































































Figure 3.9 Mitochondrial respiration in C57BL/6 and Tst-/- primary hepatocytes from control diet fed mice. 
A) A summary trace showing a standard mitochondrial stress test protocol on C57BL/6 and Tst–/– primary 
hepatocytes. The time of addition for each compound is marked with arrows. The measurement cycles used for 
further calculations are highlighted in the dashed boxes i.e. 3, 6, 7 and 12. For the method of summary statistic 
calculations refer to section 2.6.2 B) The C57BL/6 trace is used as an example to show the quantifiable 
characteristics of the mitochondria based on the compounds added. C) Sulfrhodamine B absorption was used as a 
measure of protein content in wells. D) Non-mitochondrial respiration. Data are presented as Mean ± SEM. 
Biological n = 6 for both genotypes with 10 technical replicates per plate. Experiments were performed in a 
pairwise fashion and data were tested using paired t tests. 
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Figure 3.10 Quantification of mitochondrial respiration parameters in primary hepatocytes from control 
fed C57BL/6 and Tst–/– mice.  A) Maximal respiration separated into basal respiration and spare respiratory 
capacity components. B) Basal respiration separated into ATP linked respiration and proton leak components. 
Data are presented as Mean ± SEM. Biological n = 6 for both genotypes with 10 technical replicates per plate. 



































































































3.3.7 Tst deletion increases plasma triglycerides in control diet-fed mice 
To determine whether Tst deletion altered lipid metabolism, HPLC analysis of the 
triglyceride and cholesterol carrying lipoprotein fractions in plasma was performed (example 
profiles shown in Figure 3.11). The analysis allowed for VLDL, LDL, HDL and total 
cholesterol and triglyceride content to be quantified as well as total glycerol (Table 3.2).   
All plasma cholesterol fractions (VLDL, LDL, HDL and total) were significantly increased 
following HFD feeding for 6 weeks. A similar pattern was seen following 20 weeks of HFD 
feeding although VLDL cholesterol was unaffected in this group. No differences were found 
in cholesterol content between C57BL/6 mice and Tst–/– fed either diet.  
In 6-week fed mice HFD feeding led to increased triglyceride content of the LDL fraction 
compared to chow fed controls only. Tst–/– mice fed control diet exhibited increased VLDL 
triglyceride content compared with C57BL/6 controls as detected by post-hoc testing (p < 
0.05). This effect was not seen following HFD feeding for 6 weeks (post-hoc test p > 0.05) 
in which C57BL/6 VLDL triglyceride content increased to similar levels as Tst–/– mice 
(Table 3.2) demonstrating an interaction of genotype and diet (2-way ANOVA interaction p 
= 0.01). 
In 20-week fed mice both LDL and HDL triglyceride content were increased with HFD 
feeding compared to chow fed controls. However, no differences were noted between 
genotypes in 20-week fed mice.  
Both 6 and 20-weeks of HFD feeding led to significantly increased glycerol but no 


















Figure 3.11 Example plasma cholesterol and triglyceride profiles from C57BL/6 and Tst–/– mice fed control 
diet for 6 weeks. A) Plasma cholesterol content with VLDL, LDL and HDL fraction peaks indicated. B) Plasma 
triglyceride content with VLDL, LDL, HDL and glycerol fraction peaks indicated. n = 6 for C57BL/6 and Tst–/– 





Table 3.2. Plasma cholesterol and triglyceride concentrations in 6 or 20-week control and high fat diet fed 
C57BL/6 and Tst–/– mice. Data are presented as mg/dL ± SEM. Data were tested within groups using 2-way 
ANOVA and p values are given in the final column. * indicates p < 0.05 by Bonferroni post-hoc testing (between 
genotypes). CD; Control diet, HDL; high density lipoprotein, HFD; High fat diet, LDL; low density lipoprotein, 
VLDL; very low-density lipoprotein. n = 6 (C57Bl/6 CD), 6 (Tst–/– CD), 11 (C57BL/6 HFD), 11 (Tst–/– HFD) for 
6-week data, n = 8 (C57BL/6 CD), 8 (Tst–/– CD), 7 (C57BL/6 HFD), 7 (Tst–/– HFD) for 20-week data.  
6 Week Diet 
(mg/dL ± SEM) 









Total 106 ± 5 114 ± 8 224 ± 7 218 ± 13 0.88, 
<0.0001, 0.51 
VLDL 3.0 ± 0.4 3.4 ± 0.3 6.6 ± 1 6.9 ± 0.4 0.66, 0.0001, 
0.94 
LDL 12 ± 2 11 ± 1 52.6 ± 3.6 59 ± 8 0.74, 
<0.0001, 0.52 
HDL 90 ± 4 100 ± 7 165 ± 5 153 ± 8 0.90, 
<0.0001, 0.12 
Triglycerides      
Total 45 ± 5 68 ± 8* 63 ± 3 57 ± 4 0.13, 0.53, 
0.007 
VLDL 26 ± 5 46 ± 7* 36 ± 3 33 ± 4 0.06, 0.77, 
0.01 
LDL 12 ± 1 14 ± 1 16 ± 1 14 ± 1 0.99, 0.01, 
0.07 
HDL 7.3 ± 2 8.9 ± 1 12 ± 2 9.0 ± 1 0.73, 0.10, 
0.12 
Glycerol 56 ± 3 57 ± 3 80 ± 6 77 ± 3 0.86, 
<0.0001, 0.61 
20 Week Diet 
(mg/dL ± SEM) 
Cholesterol      
Total 118 ± 6 117 ± 9 249 ± 9 214 ± 21 0.15, 
<0.0001, 0.17 
VLDL 1.8 ± 0.2 2.8 ± 0.5 2.7 ± 0.2 3.1 ± 0.4 0.06, 0.09, 
0.48 
LDL 15 ± 2 13 ± 2 80 ± 5 63 ± 12 0.17, 
<0.0001, 0.25 
HDL 101 ± 5 101 ± 6 167 ± 4 148 ± 9 0.14, 
<0.0001, 0.15 
Triglycerides      
Total 32 ± 3 36 ± 6 42 ± 2 39 ± 5 0.29, 0.0003, 
0.87 
VLDL 17 ± 2 21 ± 4 18 ± 2 19 ± 5 0.41, 0.87, 
0.64 
LDL 9.9 ± 1 9.8 ± 1 16 ± 1 14 ± 1 0.28, 
<0.0001, 0.32 
HDL 5.6 ± 0.6 5.4 ± 1 8.3 ± 1 6.4 ± 0.4 0.09, 0.007, 
0.20 




3.3.8 Tst deletion does not affect liver triglyceride accumulation on control or HFD 
To determine whether deletion of Tst altered the regulation of lipid metabolism specifically 
within liver tissue, the triglyceride content of the liver was analysed in 6- and 20-week HFD 
fed mice. No change in liver triglyceride content was found in mice fed control or HFD for 6 
weeks. There were also no effects of genotype on liver triglyceride content between 
C57BL/6 and Tst–/– mice fed control of HFD for 6 weeks (Figure 3.12A).  
Following 20 weeks of feeding, mice fed HFD exhibited increased liver triglyceride content 
overall (2-way ANOVA diet p < 0.0001) compared to chow fed controls (Figure 3.12B). 




Figure 3.12 Liver triglyceride content in C57BL/6 and Tst–/– mice fed control or HFD for 6 or 20 weeks. A) 
Liver triglyceride content following 6 weeks of control or HFD feeding. B) Liver triglyceride content following 
20 weeks of control or HFD feeding. Data are presented as Mean ± SEM. n = 5 (C57BL/6 CD), 5 (Tst–/– CD), 7 
(C57BL/6 HFD), 6 (Tst–/– HFD) for 6-week data, n = 7 (C57BL/6 CD), 6 (Tst–/– CD), 7 (C57BL/6 HFD), 6 (Tst–/– 
HFD) for 20-week data. Data were tested using 2-way ANOVA and Bonferroni post hoc testing. CD; Control 





























































This work aimed to further investigate the metabolic consequences of Tst deletion in mice, 
with the hypothesis that the diabetogenic phenotype in Tst–/– mice is driven by major 
defects in hepatic glucose metabolism and lipid metabolism. Previous work from Morton 
et al. (204) established Tst as an adipose-tissue associated ‘lean gene’ and showed that Tst 
gene deletion led to a worsening of glucose tolerance in mice fed HFD for 6 weeks. Within a 
Masters project (207) it was also found that control diet-fed Tst–/– mice exhibited increased 
gluconeogenesis in response to a pyruvate bolus (section 3.1.2). Gluconeogenesis can occur 
within the liver and kidney (218). 
Investigation of glucose metabolism has shown that the worsening of glucose tolerance due 
to Tst deletion during 6 weeks of HFD feeding also occurs following 20 weeks of HFD 
feeding, although the size of the effect is reduced compared to previous data at 6 weeks. 
Interestingly, novel data showing that insulin sensitivity is relatively preserved in Tst–/– mice 
compared to C57BL/6N mice fed HFD for 20 weeks is presented, which adds complexity to 
the biology of the Tst knockout phenotype. Tst–/– mice released less insulin over the time-
course of the GTT when fed either control or HFD and an ITT demonstrated increased 
sensitivity (30-minute decrement) of Tst–/– mice to insulin on either diet. This indicates that 
Tst–/– mice likely have suppressed endogenous insulin release, a novel observation that could 
be followed with analysis of their pancreatic β-cell function.  Increased sensitivity to insulin 
(greater glucose decrement in response to an insulin bolus) is more challenging to place 
within the context of a mouse that exhibits increased gluconeogenesis.  
Greater insulin sensitivity would predict that gluconeogenesis is suppressed, as this is a 
process that is exquisitely sensitive to the suppressing effects of insulin. However, consistent 
with the previous finding of increased gluconeogenesis in a pyruvate tolerance test (207), 
increased PEPCK activity was observed in 6-week control or HFD fed Tst–/– mice. One 
explanation for this discrepancy is that insulin sensitivity is maintained in the muscle, and 
perhaps even to some extent in the liver of Tst–/– mice, and that an insulin-independent 
mechanism drives increased hepatic gluconeogenesis and impaired glucose tolerance in Tst–/– 
mice. 
Investigations of hepatic metabolic function in vitro demonstrated that basal mitochondrial 
respiration was increased in Tst–/– hepatocytes. One potential explanation for this finding is 
that Tst–/– mice have increased energy demand because of increased synthetic metabolism. 
Synthetic (anabolic) metabolism includes gluconeogenesis and triglyceride secretion which 
require energy and have been shown to be increased in Tst–/– mice. This increase in energy 
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demand may therefore be supplied by increased basal mitochondrial respiration. Increased 
H2S signalling provides a second mechanism which may explain increased mitochondrial 
respiration in Tst–/– mice. Evidence in the literature has frequently linked a moderately (non-
toxic) increased H2S signal to increased mitochondrial respiration (219–221). As Tst–/– mice 
exhibit increased H2S in the blood (204) this may explain the changes in mitochondrial 
metabolism. 
Finally, investigations into hepatic lipid and lipoprotein metabolism also found that plasma 
triglyceride concentrations were increased in control diet fed Tst–/– mice. A similar increase 
in VLDL triglycerides has previously been observed in diabetic patients (48) and insulin-
resistant mouse models (47,86,222) and, therefore, this effect is consistent with the ‘diabetic-
like’ phenotype of Tst–/– mice. In combination, these findings suggest that multiple organ-
specific effects (suppression of islet insulin secretion, enhanced peripheral – likely muscle -  
insulin sensitivity, and an increase in insulin-independent hepatic glucose production and 
triglyceride export) conspire to engender a “diabetogenic” phenotype in Tst–/– mice. 
3.4.1 Tst deletion reduces body weight in control- and high fat diet-fed mice 
Initial observations of body weight on control and HFD showed that Tst–/– mice had reduced 
body weight when fed control diet for 6 weeks. A similar trend was seen in mice fed control 
diet for 20 weeks. The cause of this reduction in body weight following 6 weeks of feeding 
is unclear. It does not appear to be related to poor health or failure to thrive as mice are 
grossly healthy and reproduce as expected. Interestingly in 6-week chow-fed mice the liver 
was larger in size compared to the animal’s body weight, resulting in a higher liver/body 
weight ratio than in C57BL/6 mice. This effect was not seen in mice fed chow diet for 20 
weeks. Hepatomegaly (an enlargement of the liver) can be a response to several diseases 
including non-alcoholic fatty liver disease (46) and glycogen storage disease (223), which 
result in increased storage of triglycerides or glycogen in hepatocytes, respectively . 
However, triglyceride and glycogen content of the liver were not increased in 6-week control 
diet fed Tst–/– mice compared to C57BL/6. The cause of hepatomegaly in Tst–/– mice is also 
extremely unlikely to be infection (224) or tumour related as no gross changes in liver 
morphology were observed in Tst–/– mice (Emerson et al. unpublished observations). 
Therefore, at this stage the increase in liver mass in Tst–/– is unexplained. 
20 weeks of feeding with chow diet also increased the body weight of the animals compared 
to 6 weeks of control diet feeding. While this may simply represent increased aging and 
maturation of mice to higher body weights (225) it could also indicate that the control diet 
used does not merely maintain body weight, but is calorific enough to induce excessive 
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weight gain over this chronic time period. As expected, HFD feeding with Surwit diet for 6 
or 20 weeks led to an increase in body weight in both C57BL/6 and Tst–/– mice (215,226), 
with 20 weeks’ feeding leading to greater weight gain than 6 weeks. HFD feeding equalised 
body weights in Tst–/– mice compared with C57BL/6, eliminating the difference observed on 
control diet where Tst–/– mice had lower body weight. In 6-week fed mice this led to a 
significant interaction of diet and genotype suggesting that Tst–/– mice gained more weight 
when fed HFD than C57Bl/6 controls.  
HFD feeding led to an increase in liver/body weight ratios in 6-week fed mice but not in 20-
week fed mice. This discrepancy is most likely explained by the longer experimental length 
in 20-week fed mice. This extended feeding time allows for body weight to increase and 
normalise the liver/body weight ratio. However, this explanation suggests that in the early 
stages of HFD feeding the liver tends to increase in mass before body weight although, as 
this investigation has shown, this is not due to increased triglyceride or glycogen storage in 
the liver as these were not increased following 6 weeks of diet. The reason for this increase 
in liver weight is not clear from this study and little exists in the literature to explain the 
finding. One potential avenue for further investigation would be immune cell infiltration of 
the liver following HFD feeding which is known to occur as triglyceride content of the liver 
begins to increase and leads to lesion formation in the liver and steatohepatitis (213).  
3.4.2 Tst deletion worsens glucose tolerance through liver and pancreatic actions 
Consistent with previous glucose tolerance tests performed by Morton et al. (204) on 
C57BL/6 and Tst–/– fed control or HFD for 6 weeks it was found that Tst deletion did not 
alter glucose tolerance in 20-week control fed mice. However, it was noted that, compared to 
mice fed control diet for 6 weeks, 20-week control diet-fed mice had higher fasting glucose 
measurements (measured at time 0) and showed mild glucose intolerance (a slower rate of 
disposal over the 2-hour period). This worsening of glucose tolerance in mice fed chow for a 
longer period is similar to the effect seen in body weights where chow feeding for 20-weeks 
led to increased body weight compared to 6-week fed mice (discussed above). This indicates 
that either mouse age (225) or the constituents of the rodent chow diet are inducing mild 
metabolic dysfunction in mice. More closely matched control diets are available for 
experiments using ‘Surwit’ HFD and, therefore, using these in the future may help to 
elucidate any effect of long term CRM ‘rodent chow’ feeding on metabolic function. 
As expected, and previously shown, HFD feeding induced substantial glucose and insulin 
intolerance in C57BL/6 mice (215,226). It was noted that the difference in glucose tolerance 
between control and HFD groups was less clear at 20 weeks than previously seen at 6 weeks 
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(204) due to increased blood glucose concentrations in chow-fed mice. When comparing the 
genotypes in isolation Tst–/– mice fed HFD for 20 weeks are not more glucose intolerant than 
C57BL/6. fed HFD. This is not what has been seen in previous experiments (204), where 
Tst–/– mice fed HFD for 6 weeks had noticeably impaired glucose tolerance compared to 
C57BL/6 fed HFD. However, in this present study it was noticed that when comparing to the 
chow fed mice high fat feeding for 20 weeks induced greater glucose intolerance in Tst–/– 
mice than C57BL/6. This significant interaction of genotype and diet (a worsened response 
to HFD feeding in Tst–/– mice) is consistent with the previous data in these mice following 6 
weeks of HFD feeding (204). This difference may have occurred because, following 20 
weeks of HFD, C57BL/6 mice were beginning to converge in phenotype with Tst–/– mice as 
their own metabolic dysfunction became more pronounced and was equal to the glucose 
intolerance in Tst–/– mice fed HFD. Overall these data suggest that any future work focussed 
on glucose tolerance in HFD fed conditions should be conducted at the 6-week time point. 
The exact cause of worsened glucose tolerance in Tst–/– is currently unknown. Notably, 
increased H2S signalling has been linked with diabetes and hepatic dysfunction 
(171,227,228). Exogenous NaHS administration resulted in disturbed glucose homeostasis 
and the development of insulin resistance in HepG2 and primary hepatocytes (173). Primary 
hepatocytes isolated from Cse–/– mice appeared to be more insulin sensitive and to favour 
insulin driven processes, such as glycogen storage and a decrease in gluconeogenesis (173). 
However, very interestingly, H2S has been found to suppress insulin release from the 
pancreatic β cells, as a result of increased KATP channel opening following persulfidation by 
H2S (32,163,179,229,230). Given the findings presented here on insulin signalling within 
Tst–/– mice (see below) this also presents the new hypothesis that abnormal β-cell function 
contributes to worsened glucose tolerance in Tst–/– mice.  
3.4.3 Tst deletion reduces insulin concentrations leading to increased insulin 
sensitivity 
Insulin concentrations measured during the GTT performed in 18-week control or HFD 
C57BL/6 and Tst–/– mice showed clearly that Tst–/– mice have lower blood insulin 
concentrations over the entire time course. It should be noted that these concentrations were 
measured under fasted conditions (at time 0, and following glucose bolus after this) and, 
therefore, it cannot be ruled out that under normal ad libitum feeding conditions no deficit of 
insulin would be found. However, the fact that the blood insulin concentration maintains a 
distinct deficit over the entire time course of the GTT suggests that Tst–/– mice likely have 
lower blood concentrations generally.   
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A reduction in blood insulin concentration during a GTT was not found in the previous work 
performed by Morton et al. (204) following 6 weeks of HFD feeding and was not measured 
in the 6-week fed mice within this work. One explanation for the contradiction in insulin 
findings between Morton et al. and this study may be a difference in the mouse background 
between studies. Work by Morton et al. was performed on a defined C57BL/6N background 
with control animals also on this background whereas this study was performed on mice 
which were had a mixed C57BL/6N and C57BL/6J background as the work was set against 
the background of a backcrossing program to harmonise the Tst–/– allele onto the 6J strain. 
Previous studies suggested that genetic differences between the C57BL/6 N and J substrains 
in the nicotinamide nucleotide transhydrogenase (NNT) gene can have effects on insulin 
secretion in mice (211,231–233) although this has recently been disputed (234). As mice in 
this study were not genotyped for their J/N SNP background it is possible that the C57BL/6 
and Tst–/– mice used may also differed at the NNT gene; and this could explain the finding of 
reduced insulin in Tst–/– mice. However, this is unlikely as C57BL/6 and Tst–/– mice came 
from the same breeding colony which has presumably been equally diluted by J substrain 
breeding. Later data (chapter 5) also provide an argument that a difference in NNT substrain 
is unlikely to explain the findings here.  
Assuming that the Tst–/– mice used did not differ at NNT one mechanistic explanation for 
this deficit in insulin signalling may be that increased H2S concentrations in Tst–/– mice (as 
suggested by the independent whole blood measurements (204)) are indicative of increased 
H2S signalling within pancreatic β cells (179,229,230). According to general transcriptional 
data from BioGPS Tst mRNA expression has been found in the pancreas (208). However, 
Pullen et al. actually identified Tst as one of the genes which is selectively disallowed within 
pancreatic β-cells to ensure normal function (235). Therefore, deletion within pancreatic β-
cells is unlikely to lead to specific elevation of H2S on a cellular level. Instead high 
circulating H2S concentrations (as demonstrated by the high H2S levels detected in whole 
blood of Tst–/– mice) may lead to modifications which affect β-cell function. H2S has been 
shown to reduce insulin release due to activation of KATP channels (163) and suppression of 
β cell actions potentials which cause insulin release (32). This effect could explain why 
insulin is continuously suppressed in Tst–/– mice. Intriguingly the reduction in insulin does 
not result in glucose intolerance on control fed conditions possibly due to increased insulin 
sensitivity (discussed below). However, H2S inhibition of insulin release may explain why 
Tst deletion exacerbates glucose intolerance induced by HFD. As seen from C57BL/6 mice 
in this study during HFD feeding there is a clear need to increase insulin production. This is 
also observed in type 2 diabetic patients (33,77) and in rodent models of diet induced obesity 
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(236). However, Tst–/– mice are unable to sufficiently increase in insulin production due to 
the inhibition of the β cells by H2S resulting in increased hyperglycaemia. This could further 
explain why Tst–/– mice develop worsened glucose intolerance than C57BL/6 mice. 
Further to the assessment of insulin release over the GTT time course an insulin tolerance 
test was also performed for the first time on Tst–/– mice and allowed some conclusions to be 
drawn on insulin sensitivity. The raw blood glucose measurements themselves confirmed the 
findings of the GTT that Tst deletion exacerbated the glucose intolerance (i.e. mice had 
higher blood glucose concentrations) induced by HFD. However, the calculated decreases in 
blood glucose are more useful as measures of insulin sensitivity. From these it was observed 
that in both genotypes HFD feeding led to a change in profile of the response to insulin. In 
control fed mice insulin produced a larger drop in glucose at 15 minutes than in HFD fed 
mice. By 30 minutes there was no detectable difference in the decrement between diet 
groups although this appears to be due in part to high variation in the data. This observed 
reduction in response to insulin is consistent with previous studies in which insulin tolerance 
tests have been performed on HFD fed mice (237–239).  
No difference in glucose decrement was observed between the genotypes on either diet at the 
15-minute time point (representing the initial fast response to insulin). However, at 30 
minutes Tst–/– mice fed either diet demonstrated a clear accentuation of blood glucose 
decrement compared to C57BL/6 mice, indicating an increased sensitivity to insulin or 
increased ability to take up glucose during this phase of insulin response. Insulin receptors 
undergo desensitisation when exposed to higher insulin concentrations, either by a reduction 
in membrane receptors (37) or an uncoupling of receptor binding to downstream effects (36). 
It has also been shown that reducing insulin concentrations in the ob/ob experimental model 
of diabetes, through prolonged fasting, led to increased insulin binding and action on muscle 
tissue (240); consistent with the general theory that reducing hormone concentrations leads 
to sensitisation of tissues (35). Therefore, the reduction in insulin concentrations observed in 
Tst–/– mice may explain the increased sensitivity in Tst–/– mice which is able to compensate, 
at least in control fed conditions, and maintain normal glucose homeostasis. However, the 
findings in Tst–/– mice fed HFD suggest that, in conditions of dietary stress, this increase in 
sensitisation is no longer able to compensate for the reduced insulin concentrations observed 
in Tst–/– mice; therefore, glucose tolerance is worsened compared to C57BL/6 mice.  
3.4.4 Tst deletion enhances gluconeogenesis  
It has previously been shown (207)that glucose production from a pyruvate bolus is 
increased in Tst–/– mice fed control diet compared to C57BL/6 mice (section 3.1.2). This 
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pyruvate tolerance test was a simple measure of gluconeogenesis; a process which generates 
glucose from pyruvate molecules during fasting conditions in order to supply tissues such as 
the brain with a useable energy source (85). Gluconeogenesis occurs primarily within the 
liver and to some extent in the kidney (218). In this present work, it was found that PEPCK 
activity was increased in livers from Tst–/– mice. This was found to a greater extent in chow-
fed mice reflecting the original finding of increased glucose production during the PTT 
which was performed in chow-fed mice. Following HFD feeding for 6 weeks, PEPCK 
activity in C57BL/6 mice increased and was approximately the same as that in Tst–/– mice.  
Here, PEPCK activity was investigated particularly because of its role as the first committed 
step of gluconeogenesis (201). It is also highly regulated at the expression level through 
inhibition by insulin or stimulation by glucagon secretion (85). Insulin is considered to be the 
dominant factor however, due to its inhibition, via Akt-mediated phosphorylation, of many 
pro-gluconeogenic transcription factors (85). Therefore, it is possible that increased PEPCK 
activity in Tst–/– mice is simply the result of the reduction in insulin concentrations observed 
in these mice, leading to increased PEPCK expression. However, although it was not 
possible to measure PEPCK expression in the livers used to measure activity, previous work 
performed on 6-week HFD C57BL/6N or Tst–/– liver samples demonstrated that PEPCK 
expression was unchanged (207). 
Another possible explanation for the increase in gluconeogenesis in Tst–/– mice may be 
increased H2S signalling within the liver. Unfortunately, H2S concentrations were not 
measured within this study, however Morton et al. have previously demonstrated that H2S is 
elevated in whole blood samples from Tst–/– mice. In HepG2 cells and primary hepatocytes, 
exogenous H2S stimulates an increase in gluconeogenesis (173). Furthermore, reduced 
gluconeogenesis was found in primary hepatocytes from Cse–/– mice which have lower H2S 
levels than C57BL/6 mice in liver tissue (171,173). Further work has suggested that the 
increase in gluconeogenesis observed with H2S administration is the result of a specific 
persulfidation of pyruvate carboxylase (PC) leading to increased activity and production of 
oxaloacetate: the substrate for PEPCK (166). PC has previously been considered an 
anaplerotic enzyme without a regulatory role in gluconeogenesis (174). However, some work 
has suggested that this is a simplification and increased PC expression or activity is 
associated with increased gluconeogenesis in fasting and diabetic conditions (174,175,218). 
An increase in PC activity could be partly responsible for the increase in activity observed in 
our biochemical method of assessing PEPCK activity, as this method relies on the 
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production of oxaloacetate to measure activity. Therefore, future investigation of PC activity 
in Tst–/– mice is certainly warranted. 
3.4.5 Mitochondrial respiration in Tst–/– mice 
Mitochondrial function is central to the metabolic processes of the cell (241). Mitochondrial 
activity is altered in some tissues in conditions, such as diabetes, in which nutrient 
homeostasis is impaired. For example, mitochondrial activity is reduced, compared to 
normal patients, in the skeletal muscle of diabetic patients who are insulin resistant (without 
other comorbidities) (216). This finding was also expanded by work showing that elderly 
patients who exhibited age-related insulin resistance compared to body weight-matched 
young adult controls also had reduced mitochondrial respiration in muscle (217).  
In this work, we found that basal mitochondrial activity in primary hepatocytes from control 
fed mice was higher in Tst–/– than in C57BL/6 mice. Maximal activity (revealed by the 
addition of the uncoupling compound FCCP) was not increased in Tst–/– mice suggesting that 
there are not simply more mitochondria in Tst–/– hepatocytes leading to a higher O2 
consumption. The increase in basal respiration appears to be split evenly between ATP (i.e. 
useful energy producing)-linked respiration and leak respiration (non-energy producing 
respiration resulting from H+ ‘leak’ across the mitochondrial membrane without ATP 
production). This distinction means that the increase is unlikely to be the result of increased 
expression of proteins that regulate mitochondrial leak, such as the UCP protein family 
(242).  
The cause of this greater basal respiration is not clear. One explanation may be that Tst–/– 
hepatocytes require a greater amount of ATP than C57BL/6. This presents a clear 
explanation as ATP production is strictly controlled by the cell so that it is not wastefully 
overproduced. Following the classical theory of respiratory control, the activity of ATP 
synthase is solely regulated by the intra-mitochondrial concentration of its substrate ADP 
(243). Therefore, an increase in the ADP:ATP ratio, as would occur in the case of an 
increase in demand as ATP is being used up more rapidly, would result in increased 
mitochondrial respiration to meet this demand. Within this work, an increase in energy 
demand in Tst–/– mice can be hypothesised due to the increased synthetic processes which are 
occurring. Both gluconeogenesis and VLDL particle synthesis are energy demanding 
pathways which have been identified as increased in control fed Tst–/– mice in vivo. In vitro it 
was also found that Tst–/– hepatocytes exhibited higher protein concentrations than 
hepatocytes from C57BL/6 controls. Whether this represents increased protein synthesis in 
vivo is currently unknown, but this would increase energy demand in cells.  
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Two other potential explanations are suggested by research on H2S stimulation of 
mitochondrial respiration. Many groups have shown that increased H2S signalling, either as a 
result of exogenously applied H2S from mitochondrially targeted donors such as AP123 and 
AP39 (219,244,245) or overexpression of the H2S producing CBS protein (246), results in 
increased basal mitochondrial respiration. Szabo et al. have suggested several methods by 
which this can occur, including persulfidation of ATP synthase (220), and activation of a 
protein kinase signalling system within mitochondria (personal communication, 4th 
International Conference on the Biology of Hydrogen Sulfide 2016). This work suggests that 
the increased basal mitochondrial respiration in Tst–/– hepatocytes may be explained by an 
increase in H2S concentrations.  
However, much of this previous literature ignores the principle that ATP is not synthesised 
unless required when ADP concentrations increase in conditions of increased energy 
demand. In many of these experiments there is not a clear need for increased energy 
production and researchers do not suggest any precise mechanisms by which increased H2S 
allows increased respiration to occur without an increase in energy demand. Therefore, it is 
possible that the observed increases in respiration with increased H2S concentrations are 
artefactual. Bouillaud et al. have shown that the breakdown of H2S by the SOU within the 
mitochondria leads to electron donation to the mitochondrial electron transport chain and 
then consumption of O2; i.e. respiration in mammalian cells (247). In addition to this 
process, however, (which would generate ATP or leak as conventionally understood) the 
further breakdown of H2S by SDO leads to an additional consumption of O2 (Figure 3.13;  
53). This additional consumption could contribute to the increase in O2 consumption seen 
during Seahorse experiments. It has been demonstrated that inhibition of complex III of the 
mitochondrial transport chain by antimycin prevents this breakdown as the electron can no 
longer be donated to the transport chain (248–250). The resulting drop in O2 consumption 
(which is used in the Seahorse method to calculate respiration) would be indistinguishable 
from conventional respiration occurring using organic fuels. Therefore, additional H2S 
burden in the mitochondria could appear to increase in respiration but in fact be the result of 
the mitochondrial breakdown of H2S. The increase in respiration of Tst–/– hepatocytes could 
be attributed to either described mechanism but awaits definite measurement of H2S 
concentration within the liver or hepatocytes of Tst–/– mice before further investigations 












Figure 3.13 Mitochondrial O2 consumption during H2S metabolism. At non-toxic concentrations, H2S (0.1-10 
µM) has been demonstrated to act as an inorganic substrate for mitochondrial metabolism. Donation of electrons 
from H2S to the mitochondrial transport train occurs through the SQR protein in the sulfide oxidising unit (SOU) 
(a). These electrons are transported to complexes III and IV to generate the proton motive force (which generates 
ATP through complex V) before being accepted by a molecule of oxygen leading to O2 consumption and 
production of water (b). This process is identical to the donation of electrons by NADH (produced by the KREBS 
cycle) at complex I or through succinate conversion to fumarate at complex II (c). However, in addition to the O2 
consumed at complex IV the further steps of H2S metabolism result in the additional consumption (highlighted in 
the red box) of a molecule of O2 compared to organic substrates. Cyt c; cytochrome c, SOU; sulfide oxidising 
unit. Reproduced from Szabo et al. (2014) (221). 
3.4.6 Tst deletion increases plasma VLDL triglyceride content 
Another key role of the liver is to maintain homeostasis of plasma lipid concentrations. The 
liver is central to this process as it both synthesises and releases VLDL particles from the 
free fatty acids (FFA) it receives, and it is also involved in the processing and clearance of 
remnant particles from the blood (85,117). It was found that total and VLDL triglyceride 
content were increased in Tst–/– mice fed chow diet for 6 weeks. This increase was not seen 
in 20-week chow-fed diet mice. This discrepancy may be due to the general decrease in 
plasma triglyceride levels observed in chow-fed 20-week fed mice compared to 6-week 
chow-fed mice. One explanation for the reduction in plasma triglyceride concentrations in 
20-week fed mice may be that plasma triglyceride concentrations decrease with increased 
age. Lower plasma triglyceride concentrations have been described in chow-fed aged mice 
compared with young adult mice, indicating that the regulation of triglyceride may change 
with age (225). However, it should be noted that Houtkooper et al. used mice that were over 
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22 months old compared to only 26-30 weeks in this present work casting doubt on whether 
the reduction at this age would be enough to explain the findings in this current work.  
It was also noted that 20-week chow fed mice developed greater hepatic steatosis 
(triglyceride deposition in the liver) than 6-week control fed mice. This is an unusual finding 
as steatosis of the liver should not occur under control conditions (213). This may be linked 
with the other noted findings of increased body weight and worsened glucose tolerance in 
20-week chow-fed mice and again indicates that mice fed chow for 20 weeks have mild 
metabolic dysfunction compared 6-week control diet fed mice. This evidence again suggests 
that 6-week investigations should be the focus for future studies on metabolic dysfunction in 
Tst–/– mice to ensure that mice are compared with a metabolically healthy control. 
An increase in total or VLDL triglycerides specifically, as observed in 6-week control diet 
fed Tst–/– mice, has previously been associated with insulin resistance with or without 
hyperglycaemia (47,48). There are many suggested mechanisms by which a reduction in 
insulin signalling may cause increased VLDL triglyceride concentrations. One explanation 
which has been suggested is that in conditions of insulin resistance there is a lack of 
suppression of lipolysis in adipose tissue depots resulting in increased FFA delivery to the 
liver (47). The synthesis of VLDL particles is highly dependent upon substrate availability 
and, therefore, this increase in availability results in increased synthesis.  Blood insulin 
concentrations were not measured in these 6-week fed mice and, so it is not clear whether 
they also have an insulin deficit as seen in 20-week fed mice. However, if this was present 
then it may provide an explanation for increased hepatic production of VLDL via increased 
FFA delivery from adipose tissue and, therefore, would be interesting to test in this model. 
Interestingly increased H2S concentrations, as seen in by Morton et al. in Tst–/– mice (204), 
have also been linked with increased VLDL secretion in mice. Mani et al. have shown that 
Cse–/– mice exhibit lower total triglyceride than C57BL/6 controls when fed control or 
atherogenic diet, and that this was normalised in atherogenic diet-fed mice by the 
administration of NaHS, a H2S donor compound (171,187). One study has shown that the 
administration of garlic oil, which contains natural H2S donor compounds, ameliorated 
hepatic steatosis through modulation of the transcription factor sterol regulatory element 
binding protein 1c (SREBP-1c) (251). SREBP-1c regulates the expression of a large cohort 
of genes associated with de novo lipid synthesis within the liver (47). Increased SREBP-1c 
activation resulting in increased hepatic de novo lipogenesis is a suggested mechanism for 
the increase in VLDL production observed in conditions of insulin resistance (47,48,86). 
Therefore, SREBP-1c and its downstream targets such as acetyl CoA carboxylase (ACC) and 
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fatty acid synthase (FAS) also represent intriguing potential mechanisms for investigation in 
chow-fed Tst–/– mice once increased H2S within Tst–/– liver has been confirmed. This could 
initially be done by measuring mRNA expression levels of the genes of interest. 
No differences were noted in plasma triglyceride concentrations in mice fed with HFD for 6 
or 20 weeks. Within the 6-week HFD-fed mice following HFD feeding total and VLDL 
triglyceride content in C57BL/6 mice reaches similar levels to those in Tst–/– mice (which 
exhibit a slight drop in concentration compared to chow-fed mice). Therefore, following 
HFD C57BL/6 mice appear to be converging in phenotype with Tst–/– mice; reducing the 
differences between the genotypes as was seen in PEPCK activity measurements.  
Examination of hepatic triglyceride levels showed that there were no differences between 
C57BL/6 and Tst–/– mice fed control or HFD for 6 or 20 weeks. Increased H2S concentrations 
have previously been suggested to reduce hepatic steatosis in mice (171,186,252) (as a result 
of the same SREBP-1c activation which promotes VLDL production) and, therefore, this 
finding challenges the presumption within this work that Tst–/– mice have increased H2S 
concentrations. However, most of the evidence for the effects of H2S on hepatic steatosis 
come from genetic models of reduced H2S production (Cse–/– and Cbs–/–)  both of which also 
exhibit hyperhomocystinaemia as a result of their effects on the trans-sulfuration pathway 
(186,253). Increased homocysteine has been linked with hepatic steatosis (188,254) and, 
therefore, the effects of Cse and Cbs deletion on hepatic steatosis may not be solely linked to 
reduced H2S. 
3.4.7 Conclusions 
This work has confirmed the hypothesis that altered liver function affecting both 
carbohydrate and lipid homeostasis in Tst–/– mice is a major driver of the metabolic 
dysfunction observed in these mice. However, it has also raised the hypothesis that reduced 
insulin secretion by the pancreas in Tst–/– mice could be a contributing factor for many of 
these phenotypes. It is intriguing that many of the phenotypes observed in this work may be 
partly explained by a reduction in insulin concentrations. Therefore, investigation of 
pancreatic function and, especially, whether increased H2S signalling plays a role in 
supressing insulin release must be of the highest priority in future investigations. 
Many of the findings in this work (such as the increase in gluconeogenesis, the reduction in 
blood insulin concentrations, the increase hepatic mitochondrial respiration and the increase 
in VLDL triglyceride content) are also consistent with effects described for increased H2S 
concentrations in either the liver or pancreas. Therefore, a second mechanism for the 
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phenotypes observed in this work is that TST contributes to H2S breakdown and that deletion 
or inhibition of the protein can result in elevated H2S concentrations, which explain the 
phenotypes observed in the mice. Future investigations will need to specifically measure H2S 
concentrations in the tissues of interest as well as examining the effects of increased H2S 
using molecular biology techniques such as detection of persulfidated proteins (163,255). 
Overall the evidence here suggests that Tst deletion engenders a ‘diabetogenic’ phenotype in 
mice and that HFD feeding leads to exacerbation of these defects and therefore a worsened 
response to the diet resulting in overt metabolic disease. The aim of the current work is now 
to examine how this metabolic dysfunction, which has been linked to vascular injury, and 
elevated H2S, which has been linked to vascular protection, may influence the vascular 




4.0 The effects of Tst deletion on vascular function 
4.1 Introduction 
4.1.1 H2S in vasculature 
Many studies on H2S have focussed on its role within the cardiovascular system, where the 
enzymes known to synthesise H2S are  highly expressed and where it has shown functional 
effects (167,193,253,256). Gasotransmitters, such as nitric oxide (NO), are important in the 
vascular system where they can act as second messenger molecules stimulated by activation 
of  G-protein coupled receptors (257). There is also evidence that endothelial dysfunction, 
which is commonly associated with reduced production of NO, is a symptom of, or even a 
precursor to, vascular diseases such as atherosclerosis (114,258). Studies on H2S have shown 
that similar to NO exogenously administered H2S, usually given in high doses of µmol 
concentration, is protective in a number of mouse models of vascular dysfunction (reviewed 
in 16). Conversely models of reduced H2S generation, such as Cse–/– mice, exhibit inhibited 
vasodilator responses to acetylcholine and develop cardiovascular diseases such as 
hypertension (253). In addition Cse–/– mice fed western diet were also found to have 
exacerbated atherosclerosis compared to control mice (187).  
In a study of atherosclerosis Cse–/–  mice were found to have increased atherosclerotic plaque 
volume compared to control mice and this was associated with increased intercellular adhesion 
molecule 1 (ICAM1) expression on aortic endothelial cells (187). The authors therefore 
suggested that a lack of H2S production and signalling was affecting endothelial cell function, 
although the mechanism responsible for this effect was not identified. Finally, an in vitro 
investigation using endothelial cells found that exogenous H2S donor NaHS protected against 
mitochondrial dysfunction induced by reactive oxygen species (ROS) overproduction in 
response to high glucose concentrations (260).  The modulation of endothelial function by 
NaHS has, therefore, emerged as a promising target for the use of H2S donor compounds in 
common vascular pathologies. 
4.1.2 Potential mechanisms of H2S actions in the vasculature 
The mechanisms underlying the actions of H2S in the vasculature are not clearly defined. One 
potential mechanism is the direct effect of H2S is to elicit vascular relaxation (180). This is 
mediated, at least in part, through persulfidation-mediated activation of the smooth-muscle 
KATP channel (181). However, recent studies have also identified TRPA1 channels located 
within vascular nerve endings as potential targets for H2S vasodilator signalling through a 
combined mechanism involving production of HNO- molecules in a reaction of H2S and NO 
(261). Activation of these channels may then lead to the release of vasodilator signals such as 
ACh from nerve endings resulting in a secondary vasodilation. Activation of K+ channels, 
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leading to hyperpolarisation of vascular smooth-muscle cells, has been suggested as a 
component of endothelium-derived hyperpolarising factor (EDHF)-induced relaxation 
(190,191).  
It should be noted that the concentrations of H2S donor compounds used to elicit direct 
vasodilation are usually 10-1000 times the maximal predicted endogenous concentrations 
casting doubt on the role of H2S as an independent vasodilator. 
Instead H2S may act in concert with NO to mediate vasodilation. H2S signalling modulates 
phosphorylation of endothelial nitric oxide synthase (eNOS) (4,5) at the activating serine 1177 
residue, thereby increasing synthesis of NO. Further to this, H2S can decrease breakdown of 
cGMP, a downstream effector of NO signalling, through inhibition of phosphodiesterase 5 
(PDE5) (263). Taken together, these effects support the idea that H2S exhibits cross-talk with 
NO signalling and acts to augment NO signalling in the cardiovascular system. Because a lack 
of NO production has previously been linked with vascular diseases (114,258) the protective 
effect of exogenously administered H2S observed in some of these models may in fact 
represent a secondary effect on NO signalling. A recent study investigated this idea and found 
that the protective effect of exogenous Na2S in a model of cardiac ischaemia-reperfusion was 
reliant on functional eNOS expression and this protection was lost in mutant model expressing 
a non-phosphorylatable eNOS (S1179A) on an otherwise eNOS–/– background (167).  
4.1.3 H2S in Tst–/– mice 
As discussed (above), the majority of investigations addressing the vascular effects of H2S 
have focussed either on manipulation of H2S production via cystathionine-gamma lyase 
(CSE), or on pharmacological stimulation using sulfide donors (173,187,219,264). An 
alternative and under-explored approach is the elevation of endogenous H2S levels through 
inhibition of clearance pathways. Genetic deletion of proteins in the sulfide oxidising unit 
(SOU)(168) represents one potential method by which endogenous H2S levels can be 
increased. The only previous studies of SOU protein deletion were in mice with genetic 
deletion of sulfur dioxygenase (SDO, Ethe1). Ethe1 deletion resulted in rapid post-natal death 
from sulfide toxicity (170). Recently published work confirmed that genetic deletion of Tst 
(Tst–/–), a modulatory protein of the SOU, results in marked elevation of blood ‘sulfides’ 
detected using monobromobimane (MBB) (204). Despite this, Tst–/– mice remain grossly 
viable and healthy, albeit with impaired glucose homeostasis (204); unlike mice with genetic 
deletion of SDO.  
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4.1.4 Hypothesis and aims 
In this chapter, it was hypothesised that: Tst–/– mice would have to altered baseline 
vascular function in response to vasoconstrictor and dilator compounds and be 
protected from vascular dysfunction induced by high fat diet feeding. 
Aims 
 To determine whether Tst deletion alters aortic vascular constriction and relaxation 
responses. 
 To examine the extent of vascular dysfunction (in both constriction and relaxation 
responses) induced by short (7-week) and long (20-week) HFD feeding in mice. 
 To determine whether Tst deletion protected mice from the adverse vascular effects 
of HFD feeding.  
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4.2 Materials and methods 
4.2.1 mRNA collection, reverse transcription and quantification 
To generate data on the expression of Tst, C56BL/6 mice were culled, and the thoracic aorta 
and liver removed. The mRNA was then extracted from these tissues and reverse transcribed. 
Tst (Mm01195231_m1), Tbp (Mm01277042_m1) and Gapdh (Mm99999915_g1) Taqman 
assay probes were obtained from Applied Biosystems (Thermo Scientific, Loughborough, 
UK) and expression was quantified using real time polymerase chain reaction (section 2.5.3). 
NormFinder software (University Hospital, Aarhus, Denmark) was used to analyse Tbp and 
Gapdh housekeeping genes. The software compared the ‘Stability value’ of each gene 
separately and as an average. An average of Tbp and Gapdh was found to have the highest 
‘Stability value’ and was therefore used to normalise Tst expression. 
4.2.2 Myography 
C57BL/6 and Tst–/– mice were given ad libitum access to control ‘rodent chow’ (CRM diet, 
Special Diet Services, UK) or ‘Surwit’ 58% high fat diet (HFD, Research Diets, New 
Brunswick, US) for 7 or 20 weeks to induce weight gain and metabolic dysfunction, 





























Figure 4.1 Experimental design of investigations into the effect of Tst deletion on vascular function in 
control and HFD fed mice. Two studies were conducted using age matched C57BL/6 and Tst–/– mice. Note that 
at the 7-week time point no chow diet was used so only HFD fed groups were included. Wire myography was 
performed on the descending thoracic aorta (section 2.3.2). Investigations with L-NAME (an inhibitor of 
endothelial nitric oxide synthase) and Indomethacin (an inhibitor of cyclooxygenase) were performed by 
mounting 2 consecutive sections of aorta in separate myograph tissue baths and exposing one to L-NAME (10-4 
M) and indomethacin (10-5 M) for a minimum of 20 minutes prior to beginning concentration-response curves. 
Concentration-response curves were performed in response to vasoconstrictors; 5-HT and phenylephrine (10-9 – 
10-4.5 M), and vasodilators ACh (10-9 – 10-5.5 M) and sodium nitroprusside (SNP; 10-9 – 10-4.5 M). Preconstriction 
(for vasodilator responses) was elicited using a concentration of 5-HT to reach approximately 80% of maximal 5-





Figure 4.2 Signalling pathways investigated using myography. The key components of the signalling 
pathways mediating vasodilation and vasoconstriction which were investigated. Stimulator compounds 
(vasoconstrictors PE and 5-HT and vasodilator ACh and SNP) are shown in green with the eNOS and COX 
inhibitors L-NAME and indomethacin, respectively are shown in red. 5-HT; 5-hydroxytryptamine, 5-HT1A/2B; 
5-hydroxytryptamine receptor 1A/2B, α1; α1 adrenoreceptor, ACh; acetylcholine, cAMP; cyclic adenosine 
monophosphate, cGMP; cyclic guanosine monophosphate, COX; cyclooxygenase, DAG; diacylglycerol, eNOS; 
endothelial nitric oxide synthase, IP3; triphosphoinositol, L-NAME; Nω-nitro-L-arginine methyl ester, M3R;l 
muscarinic receptor type 3, PE; phenylephrine, SNP; sodium nitroprusside. 
4.2.3 Myography statistical analysis 
Vasoconstrictor responses were normalised as a percentage to the maximal constriction 
recorded with KPSS (section 2.3.2). Vasodilation responses were first normalised to a 
percentage of the preconstriction tension elicited with 5-HT (section 2.3.2) before being 
converted to ‘Relaxation’ values by subtracting responses from 100. Summary statistics for 
maximal constriction/dilation (EMax) and sensitivity, measured as the concentration required 
for 50% EMax, (EC50 or IC50 where vessels relaxed) were generated using linear regression of 
curves. EC50 values were converted to either pD2 for contraction responses or -Log(IC50) for 
relaxation responses using the formula = -Log(EC/IC50). The change in maximal 
constriction/relaxation caused by L-NAME/Indomethacin addition was also calculated 
(∆EMax). For the 20-week groups (C57BL/6 CD, Tst-/- CD, C57BL/6 HFD and Tst-/- HFD) 
statistical comparisons were made using the generated summary statistics (EMax, pD2/-
Log(IC50), ∆EMax) on the effect of diet and genotype using two-way ANOVA with 
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Bonferroni post hoc tests made between genotypes. The two 7-week groups (C57BL/6 HFD 




4.3.1 Tst–/– mice have similar body weights to C57BL/6 controls 
C57BL/6 and Tst–/– mice fed chow diet for 20 weeks had comparable body weights at the 
time of cull (Figure 4.3B). In mice fed HFD for 7-weeks, final body weights were similar to 
those in 20-week control fed mice (37-39 g) but there was no difference in body weight 
between C57BL/6 and Tst–/– mice. HFD feeding for 20 weeks induced glucose intolerance 
(shown in section 3.3.2) and increased body weight in both genotypes compared to control 
diet (2-way ANOVA p < 0.0001, Figure 4.3B) fed but there was no difference in body 
weights of C57BL/6 and Tst–/– mice at the time of cull (Figure 4.3B).  
 
 
Figure 4.3 Body weights in C57BL/6 and Tst–/– mice fed chow or high fat diet for 7 or 20 weeks. A) Final 
body weights from mice fed HFD only for 7 weeks. B) Final body weights from mice control or HFD for 20 
weeks. Data are presented as Mean ± SEM. n = 6 for both 7-week groups; for 20-week data n = 8 (C57BL/6 CD), 
8 (Tst–/– CD), 7 (C57BL/6 HFD), and 8 (Tst–/– HFD). 7-week data were compared using Student’s unpaired t test, 

































































4.3.2 Tst mRNA is expressed in aorta 












Figure 4.4. Tst mRNA is present in aortic tissue. Quantitative real time reverse transcriptase PCR was performed 
on aorta and liver samples taken from C57BL/6 mice. Analysis using a mixed standard curve showed a low but 





















4.3.3 Tst deletion reveals a NOS- and COX-independent component of ACh-mediated 
relaxation in aortae from HFD-fed mice 
ACh produced a concentration-dependent relaxation in isolated aorta and these responses 
were similar in C57BL/6 and Tst–/– mice fed chow diet (Figure 4.5A) for 20 weeks. The 
combination of L-NAME (10-4 M) and indomethacin (10-5 M) reduced ACh-mediated 
relaxation to 1/3 of its standard response in 20-week control diet-fed C57BL/6 mice 
(C57BL/6 EMax Standard 75.1 ± 2.3%, +L-NAME/Indomethacin 19.2 ± 4.8%, Figure 4.5A, 
Table 4.1). 
ACh-mediated relaxation was not impaired in either genotype by 7 or 20 weeks of HFD 
feeding (Figure 4.5B, C & Table 4.1). The addition of L-NAME and indomethacin reduced 
relaxation in aortas from C57BL/6 HFD mice to a similar degree to that seen in chow-fed 
mice (C57BL/6 CD EMax + L-NAME/Indomethacin 19.2 ± 4.8%, C57BL/6 HFD 21.4 ± 
4.8%, Table 4.1). However, in Tst–/– mice fed HFD for 7 or 20 weeks L-NAME and 
indomethacin addition was less effective at reducing relaxation than in C57BL/6 HFD 
groups (Figure 4.5B, C, Table 4.1) resulting in a significant residual relaxation compared to 
C57BL/6 mice.  
Comparison of ΔEMax values (Table 4.1) showed that the efficacy of L-NAME/Indomethacin 
in reducing ACh-mediated relaxation was unaffected by diet (C57BL/6 ΔEMax chow 55.9%, 
HFD 52.3%). However, Tst–/– mice fed either chow or HFD had a trend towards smaller 
∆EMax values compared to C57BL/6 mice (Table 4.1, genotype p = 0.06). ΔEMax also showed 
a trend towards being reduced in Tst–/– mice fed HFD for 7 weeks when compared to 
C57BL/6 fed HFD (ΔEMax C57BL/6 53.7 ± 5.8%, Tst–/– 36.9 ± 4.9%, p = 0.07, Table 4.1). 
Endothelium independent relaxation was investigated in 7-week HFD mice using the NO 
donor compound SNP. Relaxation of vessels in response to SNP was similar in C57BL/6 and 
Tst–/– mice (Figure 4.6). The addition of L-NAME and indomethacin did not affect the 
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Figure 4.5 Acetylcholine-mediated vasodilation in C57BL/6 and Tst–/– mice fed chow or HFD for 7 or 20 
weeks. A) Acetylcholine-mediated relaxation of aortae from C57BL/6 and Tst–/– mice fed chow diet. 
Pharmacological inhibitors L-NAME (10-4 M) and indomethacin (10-5 M) were used and responses + L-
NAME/Indomethacin are shown with dashed lines. B) The impact of 7 weeks of high fat diet (HFD) feeding on 
acetylcholine-mediated relaxation of aortae from C57BL/6 and Tst–/– mice. C) Acetylcholine-mediated relaxation 
following 20 weeks of HFD feeding. Data are Mean ± SEM. 20-week chow and HFD summary statistics were 
compared using 2-way ANOVA and Bonferroni post hoc testing. 7-week summary statistics were tested using 
Student’s t test. Data were compared between genotypes and diet groups and not between standard and +L-
NAME/Indomethacin responses. For 20-week data n = 8 (C57BL/6 CD), 7 (Tst–/– CD), 6 (C57BL/6 HFD), and 8 
(Tst–/– HFD); for 7-week groups n = 4 for both genotypes. † indicates genotype p<0.05 in 2-way ANOVA, ** 














Figure 4.6 Sodium nitroprusside (SNP)-mediated relaxation of aortae from C57BL/6 and Tst–/– mice fed 
HFD for 7 weeks. The effects of L-NAME (10-4 M) and indomethacin (10-5 M) on SNP-induced vessel 
relaxation are shown using dashed lines. Data are Mean ± SEM. Summary statistics for C57Bl/6 and Tst–/– 
responses were tested using Student’s unpaired t test. n = 6 for both groups. SNP; sodium nitroprusside. 




















Table 4.1 Summary statistics of vasodilator responses in C57BL/6 and Tst–/– mice fed control diet for 20 
weeks or high fat diet for 7 or 20 weeks. Data are presented as Mean ± SEM. 7-week data were tested using 
Student’s unpaired t test, 20-week data were tested using 2-way ANOVA with Bonferroni post-hoc testing. ** 
indicates p < 0.01 by Student’s t test. For 7-week ACh data n = 4 for both genotypes; for 7-week SNP data n = 6 
for both genotypes; for 20-week data n = 8 (C57BL/6 CD), 7 (Tst–/– CD), 6 (C57BL/6 HFD), and 8 (Tst–/– HFD). 
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73.7 ± 7.1 
75.9 ± 
3.1 






7.3 ± 0.1 
7.2 ± 
0.1 






21.4 ± 4.8 
37.0 ± 
3.5 






7.7 ± 0.2 
7.2 ± 
0.3 






52.3 ± 8.0 
39.4 ± 
6.3 
0.06, 0.66, 0.93 
114 
 
4.3.4 Long term HFD feeding reduces L-NAME/Indomethacin-induced enhancement 
of agonist mediated contraction in aortas from C57BL/6 but not from Tst–/– mice 
PhE and 5-HT induced concentration–dependent contractions in aortae from chow-fed 
C57BL/6 mice. These responses were not altered by in Tst–/– mice (Figures 4.7 A&B). 
Addition of L-NAME/Indomethacin led to an increase (>2 fold) in PhE-mediated contraction 
(C57BL/6 EMax Control 111.8 ± 12.9%, +L-NAME/Indomethacin 240.8 ± 8.1%, Figure 
4.7A, Table 4.2). An increase with L-NAME/Indomethacin addition was also seen when 5-
HT was used to elicit contraction (C57BL/6 EMax Control 175 ± 11.3%, +L-
NAME/Indomethacin 247.9 ± 9.9%, Figure 4.7B, Table 4.2). Maximum contraction was 
similarly increased by the addition of L-NAME/Indomethacin to aortas from chow-fed Tst–/– 
mice (Figure 4.7A&B, Table 4.2). 
7-week HFD feeding did not alter contractile responses to PhE or 5-HT in C57BL/6 or Tst–/– 
mice in the absence of inhibitors (Figure 4.7C, D; Table 4.2). Consistent with previous 
results addition of the combination of L-NAME/Indomethacin led to an increase in PhE-
mediated contraction (C57BL/6 EMax Control 143.5 ± 8%, +L-NAME/Indomethacin 235.4 ± 
10.7%, Figure 4.7C, Table 4.2). However, in 7-week HFD fed mice the increase in 
contraction caused by L-NAME/Indomethacin was not as pronounced when 5-HT was used 
to elicit contraction (C57BL/6 EMax Control 242.1 ± 12.7%, +L-NAME/Indomethacin 264.7 
± 21.3%, Figure 4.7D, Table 4.2). Similar increases in maximum contraction caused by L-
NAME/Indomethacin addition were also observed in aortae from Tst–/– mice (Figure 4.7C, 
D, Table 4.2). Calculation of ΔEMax values for PhE and 5-HT-mediated constriction with L-
NAME/Indomethacin addition confirmed the identical response of aortae from C57BL/6 and 
Tst–/– mice to L-NAME and indomethacin (Table 4.2).  
20-week HFD feeding did not alter contractile responses to PhE or 5-HT in either genotype 
in the absence of inhibitors (Figure 4.7E, F; Table 4.2). However, in the presence of L-
NAME/Indomethacin PhE- and 5-HT-mediated contraction was lower in C57BL/6 than in 
Tst–/– mice (5-HT genotype p = 0.03, PhE genotype p = 0.004, Figure 4.7E, F; Table 4.2). 
Calculation of ΔEMax values showed that the enhancement of agonist-induced constriction by 
L-NAME and indomethacin was lower in aortae from HFD-fed C57BL/6 mice than those 
from Tst–/– mice for both 5-HT (ΔEMax C57BL/6 20W HFD 30.9 ± 5.5%, Tst–/– 82.3 ± 15.3%, 
p <0.05 Bonferroni post hoc test, Table 4.2) and PhE (ΔEMax C57BL/6 20W HFD 96.2 ± 





























Figure 4.7 Phenylephrine and 5-hydroxytryptamine vasoconstriction responses in C57BL/6 and Tst–/– mice 
fed control diet for 20 weeks or high fat diet for 7 and 20 weeks. Responses are presented as normalised 
percentages to the vessels maximal constriction with KPSS. Dashed lines are responses + L-NAME and 
indomethacin (indicated by ‘+LN/I’ in figure legend). A) and B) Phenylephrine or 5-HT-mediated 
vasoconstriction in 20-week chow fed mice. C) and D) Phenylephrine or 5-HT-mediated vasoconstriction 
following 7 weeks of HFD. E) and F) Phenylephrine or 5-HT-mediated vasoconstriction following 20 weeks of 
HFD. Data are Mean ± SEM. 20-week chow and HFD data were tested with 2-way ANOVA and Bonferroni post 


































































































































































NAME/Indomethacin responses. 7-week data were tested using Student’s unpaired t test. For 20-week data n = 8 
(C57BL/6 CD), 7 (Tst–/– CD), 6 (C57BL/6 HFD), and 8 (Tst–/– HFD); for both 7-week groups n = 4-6. † indicates 




Table 4.2 Summary statistics of vasoconstrictor responses in C57BL/6 and Tst–/– mice fed control diet for 
20 weeks or high fat diet for 7 or 20 weeks. Data are Mean ± SEM. Contraction data were normalised as a 
percentage to the maximal response of the vessel to KPSS; EMax and pEC50 values were determined using linear 
regression of responses. The change in response because of L-NAME and indomethacin addition was calculated 
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5.4 ± 0.3 
5.1 ± 
0.3 






- EMax 175 ± 11 
207 ± 
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+ EMax 248 ± 10 
264 ± 
16 





+ pD2 7.0 ± 0.1 
7.0 ± 
0.03 





+/- ΔEMax 73 ± 13 
57 ± 
12 






- EMax 112 ± 13 
113 ± 
11 















+ EMax 241 ± 8 
253 ± 
12 





+ pD2 7.2 ± 0.1 
7.1 ± 
0.1 





+/- ΔEMax 129 ± 20 
136 ± 
19 







test, 20-week data were tested using 2-way ANOVA with Bonferroni post-hoc testing. * or ** indicates p < 0.05 
or <0.01, respectively by Bonferroni post-hoc test. For 20-week data n = 8 (C57BL/6 CD), 7 (Tst–/– CD), 6 
(C57BL/6 HFD), and 8 (Tst–/– HFD); for both 7-week groups n = 4-6. 5-HT; 5-hydroxytryptamine, CD; control 





The work shown in this chapter describes  the attempt to assess the effects of deletion of an 
enzyme of the sulfide oxidising unit (SQR, ETHE1 and TST) (168) on vascular function. 
The work addressed the hypothesis that impaired clearance of H2S would protect against 
endothelial cell dysfunction induced by high fat feeding. It was hypothesised that this 
protection would occur despite a potential for worsened hyperglycaemia, a predisposing 
factor for endothelial dysfunction (61), in Tst–/– mice fed HFD as previously observed 
(section 3.3.2).  
In chow-fed C57BL/6 mice ACh-induced relaxation was significantly reduced, and agonist-
induced contraction was enhanced, by inhibition of endothelium-derived vasodilator (NO, 
prostaglandins) production, consistent with published work (265–267). Contractile responses 
were largely unchanged in Tst–/– mice compared to C57BL/6. However, Tst–/– mice did 
demonstrate a small but significant residual vasodilator response in the presence of L-NAME 
and indomethacin which was not seen in C57BL/6 mice. This residual response was 
exaggerated in HFD fed Tst–/– mice following both 7 and 20 weeks of HFD feeding. HFD in 
C57BL/6 mice, perhaps unexpectedly, did not impair ACh-mediated relaxation. However, 20 
weeks HFD feeding reduced the enhancement of contractile response caused by L-
NAME/Indomethacin addition in C57BL/6 mice. In contrast, aortae from Tst–/– mice fed 
HFD for 20 weeks did not exhibit the reduced contractile response when exposed to 
inhibitors and instead maintained similar contraction responses to those of control diet fed 
mice. 
4.4.1 Tst expression in the aorta 
BioGPS data (208) suggest that Tst is abundantly expressed in many tissues including liver, 
stomach, intestine, brain, lung, kidney, heart, adipose and muscle but expression in the 
vasculature has not been previously determined. The highest expression levels of Tst are 
observed in liver and intestine (208), consistent with a role for Tst in detoxification. Data 
have previously shown that high Tst expression in tissues such as liver is correlated with 
high levels of Tst activity (Carter et al. Unpublished observations).  
Results reported in this chapter showed that Tst was expressed at a low level in aortic tissue 
compared to liver but was readily detectable and, therefore, may have a role in clearance of 
H2S within this vessel. This represents the first confirmation that Tst, a protein of the Sulfide 
Oxidising Unit (SOU) (168), is expressed within the aorta. The expression of sulfide:quinone 
reductase (SQR) and sulfide dioxygenase (SDO, historically ETHE1) which along with TST 
comprise the SOU in the mitochondria (169) has not yet been confirmed. However, the 
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expression of CSE in the aorta (253) and the reported levels of free sulfide (256) within 
aortic tissue suggest that it is likely that cells will express the proteins responsible for 
breakdown given the high toxicity of H2S.  
4.4.2 The effects of Tst deletion on vasodilator responses 
This chapter addressed the hypothesis that deletion of Tst would influence arterial function, 
particularly in the presence of the metabolic stress (e.g. hyperglycaemia) induced by high fat 
feeding. Surprisingly, HFD did not impair ACh-mediated relaxation in either C57BL/6 or 
Tst–/– mice. This was unexpected given previous findings of reduced reactivity to ACh in 
aortas from HFD fed mice (15, 39) and due to the suggested role of hyperglycaemia in 
causing endothelial dysfunction in humans and mouse models (12, 27, 32). However, the 
published literature on the influence of high fat diet on vascular function is somewhat 
contradictory. Groups have previously reported that C57BL/6 mice do not develop aortic 
endothelial dysfunction following exposure to high fat diet (268). For example, d’Uscio et 
al. demonstrated that aortae from 30-week-old C57BL/6 mice fed a “western diet” for 26 
weeks did not develop endothelial dysfunction with ACh inducing >85% relaxation in 
preconstricted vessels (9). HFD-induced endothelial dysfunction is also contentious in 
atherosclerosis-prone ApoE–/– mice (23). Jiang et al. reported that aortic endothelial cell 
dysfunction in ApoE–/– mice developed only in the abdominal aorta and no changes were 
observed in the thoracic aorta (14). Furthermore, Gervias et al. also demonstrated that 20-
week western diet feeding had no effect on aortic endothelial cell function in ApoE–/– mice 
compared with C57BL/6 controls (11). Studies in humans using brachial flow-mediated 
dilation measurements to assess endothelial function have revealed contradictory results 
where short-term high fat diets either induced dysfunction (25) or had no effect (29). These 
data suggest that endothelial dysfunction because of HFD feeding remains controversial and 
further studies are needed.  
The marked reduction of ACh-mediated relaxation by the combination of L-NAME and 
Indomethacin is consistent with previous observations from eNOS–/– mice (265) that ACh-
mediated relaxation of the aorta is predominantly mediated by the release of endothelium-
derived NO. In aortas from Tst–/– mice the L-NAME/Indomethacin-induced inhibition of 
ACh-mediated relaxation was decreased compared to C57BL/6 controls. In the 20-week 
cohort this effect was more pronounced in HFD-fed mice. After 7-weeks of HFD the reduced 
effectiveness of L-NAME/Indomethacin-induced inhibition of ACh-mediated vasodilation in 
Tst–/– mice compared to C57BL/6 is striking. The residual relaxation response in aortae from 
Tst–/– mice (particularly those fed HFD) in the presence of L-NAME/Indomethacin suggests 
a role for additional endothelium-derived relaxing factors (EDRFs), of which several have 
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been identified in other arteries (269). Previous investigations have shown that alterations in 
the balance of EDRFs can occur. In patients with Normal Pressure Glaucoma (NPG) it was 
noted that endothelium-derived hyperpolarising factor (EDHF) made a greater contribution 
to resistance artery relaxation than observed in non-diseased controls, suggesting endothelial 
cells from NPG patients had an altered balance of EDRFs. This supports the idea that similar 
alterations to the balance of EDRFs could occur in Tst–/– mice. Given the suspected effects of 
Tst deletion on H2S signalling (inferred from the findings of Morton et al. of increased whole 
blood H2S concentrations), a primary candidate for the additional relaxant response observed 
in the presence of L-NAME and indomethacin is H2S. Persulfidation and activation of 
smooth muscle KATP as well as involvement of Intermediate potassium (IKCa) and small 
potassium (SKCa) calcium sensitive channels leading to hyperpolarisation of the smooth 
muscle have established H2S as an EDHF (181). However, confirmation that H2S mediated 
EDHF was responsible for the observed effects in this chapter would require a detailed, 
systematic study using exposure to the relevant inhibitors of KATP (glibencamide), IKCa 
(charybdotoxin) and SKCa (apamin) to investigate their contribution to the additional 
vasodilation response (270,271).  
4.4.3 The effects of Tst deletion on vasoconstrictor responses 
Functional analysis in aortae from chow fed mice demonstrated that deletion of Tst had no 
effect on PhE, 5-HT or K+-mediated contraction in endothelium-intact blood vessels. These 
data suggest that Tst deletion does not induce a change in aortic constrictor function in chow 
fed mice. Addition of L-NAME/indomethacin promoted contraction in aortae from chow fed 
animals, consistent with previous evidence that endothelium-derived relaxant factors modify 
the vascular response to constrictors (266,267). This was not different in chow fed Tst–/– 
mice. Consistent with the investigations of vasodilator function, it appears that Tst deletion 
has no modulatory effect on vasoconstriction in mice fed a chow diet.  
20-week HFD feeding reduced the ability of L-NAME/Indomethacin to increase agonist-
induced contraction in aortae of C57BL/6 mice. Strikingly, this reduction did not occur in 
the aortae from Tst–/– mice. The reduction of L-NAME/Indomethacin’s ability to enhance 
contraction only occurred in the 20-week HFD fed C57BL/6 mice and not in 7-week fed 
mice. These data suggest that the reduction in L-NAME/Indomethacin enhancement of 
contraction only occurs with longer periods of HFD feeding or increased age of mice. The 
reduction of L-NAME/Indomethacin enhancement of contraction in 20-week HFD fed 
C57BL/6 mice is likely the result of reduced release of EDRFs by the endothelium in 
response to vasoconstrictors. This is supported by the finding that KPSS-induced contraction 
of vessels from HFD-fed mice was unchanged compared to chow fed mice, showing that 
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vessels do not simply have a decreased ability to contract in response to increased 
intracellular calcium. Instead the data suggest that HFD affects agonist-mediated receptor 
signalling in the endothelium and that deletion of Tst is protective against this effect. The 
mechanism of this protection is currently unknown however, a hypothesised mechanism is 
that H2S-induced activating phosphorylation of eNOS protein (167) or antioxidant effects of 
elevated sulfide lead to a reduction of oxidative stress in endothelial cells (260). Previous 
studies have not investigated this process as an aspect of aortic function in HFD fed mice 
and, therefore, these findings represent a first insight into the effects of HFD on the ability of 
the endothelium to modulate contractile responses. 
4.4.4 Conclusions 
Overall these data suggest that Tst deletion has little effect on baseline vasodilator or 
vasoconstrictor function in chow or HFD fed mice. In addition, only mild detrimental effects 
of HFD on vascular function were observed. HFD for 7 or 20 weeks did not reduce ACh-
mediated vasodilation or increase constrictor-mediated contraction, meaning it is hard to 
evaluate the effect of Tst on overt vascular dysfunction (i.e. a reduction in NO production) as 
this was not evident. However, investigations with L-NAME and indomethacin did reveal 
some latent changes in aortic responses in Tst–/– mice; these retained residual relaxation to 
ACh whereas this response in aortas from C57BL/6 were nearly completed inhibited. 
Finally, it was also observed that 20-week HFD did in fact reduce L-NAME/Indomethacin-
induced enhancement of constrictor-mediated contraction in C57BL/6 mice. 
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5.0 The effects of Tst gene deletion on atherosclerosis 
development in ApoE–/– mice 
5.1 Introduction 
5.1.1 Atherosclerosis 
Cardiovascular disease (CVD) is the leading cause of death worldwide and research from the 
WHO has shown it is highly prevalent in both developed and developing nations (109). 
Atherosclerosis, the formation of fatty plaques within blood vessels, is a frequent cause of 
CVD as plaque development within vessels creates a risk of rupture and thrombosis leading 
to vascular occlusion. This is the most common cause of stroke and myocardial infarction: 
two serious CVD events (45,112).  
Previous research has identified a number of modifiable risk factors associated with the 
development of atherosclerosis, including: increased plasma LDL cholesterol content, 
hyperglycaemia, high blood pressure and endothelial dysfunction (45). Therapies which can 
counter these risk factors, such as the reduction in blood cholesterol concentration using 
statins, have proven useful in reducing the occurrence of severe CVD events associated with 
atherosclerotic disease (140,272). Small scale studies in atherosclerotic patients have also 
suggested that short term intensive statin therapy may be able to reduce the lipid content and 
size of atherosclerotic lesions directly (273). However, statins are not universally tolerated 
and studies have shown that they may increase patients risk of developing diabetes by 9% 
(140).  Therefore, they do not eliminate the need for other therapies. Moreover, there is some 
evidence that statins may increase the risk of T2DM, in part by increasing weight gain (274). 
Therefore, given the increasing rate of CVD worldwide there is extensive need for new 
treatments which can reduce atherosclerotic lesion development through alternative 
mechanisms of action. 
5.1.2 H2S and atherosclerosis 
Recent work by Mani et al. established a link between the availability of H2S and the 
development of atherosclerosis (187,275). They demonstrated that Cse–/– mice, which have 
low H2S levels, develop atherosclerotic lesions when fed a high fat (42% kcal) high 
cholesterol ‘western diet’. This occurred even in mice which did not have ApoE gene 
deletion: an unusual finding as atherogenesis in mice commonly requires severe alteration of 
the plasma cholesterol profile through ApoE or Ldlr gene deletion (44,125). Further to this, 
deletion of the Cse gene on an ApoE–/– background (ApoE–/–Cse–/– mice) led to a worsening 
of lesion development compared to ApoE–/– controls (187). The authors identified a number 
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of potential causes for the increase in lesion development, including: increased plasma LDL 
cholesterol, increased systolic blood pressure (SBP), and increased oxidative stress and 
endothelial cell expression of the macrophage adhesion molecule intercellular adhesion 
molecule 1 (ICAM-1); a feature of endothelial dysfunction (276). Hydralazine and ezetimibe 
were used to reduce SBP and plasma cholesterol, respectively in mice with Cse deletion, but 
this did not reduce lesion area. The authors therefore concluded that increased endothelial 
ICAM-1 expression because of decreased H2S signalling which led to increased endothelial 
ROS and ICAM-1 expression. Therefore, it appears that with regards to atherosclerotic 
lesion development the availability of H2S within the vascular endothelium is more 
important than modulation of risk factors such as cholesterol and SBP.   
Strikingly, in Cse–/– and ApoE–/–Cse–/– mice, administration of intravenous NaHS reduced 
lesion volume and in Cse–/– only also reduced SBP and plasma cholesterol. In combination, 
these findings presented clear evidence that exogenous H2S donor protects against 
atherosclerosis and should be investigated as a therapy for the reduction of atherosclerotic 
lesion volume.  
Mani et al. and many other researchers in related fields have used exogenous H2S 
administration or reduced endogenous production to investigate the effects of H2S. However, 
no group to date has investigated whether decreased H2S elimination through endogenous 
breakdown pathways could elicit similar effects in models of CVD disease. As previously 
discussed (sections; 1.5, 3.0 and 4.0) Tst–/– mice represent a model in which a protein of the 
mitochondrial H2S breakdown pathway is absent logically suggesting that H2S breakdown 
will be compromised. Pilot data has shown that circulating H2S concentrations are increased 
in Tst–/– mice compared to C576BL/6 controls (section 1.5.1) and in addition the glucose 
intolerance observed in Tst–/– mice is also consistent with the literature findings of increased 
H2S concentrations (section 3.0). Tst–/– mice therefore represent a useful model for the 
investigation of whether endogenously elevated H2S concentrations can affect atherosclerotic 
lesion size. 
5.1.3 Hypothesis and aims 
In this chapter, it was hypothesised that:  vascular protective actions in Tst–/– mice 
predominate over the detrimental metabolic changes and result in decreased 






 To generate an ApoE–/–Tst–/– double knockout mouse for use in atherosclerotic 
investigations and confirm Tst deletion. 
 To determine whether Tst gene deletion on the ApoE–/– genetic background induces 
metabolic dysfunction by examining glucose homeostasis (glucose tolerance test) 
 To determine whether Tst gene deletion reduces atherosclerotic lesion formation 
induced by 12 weeks of western diet feeding in ApoE–/– mice using optical projection 
tomography. 
 To investigate the consequences of Tst gene deletion on key risk factors for 
atherosclerosis on the ApoE–/– genetic background by examining SBP (tail cuff 
plethysmography) and plasma lipid concentrations in western diet fed ApoE–/– and 
ApoE–/–Tst–/– mice.  
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5.2 Materials and methods 
5.2.1 TST activity 
Liver and aortic protein samples were isolated from chow diet-fed ApoE–/– and ApoE–/–Tst–/– 
mice (section 2.5.1). Protein concentration was assayed (section 2.5.2) and 50 µg of protein 
were used to prepare TST activity reactions (section 2.4.5). A negative (no enzyme) control 
was run in parallel with samples and its absorbance subtracted from samples before further 
analysis. Unknown SCN- concentrations (a measure of TST activity) from experimental 
samples were then interpolated from a linear SCN- standard curve prepared on the same 96 
well plate as samples. 
5.2.2 Atherosclerotic lesion quantification and metabolic phenotyping in ApoE–/– and 
ApoE–/–Tst–/– mice fed western diet 
ApoE–/– and ApoE–/–Tst–/– mice (bred as described in section 2.1.3) were maintained in a 12-
hour light/dark cycle and humidity-controlled environment (section 2.1). During experiments 
mice were given ad-libitum access to 42% fat (kcal) and 0.15% (w/w) cholesterol – the so 
called ‘western Diet’ (829100, Special Diet Services, Witham, UK) for 12 weeks to induce 
lesion formation in line with previous literature (8, Figure 5.1). The operator was blinded to 
mouse genotype at the beginning of feeding and mice were selected for experimental days 















Figure 5.1 Experimental design of investigations into the effect of Tst gene deletion on atherosclerosis. 
ApoE–/– or ApoE–/–Tst–/– mice were fed for 12 weeks with 42% (kcal) fat and 0.15% (w/w) cholesterol ‘western 
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diet’ to induce lesion formation. During feeding a glucose tolerance test (section 2.2.2) was performed on mice 
following 5 or 6 weeks of western diet feeding for female or male mice, respectively. Systolic blood pressure was 
measured during weeks 10 &11 using a tail cuff measurement system (section 2.2.4). Mice were measured 
twice/week over 2 weeks to reduce the stress response to the procedure and the final day measurements were used 
for analysis. Following completion of the diet, final body weights were recorded and the aortic arch including the 
brachiocephalic, left common carotid and left brachiocephalic arteries was dissected following perfusion fixation 
(section 2.7.1). In male mice, a terminal blood sample was also collected for measurement of plasma cholesterol 
and triglyceride content (section 2.3.1). Lesion volume quantification in the right brachiocephalic branch was 
measured using optical projection tomography (OPT, section 2.7.1). Scanning and analysis of aortic arches from 
female mice was performed by Ms. Charlotte Hickman. Male body weight data from western diet fed mice was 
combined with age matched animals from a subsequent study including control diet fed mice and tested using 2-
way ANOVA. All other data were tested using Student’s t test. Glucose tolerance test data was analysed using 
General Linear Model ANOVA due to the number of relevant factors for testing (time, genotype, diet). 





5.3.1 Confirmation of Tst deletion in ApoE–/–Tst–/– mice liver and aorta 
Genotyping of mice for Tst and ApoE was performed by Transnetyx (Cordova, US). For 
confirmation, a TST activity assay was performed using protein isolated from ApoE–/– and 
ApoE–/–Tst–/– control fed mice (Figure 5.2). Equal protein concentrations were added for each 
tissue (50 µg). TST activity in ApoE–/– mice liver was 20x higher in liver tissue than in aorta. 
This was especially notable as liver samples were incubated for only 30 minutes compared 
with 4 hours in aorta. Despite this there was still a clear loss of activity in both tissues from 
ApoE–/–Tst–/– mice (liver p < 0.0001, aorta p = 0.003) confirming successful breeding of the 




Figure 5.2 TST activity measured in liver and aortic protein samples from ApoE–/– and ApoE–/–Tst–/– control 
fed mice. A) TST activity (measured as SCN- production from S2O32- and KCN) in 50 µg of liver protein. 
Samples were incubated for 30 minutes. B) TST activity in 50 µg of protein isolated from aorta, note the 
difference in y-axis scale between graphs. Samples were incubated for 4 hours. Data are presented as Mean ± 









































 5.3.2 Tst deletion reduces final body weight in ApoE–/– fed western diet 
Male ApoE–/– and ApoE–/–Tst–/– mice were fed control AIN93M diet or western diet for 12 
weeks. Weekly body weights showed that WD feeding led to increased body weight in both 
genotypes. Body weights at week 12 were not taken as mice were fasted. ApoE–/–Tst–/– mice 
did not appear to gain as much weight and this was particularly noticeable at later weeks. 
Analysis of the body weights at week 11 confirmed that diet significantly increased body 
weight (2-way ANOVA diet p < 0.0001) but that ApoE–/–Tst–/– fed WD had lower body 
weight than ApoE–/– controls (Bonferroni post-hoc test p < 0.05).  
A cohort of Female ApoE–/– and ApoE–/–Tst–/– were also fed WD for 12 weeks. As seen in 
male mice, WD feeding led to weight gain in female mice (Figure 5.3C). However, there was 
no difference in body weight between ApoE–/– and ApoE–/–Tst–/– mice when this was 










Figure 5.3 Body weight measurements in male or female ApoE–/– and ApoE–/–Tst–/– mice fed AIN93M 
control or ‘western’ diet. A) Body weights were taken weekly over an 11-week period in male ApoE–/– and 
ApoE–/–Tst–/– mice fed AIN93M or western diet. B) Final body weights in male mice. C) Body weights were 
taken weekly over an 11-week period in female ApoE–/– and ApoE–/–Tst–/– mice fed AIN93M or western diet. 
Week 12 data are not shown as these measurements were taken after a fasting period. D) Final body weights 
(unaffected by fast) in female mice. Data are presented as Mean ± SEM. n = 8 (ApoE–/– CD), 5 (ApoE–/–Tst–/– 
CD), 16 (ApoE–/– WD) and 14 (ApoE–/–Tst–/– WD) for male mice and 7 (ApoE–/– WD) and 11 (ApoE–/–Tst–/– WD) 
for female mice. Data from male mice were tested using 2-way ANOVA and Bonferroni post-hoc tests. Data 
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from female mice were tested using Student unpaired t test. * indicates p < 0.05 by Bonferroni test. CD; control 




5.3.3 Tst deletion worsens glucose tolerance in male ApoE–/– mice fed western diet 
Glucose tolerance tests were performed in female and male mice following 5 or 6 weeks of 
western diet feeding, respectively. In male mice, the degree of glucose intolerance was more 
severe than female mice (Figure 5.4B). Male ApoE–/–Tst–/– mice also presented with more 
glucose intolerance compared with ApoE–/– controls (General Linear Model; genotype p = 
0.006). No differences were observed between female ApoE–/– and ApoE–/–Tst–/– genotypes 
(General Linear Model; genotype p = 0.28).  
Blood insulin concentrations were measured over the time course of the GTT for male mice. 
These data (Figure 5.5) showed a clear deficit of insulin production in ApoE–/–Tst–/– mice 
compared to ApoE–/– (General Linear Model; genotype p < 0.0001).  
 
 
Figure 5.4 Glucose tolerance tests (GTT) in male and female ApoE–/– or ApoE–/–Tst–/– mice fed western diet. 
A) Glucose tolerance tests on male ApoE–/– and ApoE–/–Tst–/– mice fed Western diet for 6 weeks. B) Glucose 
tolerance tests on female ApoE–/– and ApoE–/–Tst–/– mice fed Western diet for 5 weeks. Data are presented as 
Mean ± SEM. n = 9 for both Male groups. n = 7 ApoE–/–/11 ApoE–/–Tst–/– for Female groups. Data were tested 
















Genotype p = 0.006




























































Figure 5.5 Blood insulin concentration across the glucose tolerance test in male ApoE–/– and ApoE–/–Tst–/– 
mice fed western diet for 6 weeks. Blood insulin concentration was recorded over the time course of a glucose 
tolerance test in male ApoE–/– and ApoE–/–Tst–/– mice fed Western diet for 6 weeks. Data are presented as Mean ± 
SEM. n = 9 for both groups. Data were tested using General Linear Model ANOVA (genotype, mouse number, 

























l) Genotype p < 0.0001
133 
 
5.3.4 Tst deletion reduces lesion volume in ApoE–/– mice fed western diet 
Volumetric and mean cross sectional area measurements of atherosclerotic lesion size were 
assessed in male and female ApoE–/– and ApoE–/–Tst–/– mice following 12 weeks of western 
diet feeding using OPT. CTan analysis software generated summary statistics for assessment 
including: volume of the vessel lumen (lumen volume); volume of the lesion (lesion 
volume); percentage lesion volume (lesion volume/lumen volume); mean lumen area 
(average 2D lumen area) and mean lesion area (mean 2D area of lesion). Additional 
information collected included maximal lesion area and maximal narrowing % (maximal: 
lesion area/region of interest). All statistics are detailed in Table 5.1.  
Overall male ApoE–/–Tst–/– mice had significantly reduced lumen volume, lesion volume, 
mean lumen area, mean lesion area and maximal lesion area compared to ApoE–/– mice. 
Percentage lesion volume and maximal narrowing were unchanged (Table 5.1). Lesion 
quantification in female mice was performed by Ms Charlotte Hickman. In these female 
mice, the ApoE–/–Tst–/– group exhibited a similar pattern in most parameters, i.e. decreased 
lumen and lesion volume/area compared to ApoE–/–, although this failed to reach significance 
(Table 5.1). Trends towards reduced lumen and lesion volume were noted (Total VOI p = 
0.098, object volume p = 0.077) as well as a trend for reduced maximal lesion area (p = 













BCA LCC LSA 















Figure 5.6 Atherosclerotic lesion volume measurement by Optical Projection Tomography (OPT). A) An 
example image generated during 360o scanning. Signal was recorded from the tissues auto-fluorescence in the 
GFP channel. The black lines indicate the volume of interest where lesion volume was measured; between the 
emergence of the brachiocephalic trunk from the aortic arch and the bifurcation into the right subclavian and 
common carotid arteries. The red line indicates the transverse slice show in image B. B) Examples showing the 
different steps of analysis for lesion quantification from transverse reconstructed slices (i). A region of interested 
is manually drawn around the lumen of the vessel (ii), thresholds for signal detection are adjusted (iii) and finally 
the program models and measures the identified object (iv). BCA; brachiocephalic artery, LCC; left common 
















Measurement ApoE–/– ApoE–/–Tst–/– P 
Lumen volume (x106 µM3) 260.1 ± 14.2 220.0 ± 12.1 0.046 
Lesion volume (x106 µM3) 121.6 ± 11.4 81.2 ± 15.1 0.048 
Percentage lesion volume (%) 46.0 ± 2.6 35.9 ± 6.0 0.14 
Mean lumen area (x103 µM2) 218.2 ± 11.0 176.9 ± 10.4 0.02 
Mean lesion area (x103 µM2) 101.6 ± 9.2 66.5 ± 12.8 0.04 
Maximal lesion area (x103 µM2) 166.0 ± 9.2 115.8 ± 14.5 0.01 
Maximal lumen narrowing (%) 67.3 ± 3.1 59.2 ± 6.4 0.27 
Females 
Lumen volume (x106 µM3) 221.4 ± 23.5 181.4 ± 10.6 0.10 
Lesion volume (x106 µM3) 108.1 ± 28.2 57.7 ± 11.9 0.08 
Percentage lesion volume (%) 44.3 ± 10.3 30.7 ± 5.7 0.23 
Mean lumen area (x103 µM2) 185.3 ± 17.0 163.6 ± 10.0 0.25 
Mean lesion area (x103 µM2) 90.3 ± 22.4 53.6 ± 12.4 0.14 
Maximal lesion area (x103 µM2) 166.9 ± 40.1 98.9 ± 16.0 0.09 
Maximal lumen narrowing (%) 63.1 ± 11.2 49.4 ± 5.6 0.24 
Table 5.1 Atherosclerotic lesion quantification in male and female ApoE–/– and ApoE–/–Tst–/– mice fed 
western diet for 12 weeks. Data are presented as Mean ± SEM. n = 9 for both Male groups. n = 7 ApoE–/–/11 
ApoE–/–Tst–/– for Female groups. Data were tested using Student’s unpaired t test.  
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5.3.5 Tst deletion induces a trend towards decreased systolic blood pressure in male 
ApoE–/– mice fed western diet  
SBP was recorded in ApoE–/– and ApoE–/–Tst–/– mice fed western diet for 11 weeks. No 
difference in genotype was noted in female mice (Figure 5.7B); however, a trend towards 
reduced SBP in ApoE–/–Tst–/– compared to ApoE–/– mice was noted in male animals (Figure 
5.7A, p = 0.09).  
 
 
Figure 5.7 Systolic blood pressure in male and female ApoE–/– and ApoE–/–Tst–/– mice fed western diet for 11 
weeks. A) SBP in male ApoE–/– and ApoE–/–Tst–/– mice fed western diet for 11 weeks. B) SBP in female ApoE–/– 
and ApoE–/–Tst–/– mice fed western diet for 11 weeks. Data are presented as Mean ± SEM. n = 9 for both Male 



















































5.3.6 Tst deletion reduces plasma cholesterol content in male ApoE–/– mice 
Plasma cholesterol quantification was performed by Dr Anne Muhr-Tailleux in collaboration 
with Prof. Bart Staels (Figure 5.8). This showed that total cholesterol was lower in ApoE–/–
Tst–/– mice than in ApoE–/– controls. This was the result of a significant reduction in VLDL 
cholesterol content and a trend towards reduction in LDL cholesterol (Table 5.2).  
 
Figure 5.8 Plasma cholesterol gel filtration chromatography profile in Male ApoE–/– and ApoE–/–Tst–/– mice 
fed western diet for 12 weeks. Cholesterol concentrations in the major lipoprotein fractions are detected by 
filtration of the sample through a gel column. As the sample is eluted it reacts with a cholesterol detection agent 
(section 2.3.1). Data are presented as Mean. n = 8 (ApoE–/–), 9 (ApoE–/–Tst–/–). HDL; high density lipoprotein, 
LDL; low density lipoprotein, VLDL; very-low density lipoprotein.  
Table 5.2 Plasma cholesterol quantification in male ApoE–/– and ApoE–/–Tst–/– mice fed western diet for 12 
weeks. Data are Mean ± SEM. n = 8 ApoE–/–/9 ApoE–/–Tst–/–. Data were tested using Student’s unpaired t test.  
Measurement (mg/dL) ApoE–/– ApoE–/–Tst–/– P 
Total Cholesterol 1203 ± 85.2 983.2 ± 47.5 0.03 
VLDL Cholesterol 540.9 ± 53.5 396.3 ± 23.8 0.02 
LDL Cholesterol 552.2 ± 34.2 473.0 ± 28.0 0.09 






This chapter tested the hypothesis that Tst gene deletion was protective in a model (ApoE–/– 
mice fed western diet) of atherosclerosis. Specifically, it was hypothesised that protection, in 
this case defined as a reduction in lesion volume, would occur in ApoE–/–Tst–/– mice despite 
any metabolic dysfunction induced by Tst deletion (as shown in previous chapters). 
The data presented broadly support this hypothesis. Male ApoE–/–Tst–/– mice demonstrated a 
reduction in various parameters used to assess lesion size compared to ApoE–/– mice. This 
reduction occurred despite worsened glucose tolerance in ApoE–/–Tst–/– mice; a known risk 
factor for atherosclerosis, and a finding consistent with previous investigations in  Tst–/– mice 
(204).  
Most likely due to a lack of statistical power only a trend towards reduced lesion volume was 
also observed in female ApoE–/–Tst–/– mice. No difference in glucose tolerance was noted in 
female mice. The lack of a metabolic phenotype in both ApoE–/– and ApoE–/–Tst–/– female 
mice is not surprising as it is known that female mice are resistant to a number of 
cardiovascular and metabolic diseases due to the protective actions of oestrogen (238,277). 
However, the finding that Tst deletion does not induce metabolic dysfunction in female mice 
is novel.  
Potential mechanisms were identified that may explain the reduction in lesion volume in 
male mice. Most prominently ApoE–/–Tst–/– mice had reduced plasma cholesterol compared 
to ApoE–/– mice. A trend towards reduced systemic blood pressure in ApoE–/–Tst–/– mice was 
also noted. 
5.4.1 Tst deletion reduces body weight in male ApoE–/– mice 
As expected, and previously shown, WD feeding induced substantial weight gain above that 
of the low-fat control diet (278,279) (in this case AIN93M). ApoE–/–Tst–/– mice had reduced 
body weight following 12 weeks of WD feeding but not when fed the AIN93M control diet. 
The cause of lower body weight in ApoE–/–Tst–/– mice is not clear from this study although 
interestingly data from chapter 3 also identified lower body weight in Tst–/– mice fed chow 
diet. Whether a common mechanism could be found to explain these findings is a topic for 
future investigation. 
Consistent with the normal parameters of the background strain (JAX C57BL/6 strain body 
weight information) female mice were found to have lower body weights than male mice 
even when fed WD. No difference in body weight was noticed in female mice between 
ApoE–/–and ApoE–/–Tst–/–. The findings of a lower  body weight in female than male mice was 
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expected as less weight gain on high fat diet has been observed and is attributed to the 
actions of oestrogen through the oestrogen receptor α promoting the use of lipids as an 
energy source and decreasing storage (238,277). The lack of body weight gain in female 
mice fed WD means that it is difficult to detect whether ApoE–/–Tst–/– mice fed WD have 
lower body weight than ApoE–/– as was found in male mice. 
5.4.2 Tst deletion worsens glucose tolerance and decreases insulin concentrations in 
male ApoE–/– mice 
In male mice both ApoE–/–and ApoE–/–Tst–/– genotypes exhibited substantial glucose 
intolerance at week 6 of western diet feeding. No control diet mice were tested for glucose 
tolerance within this study however, by comparing the glucose tolerance in WD fed mice to 
control diet fed mice from other studies or those tested in chapter 3 it is clear that 6-week 
WD fed male mice have severe glucose intolerance. Whether the glucose intolerance is a 
result of western diet feeding or just ApoE deletion cannot be assessed in this study. 
However, previous studies have shown that ApoE–/– mice fed a control diet of similar total fat 
content (11% kcal compared to 9.4% in this study)  for 12 weeks exhibit normal glucose 
tolerance (280). Therefore, it is likely that the poor glucose tolerance seen in both genotypes 
is a result of western diet feeding which has been shown to cause glucose intolerance in 
ApoE–/– and C57BL/6 mice (281,282). Female mice did not develop glucose intolerance 
when fed WD. This is not surprising as it is well known that oestrogen has a protective effect 
on glucose intolerance by increasing insulin sensitivity (283). For example it has previously 
been shown that female C57BL/6 mice fed 60% kcal fat HFD for 14 or 20 weeks are 
protected from glucose intolerance compared to male C57BL/6 mice (238,284). 
Tst deletion in male ApoE–/–mice led to a worsening of glucose tolerance. This effect is 
consistent with the previously published findings on C57BL/6N and Tst–/– mice fed ‘Surwit’ 
HFD for 6 weeks (204) and also with the evidence from chapter 3 that Tst deletion led to a 
worsening of glucose tolerance. Previously a difference in the genetic background at the 
NNT gene of the mice was suggested as a possible explanation for the difference in glucose 
tolerance of Tst–/– mice. C57BL/6N and 6J mice differ at the NNT gene and this has been 
found to worsen glucose tolerance in C57BL/6J mice (211,231,232). This was unlikely as 
mice were of a mixed N/J background, but it could not be ruled out as a cause of the altered 
glucose tolerance. In this study however, mice were bred, using a speed congenics 
backcrossing technique, to the C57Bl/6J background of ApoE–/–mice. During this 
backcrossing SNP genotyping at key 6N/J differences was performed to select the best 
animals for further breeding until animals were found to be of C57BL/6J background at all 
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SNPs. Therefore, it is now extremely unlikely that ApoE–/–and ApoE–/–Tst–/– could differ at 
the NNT gene. Instead the worsened glucose tolerance in ApoE–/–Tst–/– mice must be the 
result of Tst deletion.  
Glucose tolerance in female mice fed WD was unchanged by Tst deletion and both 
genotypes exhibited comparable glucose tolerance results to those observed in control diet 
fed mice in chapter 3. Similar to the lack of phenotype observed in body weight in female 
mice, it is possible that the protection of female mice from metabolic disease through the 
actions of oestrogen (238) means that a difference between ApoE–/– and ApoE–/–Tst–/–cannot 
be tested.   
The most likely explanation for glucose intolerance in male mice is the reduction in insulin 
found over the time course of the glucose tolerance test. This was also observed in 20-week 
‘Surwit’ HFD fed Tst–/– mice. A failure of the pancreas to meet the insulin requirements of 
insulin resistant patients or mice has been suggested as a formative feature of type II diabetes 
(33,35,77). As insulin is solely produced and secreted by the β-cells within the pancreatic 
islets (31) the mechanism by which Tst deletion affects blood insulin concentrations is likely 
to lie in this tissue. A potential mechanism for this reduction could be increased H2S 
signalling with the pancreatic cells.  
Pullen et al. have previously shown that transcription of Tst is supressed within the pancreas 
(235) which rules out a direct action of the enzyme within the β-cells of the pancreas. 
However, high circulating H2S levels, which have been reported in a separate cohort of Tst–/– 
mice (204), could potentially still act upon channels within the pancreatic β-cell to decrease 
insulin release. In vitro evidence from using an insulin expressing cell line has demonstrated 
that exogenously applied H2S led to a decrease in insulin release through a KATP channel 
dependent mechanism (179). H2S has previously been shown to result in persulfide 
modification of KATP channels, leading to an increase in function and hyperpolarisation of 
vascular smooth muscle (181) and insulin expressing cell lines (179). Hyperpolarisation of 
pancreatic β cells would lead to prevention of the action potentials associated with insulin 
release (32). Consistent with this hypothesis L-cysteine, which serves as a substrate for H2S 
generation, inhibited insulin release from isolated pancreatic islets (172). In addition to this 
mechanism, it has also been shown that exogenous H2S can reduce insulin secretion through 
inhibition of L-type Ca2+ channels in pancreatic β-cells (178). Increased H2S signalling 
within pancreatic β-cells may explain the insulin reduction observed in male Tst–/– HFD fed 
and ApoE–/–Tst–/– western diet-fed mice and the worsening of glucose tolerance in both 
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models. Therefore, electrophysiology studies should be used to investigate the functioning of 
pancreatic β-cells with Tst deletion. 
5.4.3 Tst deletion reduces atherosclerotic lesion formation in ApoE–/– mice 
The main aim of this study was to investigate whether Tst deletion was protective against 
atherosclerotic lesion formation. It was found that Tst deletion in male mice reduced both 
final lesion and vessel lumen volumes following 12 weeks of western diet feeding. The 
smaller lesion volume clearly demonstrates the protective effect of Tst deletion against 
atherosclerotic lesion formation in ApoE–/– mice. Both volume and mean area of lesion were 
smaller by approximately 33%. The magnitude of this effect is similar to that found in other 
ApoE–/– double knockout studies (such as ApoE–/– interleukin 18, 11β-HSD1, and PPARα 
double knockouts) investigating protective actions in ApoE–/–mice fed western diet 
(281,285–287).  
In female mice, a trend towards smaller lesion volumes was also observed although this 
failed to reach significance. The most likely explanation for this is a lack of statistical power 
to detect the reduction due to the low biological group size and high variation of the ApoE–/–
group. Power calculations (DSS Research, Statistical Power Calculator, Average, 2-sample) 
showed that the current data have only 42.6% power to detect a difference in lesion volume. 
Using the power calculator along with the standard deviation figures for the data shows that 
increasing the number of animals to 15 for each group would increase the statistical power to 
detect a difference in lesion volume to 80%. 
Male ApoE–/–Tst–/– mice also had smaller lumen volumes than ApoE–/–controls. This finding 
is likely to be influenced by expansive vascular remodelling during atherosclerotic lesion 
development. Expansive remodelling or ‘compensatory enlargement’ has been demonstrated 
to occur in the aorta of ApoE–/–mice (189,288–291). As lesion volume increases, there is a 
compensatory increase in vessel volume either due to unavoidable changes in the pressure 
and flow of vessels or as a compensatory mechanism to attempt to reduce the burden of the 
lesion on the vessel. Therefore, the fact that total vessel volume was reduced in ApoE–/–Tst–/– 
mice may also be explained by the protective phenotype in these mice resulting in smaller 
lesions and less need for vessel expansion. Again, the same trend was observed in female 
mice although the lack of statistical power prevents this from being detected. To examine 
this further it would be useful to measure vessel volume in control fed ApoE–/–and ApoE–/–
Tst–/– to confirm that it is development of atherosclerotic lesions which leads to vessel 
expansion and not a feature of Tst deletion generally. The adaptation of the vessel and 
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expansion during lesion formation also potentially explains why the calculated ‘percentage 
measurements’ (percentage lesion volume, maximal narrowing) are not significant. 
Although OPT analysis has allowed detailed examination of lesion size in 3D it cannot 
accurately define the cause of smaller lesion size in ApoE–/–Tst–/– mice. To further investigate 
the atherosclerotic lesions in ApoE–/–Tst–/– mice 2D histology would allow for staining and 
quantification of lesion components (292). This could be used to assess if there is a specific 
action to reduce one constituent of atherosclerotic lesions or a general reduction in all 
constituents (292). Therefore, 2D histological staining of lesions from ApoE–/–and ApoE–/–
Tst–/– mice to quantify lipid, collagen, immune cell and α smooth muscle actin (αSMA) 
content of lesions will be a vital component of future investigations to further understand the 
mechanism responsible for the reduction in lesion volume demonstrated here.  
5.4.4 Potential mechanisms of reduced lesion volume in ApoE–/– mice with Tst 
deletion 
5.4.4.1 Tst deletion reduces systolic blood pressure 
SBP was measured in this study using a tail cuff method. Data from male mice showed a 
trend towards reduced SBP in mice with Tst deletion. Increased blood pressure has been 
repeatedly linked to increased risk of atherosclerosis  and to development of lesions in both 
humans and mice (293). The cause for this is hypothesised to be linked to increased vascular 
shear stress, increased oxidative stress in the vascular wall and endothelial cell damage 
(128,294); processes which are linked to the initiation of atherosclerosis. Although the trend 
for reduction in blood pressure demonstrated in this chapter appears numerically small at 5 
mmHg, even slight reductions in SBP have been linked to improved cardiovascular health 
(295) and reduced atherosclerotic lesion formation in ApoE–/– mice (293,296,297). Therefore, 
if this trend towards lower SBP is confirmed this finding could provide an explanation for 
reduced lesion development in ApoE–/–Tst–/– mice. 
Although circulating H2S concentrations were not measured in this work a reduction in SBP 
is consistent with the previous finding by Morton et al. that circulating H2S concentrations 
are increased in Tst –/– mice (204). H2S is a known physiological vasodilator and H2S 
administration in vivo has been demonstrated to reduce SBP in wild type and Cse–/– mice 
(253). In Cse–/– mice, which exhibit low H2S concentrations, an increase of approximately 20 
mmHg SBP has been demonstrated in several studies (181,187,253), again suggesting that 
global knockout of enzymes which regulate H2S signalling can alter blood pressure.  
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It should be noted that the reduction in SBP in ApoE–/–Tst–/– mice was only observed in 
males. Female ApoE–/–Tst–/– mice appeared to have identical SBP to ApoE–/–controls. 
Because lesion volume was also reduced in female mice this argues that a reduction in blood 
pressure is not be linked to the protective phenotype. However, as SBP is a known risk factor 
for atherosclerosis it is certainly worth further investigation in males. This should be 
performed using the more accurate arterial cannulation telemetry method to confirm the 
reduction and assess blood pressure in mice under unstressed conditions, and to observe any 
potential circadian alterations in the normal SBP rhythm. Further to this the contribution of 
any reduction in SBP to the reduced lesion volume in ApoE–/–Tst–/– mice could be examined 
by using antihypertensive agents, such as hydralazine, to reduce the SBP of ApoE–/–mice to 
levels of ApoE–/–Tst–/– mice. If the reduction in lesion volume was attenuated in this type of 
investigation it would provide evidence that the reduction in SBP is a causal factor of the 
protective phenotype in ApoE–/–Tst–/– mice. 
5.4.4.2 Tst deletion reduces plasma cholesterol content 
In this study ApoE–/–Tst–/– mice demonstrated a clear reduction in total and VLDL plasma 
cholesterol concentrations. There was also a trend towards reduction in the LDL fraction but 
no change in HDL content. Increased plasma cholesterol content in the VLDL and LDL 
fractions is a well-known risk factor for atherosclerosis (45,272). Human population studies 
have shown that reducing LDL cholesterol, using pharmacological compounds such as 
statins which inhibit cholesterol production, is one of the few therapeutic options for 
reducing rates of cardiovascular disease (142). Lowering plasma cholesterol using statins or 
inhibitors of cholesterol absorption from the gastrointestinal tract (e.g. ezetimibe) has also 
been shown to reduce atherosclerotic lesion size in the ApoE–/–mouse model of 
atherosclerosis (125,298).  
The mechanism by which Tst deletion reduces circulating cholesterol levels is unknown but 
the reduction is consistent with the hypothesised effects of H2S on cholesterol production 
(171). Wang et al. showed that total and LDL cholesterol content were increased in Cse–/– 
mice fed western diet for 12 weeks compared to C57Bl/6 controls (187). Studies in rat 
adipose and liver tissues have also shown that the administration of certain statins, such as 
atorvastatin, leads to an increase in H2S concentrations and inhibition of H2S breakdown 
(299,300). These studies suggest that increases in H2S signalling within these tissues may be 
partly responsible for the effectiveness of statins in normalising blood cholesterol 
concentrations and decreasing atherosclerosis risk. In addition to these studies, more recent 
evidence has demonstrated that atorvastatin can also increase Cse mRNA expression in a 
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macrophage cell line leading to increased H2S production (301). Although H2S 
concentrations were not measured directly in this work Morton et al. have shown that H2S 
concentrations are increased in whole blood samples of Tst–/– mice. 
Cholesterol content was not measured in female mice, so it cannot be concluded whether, as 
in male mice, they exhibit a reduction in total and VLDL cholesterol which could explain the 
reduction in lesion volume. Therefore, examining cholesterol concentrations in female mice 
would be a useful future experiment to provide further evidence of whether the reduction in 
circulating cholesterol is an important mechanism or not. Further to this, the importance of 
cholesterol could be assessed by reducing the total and VLDL cholesterol concentrations of 
ApoE–/–mice to ApoE–/–Tst–/– levels using a pharmacological agent such as ezetimibe to lower 
absorption of cholesterol. Ezetimibe treatment of ApoE–/– mice has previously been 
performed and resulted in reduced lesion development compared to control ApoE–/– mice 
(298). Similar to manipulation of SBP, this type of study should be able to demonstrate 
whether the reduction in cholesterol in ApoE–/–Tst–/– is a causal mechanism for the reduction 
in lesion volume. 
5.4.5 Conclusions 
This study has confirmed the overall hypothesis that Tst deletion is protective in a model of 
atherosclerosis despite worsened metabolic function. Interestingly it has also suggested 
several mechanisms by which Tst deletion may lead to this protection, including: reduced 
SBP, reduced plasma cholesterol and potential improvement of vascular endothelial 
function. A common mechanism which has emerged from both this and previous chapters is 
increased H2S signalling within tissues. This is consistent with the hypothesised role of TST 
in breaking down H2S and therefore should be pursued in mechanistic investigations to 





This project aimed to investigate the metabolic and vascular consequences of Tst gene 
deletion in mice. Previous work had demonstrated that when fed HFD for 6 weeks Tst–/– 
mice developed more severe glucose intolerance than C57BL/6N controls (204). Given the 
high level of Tst expression in the liver (208), it was hypothesised that this organ played a 
key role in mediating the metabolic effects of TST.  Thus, the liver was a logical target for 
investigation regarding metabolic phenotypes. A number of phenotypes associated with 
altered glucose metabolism were identified, including increased activity of the 
gluconeogenic enzyme PEPCK, consistent with the previous work showing impaired glucose 
tolerance (204), and a decrease in insulin concentrations, which remain unexplained. At the 
cellular level, hepatocytes from Tst–/– mice exhibited increased mitochondrial respiration. 
Finally, studies of lipid metabolism showed increased triglyceride secretion from the livers 
of control diet-fed Tst–/– mice, a finding which is consistent with “diabetic-like” liver 
function.  
Investigations into vascular function were stimulated by initial data showing that Tst deletion 
led to increased H2S (or sulfides/sulfide species) detected in whole blood (204). H2S is a 
known vasodilator (181,253) and increased H2S concentrations are linked to protection from 
atherosclerosis in an ApoE–/– model (187). Therefore, in this study, vascular function was 
investigated in aortae from C57BL/6 and Tst–/– mice, either under control diet-fed ‘baseline’ 
conditions or when mice were fed a high fat diet (HFD) to induce vascular dysfunction, as 
has previously been performed by others (302,303). Unfortunately, in this work HFD failed 
to induce overt endothelial dysfunction in this study. However, there were clear indications 
of altered vasodilator function of Tst–/– aorta and a protective phenotype resulting from Tst 
gene deficiency in conditions of HFD feeding.  
Finally, atherogenesis was investigated through the generation of a unique atherosclerosis-
susceptible ApoE–/–Tst–/– double knockout mouse. As hypothesised, Tst deletion on an ApoE–
/– background led to a reduction in atherosclerotic lesion development, despite impaired 
glucose intolerance in the mice. Several potential mechanisms to explain this effect were 
identified, including a reduction of plasma cholesterol and trend for reduced SBP.  
Overall this project has confirmed the central hypothesis that Tst deletion engenders vascular 
protection despite worsening of metabolic function. It has also satisfied the primary aims of 
investigating the phenotypes associated with Tst deletion and has identified several avenues 
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for future investigation which will aim to study in detail the mechanistic changes responsible 
for the phenotypes described. 
6.1 Tst deletion and metabolic dysfunction 
6.1.1 Glucose metabolism 
Glucose metabolism appears to be the key metabolic process affected by Tst deletion. In this 
work it was shown that, consistent with the previous results at 6 weeks (204), Tst–/– mice 
exhibited worsened glucose tolerance when fed HFD for 20 weeks compared to C57BL/6 
control mice (section 3.3.2). Investigations into the molecular basis of increased 
gluconeogenesis (higher glucose production in response to pyruvate challenge) observed in 
Tst–/– mice found that the activity of PEPCK, the key regulatory enzyme of gluconeogenesis 
(175), was increased in Tst–/– mice fed control or HFD for 6 weeks (section 3.3.4). Further, a 
worsening of glucose tolerance was also observed in ApoE–/–Tst–/– mice compared to ApoE–/– 
controls fed 6 weeks of western diet (section 5.3.3). The findings in ApoE–/–Tst–/– mice lend 
support to the idea that the alterations in glucose metabolism in Tst–/– mice represent a true 
biological effect and are not specific to only one model. Glucose intolerance and increased 
gluconeogenesis are two common features of type II diabetes (77). Therefore, these data 
suggest that deletion or inhibition of Tst/TST may be associated with the development of 
diabetes. This is especially interesting as Tst–/– mice in these studies had either no difference 
in gross body weight or under certain conditions (chow for 6 weeks or when fed western 
diet) were significantly lighter. The latter is a new observation that could be related to the 
isogeneity of the background genetic strain achieved in these more recent studies compared 
to the mixed 6N/6J background used in the original body mass studies (204). Therefore, it 
appears that the effect of Tst on glucose metabolism is not related to a worsening of obesity 
and, instead, may help to delineate actions of specific organs, particularly the liver, which 
contribute to diabetes.  
The full causal relationship for the diabetogenic phenotype observed in Tst–/– mice cannot be 
concluded from this work, but the data generated suggest that insulin production or secretion 
may also be involved. Blood insulin concentrations were measured over the time course of 
the glucose tolerance tests performed in 20-week chow or HFD fed C57BL/6 and Tst–/– mice 
(section 3.3.3) and 6-week western diet fed ApoE–/– and ApoE–/–Tst–/– mice (section 5.3.3). In 
both experiments (during which mice with Tst deletion exhibited worsened glucose 
tolerance) blood insulin concentrations were reduced in mice with Tst deletion. As insulin 
concentration is not increasing to levels seen in the control mice despite the worsening of 
glucose tolerance this implies that the insulin concentrations may be insufficient and that the 
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production or release of insulin by the pancreatic β-cells may be defective. It has been 
suggested by previous work that H2S signalling within pancreatic β-cells could inhibit their 
normal depolarisation in response to increasing glucose which results in insulin secretion 
(32,172,178,179). However, to the author’s knowledge this has not been tested in mouse 
models of decreased or increased H2S concentrations. 
Investigations of mitochondrial respiration in hepatocytes from Tst–/– mice were proposed 
based on the hypothesis that the impaired glucose tolerance and inferred insulin resistance 
may be associated with decreased respiration, as observed in the muscle of insulin resistant 
humans (216,217). In fact, it was found that mitochondrial respiration was increased in Tst–/– 
hepatocytes (section 3.3.6). The cause of this increase is unknown; however, it is intriguing 
that both glucose and lipid data suggest that synthetic pathways may be increased in Tst–/– 
hepatocytes. As these pathways are highly energy demanding this may be a compensatory 
increase (85). Further to this, an increase in mitochondrial respiration has been frequently 
associated with increased H2S concentrations in mitochondria (219,221,260) despite the 
known toxic inhibitory effects of H2S at very high concentrations (170). Therefore, the 
increase in mitochondrial respiration seen in Tst–/– hepatocytes could also be the result of 
exposure to increased H2S in vivo.  
Overall this work has augmented the previous work by Morton et al., confirming the effects 
of Tst deletion on glucose metabolism without effects on weight gain (204). However, a key 
difference between this work and that of Morton et al. is the finding of decreased blood 
insulin concentrations in Tst–/– mice. Contrary to this Morton et al. found that insulin 
concentrations measured over the time course of a glucose tolerance test was identical 
between HFD fed C57BL/6N and Tst–/– mice. This difference may again be associated with 
genetic differences in the substrain background of mice. Within this work however, 
decreased insulin release could explain several phenotypes identified including increased 
gluconeogenesis and worsened glucose tolerance and therefore it is an essential topic for 
further investigation. Further to these findings the data are also strikingly consistent with the 
proposed effects of increased H2S on glucose metabolism, insulin release, and mitochondrial 
respiration. Therefore, they also lend weight to the suggestion that increased H2S in Tst–/– 
mice is a major cause of the observed phenotypes. 
6.1.2 Lipid metabolism 
The effect of Tst deletion on lipid metabolism in the liver had not been previously 
investigated but it was hypothesised that triglyceride content would be increased and 
cholesterol content decreased due to increased H2S concentrations in Tst–/– mice. Previous 
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work linked increased H2S signalling to increased VLDL triglyceride secretion (171), 
decreased cholesterol secretion (187), and protection from hepatic steatosis (accumulation of 
lipids within hepatocytes) (251). Although H2S was not measured directly in this work based 
on previous work by Morton et al. Tst–/– mice are presumed to have increased circulating 
H2S. In Tst–/– mice fed with chow diet for 6 weeks, an increase in plasma VLDL triglyceride 
content was observed compared to C57BL/6 mice (section 3.3.7), consistent with the 
hypothesised effect of increased H2S (171,187) in these mice. However, this increase in 
VLDL triglycerides was not found under any other conditions including in 20-week control 
diet-fed mice. The cause of this discrepancy is unknown.  One possible explanation may be 
that triglyceride concentrations are reduced in older mice resulting in a loss of this 
phenotype. Comparison of triglyceride concentrations between 6 and 20-week chow fed 
mice does suggest that plasma triglyceride concentrations were generally reduced in older 
20-week chow fed mice. A reduction in plasma triglyceride has also previously been shown 
to occur in a study of the metabolic effects of aging in mice (225). 
Plasma cholesterol content was unchanged in Tst–/– mice fed either chow or HFD (section 
3.3.7). However, in ApoE–/–Tst–/– mice fed western diet total and VLDL cholesterol 
concentrations were significantly lower than in ApoE–/–controls (section 5.3.6). The lack of 
effect in mice without ApoE deletion may be explained by the differences in plasma lipid 
profiles between ApoE–/– and C57BL/6 mice. While C57BL/6 mice carry cholesterol almost 
exclusively in the HDL lipoprotein fraction the deletion of ApoE disturbs normal 
homeostasis and instead shifts cholesterol predominantly into the VLDL and LDL fractions 
(125). This difference may mean that Tst deletion exerts a greater effect on cholesterol 
content in ApoE–/– mice as VLDL, and to an extent LDL, content and secretion is determined 
by liver-mediated processes where Tst is highly expressed (48,117,208). It is also worth 
noting that the initial suggestion that H2S could reduce circulating cholesterol content was 
implied from the finding that Cse–/– mice, which have lower H2S concentrations, exhibited 
increased circulating cholesterol (187). However, this was only found in mice fed an 
‘atherogenic’ (i.e. high cholesterol) diet which also raised VLDL and LDL cholesterol 
concentrations in control mice. Therefore, it may be that H2S can influence circulating 
cholesterol concentrations (but only in conditions where VLDL and LDL cholesterol content 
is increased initially. This would explain the lack of effect of Tst deletion in ApoE+/+ models.  
No effect of Tst gene deletion was found on hepatic accumulation of triglyceride (steatosis) 
when mice were fed control or HFD (section 3.3.8). This finding is seemingly at odds with 
the notion that Tst–/– mice have elevated circulating H2S concentrations as H2S has been 
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suggested to inhibit hepatic steatosis and maintain healthy lipid metabolism by the liver 
(171,186,251). However, it should be noted that the evidence for protection from steatosis of 
the liver is again proposed from results in Cse–/– and Cbs–/– mice (models of low H2S 
concentrations where triglyceride accumulation in the liver was found to be enhanced 
(171,186,254)) and is, therefore, indirect. There is no direct evidence that increased H2S can 
prevent hepatic steatosis in mice fed HFD. Cse–/– and Cbs–/– mice exhibit increased levels of 
homocysteine due to inhibition of the trans-sulfuration pathway (171,254). Homocysteine is 
linked to the development of hepatic steatosis (188) and, although they challenge the notion 
that increased homocysteine can cause hepatic steatosis alone, the authors of this paper also 
do not provide evidence that it is not the cause of steatosis in their mice. Therefore, the lack 
of effect of Tst deletion on hepatic steatosis does not necessarily provide a strong argument 
against increased H2S levels in Tst–/– mice.  
Overall investigations into lipid metabolism have shown that the effects of Tst deletion are 
less dramatic when compared to the effects of this deletion on glucose metabolism and may 
depend on the nature of the model being investigated. However, the fact that the changes in 
lipid were exclusively observed in the VLDL lipoprotein fraction is consistent with TST 
having key metabolic roles in the liver. Both findings may also be linked to increased H2S in 
the liver based on the available information from the literature. This would lend weight to 
the hypothesis that altered H2S signalling is a primary mechanism for the effects of Tst 
deletion.  
6.2 Tst deletion and vascular function 
H2S is a known vasodilator via its action as an endothelium-derived hyperpolarising factor 
(EDHF) (181,253,258) and is also hypothesised to interact with, and enhance, NO signalling 
(167,304). As increased whole blood H2S levels have previously been found in mice with Tst 
deletion (204), it was hypothesised that vasodilation would be increased in mice with Tst 
deletion. Interestingly no changes were noted in vascular relaxation or contraction of aortae 
from Tst–/– mice fed control or HFD (section 4.3.3&4). The lack of effect of Tst deletion on 
normal vascular function is surprising and was unexpected given the inhibition of 
vasorelaxation previously observed in Cse–/– mice (253). As this study focussed only on 
aortic function it is possible that further investigations of vascular function in other vessels 
which have a greater EDHF component (such as mesenteric arteries) (258,305) may be able 
to reveal an influence of Tst deletion on vascular function. 
Another hypothesised action of increased H2S signalling at vascular endothelial cells is the 
protection of vessels in conditions of vascular stress, such as hyperglycaemia (260) from 
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endothelial dysfunction (259). This work aimed to investigate this process in Tst–/– mice by 
inducing endothelial dysfunction through HFD feeding in C57BL/6 and Tst–/– mice (section 
4.3.3). Unfortunately, HFD feeding failed to cause overt endothelial dysfunction (defined as 
a reduction in ACh-mediated relaxation (114,306)) so this could not be tested. However, 
HFD feeding in C57BL/6 for 20 weeks did reduce the ability of L-NAME and indomethacin 
to increase maximal contraction in response to PhE or 5-HT (section 4.3.4). L-NAME and 
indomethacin inhibit endothelial cell production of NO and prostaglandins, respectively, and, 
therefore, the impact of HFD on the effectiveness of these compounds reflects a reduction in 
endothelial production of NO and/or prostaglandins. Interestingly Tst–/– mice did not exhibit 
the same reduction when fed HFD and maintained maximal contractions similar to those 
seen in control diet-fed mice, suggesting a protective role for Tst. 
Within this work it has not been possible to test the effect of Tst deletion in conditions of 
overt endothelial dysfunction because HFD did not affect endothelial mediated relaxation in 
either genotype. However, these data do suggest that deletion of Tst confers some protection 
to the endothelium which can be observed indirectly when compounds inhibiting the NO and 
prostaglandin systems are used. Protection of the endothelium would be consistent with 
previous evidence that H2S can protect endothelial cells from dysfunction under conditions 
of vascular stress. Based on the findings in this work it would be interesting to investigate 
whether in models of decreased H2S (such as Cse–/– mice) the ability of L-NAME and 
indomethacin to inhibit relaxation or augment contraction is increased or reduced, 
respectively.  
6.3 Tst deletion and atherosclerosis 
Investigations into the effect of Tst deletion on atherosclerosis have clearly shown that it 
reduces atherosclerotic lesion size in ApoE–/– mice (section 5.3.4). This confirms the original 
hypothesis that, despite worsened metabolic function (which was observed in ApoE–/–Tst–/– in 
the form of worsened glucose tolerance), Tst deletion protects against atherosclerosis. Based 
on the data presented in this work however, the exact mechanism behind this protection 
cannot be defined. A trend towards reduced SBP (section 5.3.5) and a clear reduction in total 
and VLDL plasma cholesterol concentrations (section 5.3.6) were identified in ApoE–/– Tst–/– 
mice and, if the reduction in SBP is confirmed, are two possible mechanisms responsible for 
the protection. Both increased plasma cholesterol and increased SBP are recognised risk 
factors for atherosclerosis (307–310) and, therefore, lower values in ApoE–/– Tst–/– mice 
could explain the decreased size of lesions. The reduction in plasma cholesterol levels is 
more likely to be the result of changes within metabolic tissues, such as the liver, and, 
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therefore, the protection afforded by Tst deletion may not be exclusively linked to vascular 
actions. Further investigations into lesion composition, for example using 2D histology, may 
reveal information such as the lipid content. This data could help to refine the hypothesis as 
to which specific mechanism(s) underlie the phenotype in ApoE–/–Tst–/– mice that ultimately 
account for the reduced lesion size in ApoE–/– Tst–/– mice.  
Strikingly, in this study all of the findings in ApoE–/–Tst–/– mice (including worsened glucose 
tolerance (171,173), reduced blood insulin concentrations (172,178,179), a trend for reduced 
SBP (180,253,311), reduced plasma cholesterol (171,187), improved endothelial function (in 
control diet fed mice (187,259,260)) and reduced atherosclerotic lesion development (187)), 
are consistent with the published literature on the effects of increased H2S concentrations. 
Therefore, this work lends substantial support to the hypothesis that increased H2S 
concentrations as a result of Tst deletion are responsible for the phenotypes observed in Tst–/– 
and ApoE–/–Tst–/– mice and that H2S availability can plays a role in atherosclerosis disease 
progression.  
6.4 Future investigations 
6.4.1 Metabolic dysfunction in Tst–/– mice 
The key findings from the work presented here have confirmed that deletion of Tst results in 
worsened glucose tolerance (section 3.3.2 & section 5.3.3) when mice are fed HFD. 
However, limited information is available regarding the mechanism behind this. Therefore, 
this should be the key concern for future work. From the data here, potential mechanisms can 
be identified, including biochemical alterations in the gluconeogenic pathway and reduced 
blood insulin concentrations. 
6.4.1.1 What is the cause of increased gluconeogenesis in Tst–/– mice and what is its 
contribution to worsened glucose tolerance? 
Increased PEPCK activity was observed in Tst–/– mice (section 3.3.4). This finding supports 
the previous finding of increased gluconeogenesis measured using a pyruvate tolerance test 
found in control diet fed Tst–/– mice (207). Increased gluconeogenesis has also been observed 
in diabetic patients (31,175). Therefore, inappropriately increased PEPCK activity in Tst–/– 
mice may contribute to their increased gluconeogenesis and lead to the worsened glucose 
tolerance seen in Tst–/– mice fed HFD (204). PEPCK protein expression was previously 
investigated and found to be unchanged in Tst–/– mice fed HFD for 6 weeks (207) and, 
therefore, this was not pursued here. However, it would be important to measure PEPCK 
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protein expression in livers from control diet fed mice to determine whether increased 
PEPCK expression could account for the increased PEPCK activity in these mice.  
Intriguingly, however, increased gluconeogenesis has been linked to increased H2S 
signalling (173) in the liver and specifically to persulfidation of pyruvate carboxylase (PC), 
leading to increased activity of this enzyme (166). PC catalyses the reaction in 
gluconeogenesis that precedes the reaction catalysed by PEPCK; the conversion of pyruvate 
to oxaloacetate (174,312). Increased PC activity may have resulted in our finding of 
increased PEPCK activity through contribution to oxaloacetate production which was the 
biochemical method for assaying PEPCK activity. Recent papers have also assigned PC a 
more substantial role in gluconeogenesis than previously thought (174) and, therefore, 
increased activity could contribute to the increased gluconeogenesis observed in Tst–/– mice. 
Therefore, PC represents an interesting target for further investigation to find the cause of 
increased gluconeogenesis in Tst–/– mice and assess its contribution to worsened glucose 
tolerance.  
Initial investigations should focus on assessing PC activity in control diet fed Tst–/– mice. If 
this were found to be increased, further work to accurately measure H2S levels in the liver of 
these mice would provide support for the hypothesis that H2S was responsible for this 
increase. Molecular biology techniques could then confirm the presence of increased PC 
persulfidation of the enzyme using a ‘biotin-switch’ assay to pull down, and then measure, 
the percentage of persulfidated protein. Finally, site-specific mutation of the enzyme to 
remove this modification site and expression of the modified PC form in Tst–/– mice would 
provide evidence of whether increased PC activity is linked to increased gluconeogenesis in 
Tst–/–. This would allow assessment of whether this increase is responsible for worsened 
glucose tolerance when mice are fed HFD. 
6.4.1.2 What is the cause of decreased blood insulin concentrations in Tst–/– mice and what is 
its contribution to worsened glucose tolerance? 
Decreased plasma insulin concentrations were observed in 20-week control or HFD fed Tst–/– 
mice (section 3.3.2) and in male ApoE–/–Tst–/– mice fed western diet for 6 weeks (section 
5.3.3). This reduction was not found in the original work of Morton et al. (204) and this may 
be explained by differences in the genetic background of the mice used in the current and in 
the original studies. Within this current work, however, the reduction is clear and the 
insufficient increase in insulin concentrations in response to high fat diets could explain the 
worsened glucose tolerance in mice with Tst deletion. A decrease in the release of insulin 
from pancreatic β-cells could also be linked to increased H2S signalling within the pancreatic 
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islets (172,178). Given the previous evidence of increased H2S in Tst–/– mice, investigation 
into insulin secretion is clearly warranted in Tst–/– mice.   
Pancreatic islet number should be assessed in mice fed control and HFD initially to confirm 
that Tst deletion does not lead to a simple reduction in the number of islets within the 
pancreas. Islet health could then also be investigated in vitro to assess whether islets from 
Tst–/– mice are at greater risk of death or have impaired function. This could potentially be 
achieved using Seahorse extracellular flux analysis to detect any metabolic abnormalities in 
glycolytic function between genotypes. Insulin concentrations within islets and released into 
the in vitro cell media, both at rest and following glucose stimulation, could then be 
measured to address the question of whether synthesis or release of insulin is impaired in 
Tst–/– mice.  
Assuming release of insulin was found to be impaired, the next steps would require patch 
clamp investigation of pancreatic β-cell membrane potential to confirm a reduction in action 
potentials. KATP channel blockers (sulfonylureas e.g. glibencamide (178)) could then 
determine the involvement of these channels in suppression of glucose-stimulated action 
potentials. To link increased KATP activity with increased H2S concentrations in Tst–/– mice 
accurate measurement of H2S in the pancreas would be essential; followed potentially by 
patch clamp experiments in the presence of H2S inhibitor propylargylglycine (PAG (313)) or 
a suitable absorber compound such as bismuth subnitrate (314). Finally, intervention (e.g. 
using glibencamide) treatment in Tst–/– mice could confirm whether insulin concentrations 
returned to normal and whether this in turn returned glucose intolerance on HFD to levels 
similar to C57BL/6 mice. Additionally, exogenous treatment of control mice with H2S donor 
compounds could be performed to compare the diabetic phenotype with that of Tst–/– mice 
potentially providing evidence that increased H2S signalling is behind the effects of Tst 
deletion. 
6.4.2 Vascular function and protection in Tst–/– mice 
The central findings in this work showed that deletion of Tst engendered some protection of 
endothelial NO production in conditions of vascular stress (section 4.3.4). The mechanism of 
this protection is currently unclear and, therefore, would be worth further investigation. In 
addition, the work suffered from an inability to test the effect of Tst deletion on severe 
endothelial dysfunction and, so it could not be concluded whether Tst–/– mice are protected 
from endothelial dysfunction. Therefore, a study which induced clear endothelial 
dysfunction and robust controls would be useful. This may be achieved through the use of 
other high fat diets or feeding regimes as several studies have observed aortic endothelial 
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dysfunction induced by high fat diet feeding (302,303,315). In addition, 
hyperhomocystinaemia has been consistently linked to endothelial dysfunction (316). 
Therefore, inducing hyperhomocystinaemia in mice by feeding a methionine rich and folate 
deficient diet should lead to the development of endothelial dysfunction (317). This would 
allow the effects of Tst deletion to be assessed in a clear model of endothelial dysfunction.  
6.4.2.1 How does deletion of Tst protect the endothelium’s ability to modulate constriction in 
conditions of vascular stress? 
All the studies in this work were performed in the aorta. As it is known that NO is the main 
vasodilator in the mouse aorta (305) it is, therefore, likely that the findings of increased 
maximal constriction in response to L-NAME and indomethacin are the result of increased 
NO production. Activating phosphorylation of eNOS protein has previously been linked with 
increased H2S signalling (167,304) and so this regulatory mechanism should be of particular 
interest. A small study has shown that phosphorylation of eNOS at the activating S1177 site 
is increased in control diet-fed Tst–/– mice (Emerson et al. Unpublished observations). 
Therefore, an obvious next step would be to repeat this measurement in 20-week HFD fed 
C57BL/6 and Tst–/– mice to confirm whether phosphorylation was also increased following 
HFD feeding. It would also be key to compare the effect of HFD on C57BL/6 mice to Tst–/– 
mice. If HFD induced a loss of eNOS phosphorylation in C57BL/6 mice which was not seen 
in Tst–/– mice, this may explain the protection observed. 
To link this finding with increased H2S it would also be important to perform accurate 
measurements of circulating and, if possible, aortic H2S concentrations in control and HFD 
fed C57BL/6 mice. A reduction in H2S with HFD in C57BL/6 could be implicated in the 
worsened vascular function and (as above) if this was restored in Tst–/– mice it would provide 
a clear mechanism for the protection of vascular function in these mice. Finally, an 
experiment in which C57BL/6 mice fed with HFD were supplemented with exogenous H2S, 
using NaHS given intravenously as has previously been performed (187), should provide 
evidence of whether the increase in H2S signalling can lead to protection of vascular 
function. 
6.4.2.2 Can Tst deletion protect ACh-mediated relaxation in a model of endothelial cell 
dysfunction? 
The initial hypothesis of the vascular investigations in this work was that Tst deletion would 
protect mice from endothelial dysfunction; classically defined as a reduced response to ACh 
due to reduced NO production. In this work, some evidence was found of improved NO 
production and, hence, endothelial function (section 4.3.4). However, it was not possible to 
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evaluate the effect of Tst deletion in a model of overt endothelial dysfunction as HFD failed 
to reduce ACh-mediated relaxation (section 4.3.3). To answer this question further studies 
are needed in which endothelial dysfunction is clearly induced by the treatment and not 
observed in control mice. The effect of Tst on this development could then be assessed. As 
discussed above a different model of diet induced dysfunction (302,303,315) or the use of 
hyperhomocystinaemia inducing diets (316,317) may be useful to induce clear endothelial 
dysfunction for testing. 
6.4.3 Atherosclerosis in Tst–/– mice 
This work has clearly shown that deletion of Tst in ApoE–/– mice reduces the size of 
atherosclerotic lesions induced by 12 weeks of western diet feeding (section 5.3.4). The 
initial hypothesis proposed that this would be due to vascular specific actions of Tst deletion 
since Tst deletion was also expected to induce metabolic dysfunction. Whilst the latter was 
true for glucose homeostasis, which was worsened in ApoE–/–Tst–/– mice, plasma cholesterol 
concentrations were actually reduced in these animals (section 5.3.6). Therefore, the question 
remains as to what mechanism is important for protection in ApoE–/–Tst–/– mice. To 
investigate the reduction in lesion formation initial studies should focus on further assessing 
the changes in the lesions from ApoE–/–Tst–/– mice. Follow on experiments using either 
pharmacological manipulation of risk factors or tissue-specific Tst knockouts could then 
assess the contribution of individual phenotypes to the overall protection. 
6.4.3.1 Is atherosclerotic lesion composition altered by Tst deletion? 
While the investigations in this work have been able to conclude that lesion volume is 
reduced in ApoE–/–Tst–/– mice they do not give any insight into the cause of this reduction. 
Traditional 2D histology of lesion area should allow for staining of the major lesion 
components including lipid, immune cells, collagen and αSMA to provide data on whether 
there is a specific reduction in one or more components within ApoE–/–Tst–/– lesions (292). 
These data could also provide information on the mechanisms leading to lesion reduction 
within ApoE–/–Tst–/– mice. For example, if lipid was the main component that was reduced in 
lesions from ApoE–/–Tst–/– mice (compared to ApoE–/–  controls) it would strongly implicate 
alterations in lipid transport/accumulation in lesions as the mechanism for reduced lesion 
size in ApoE–/–Tst–/– mice. 
2D histology should also allow for investigation of endothelial adhesion molecule expression 
in ApoE–/– and ApoE–/–Tst–/– mice. This should be investigated as an increase in ICAM1 
expression was previously observed in Cse–/– mice and was defined as the cause of increased 
atherosclerotic lesion volume in these mice (187). Further to this, exogenous H2S treatment 
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appeared to reduce ICAM1 expression. The decrease in ICAM1 expression was indirectly 
attributed to a reduction in endothelial ROS mediated by increased H2S signalling leading to 
an improvement of endothelial cell function. 
6.4.3.2 What is the cause of reduced atherosclerotic lesion volume in ApoE–/–Tst–/– mice? 
This work has identified several potential mechanisms which could explain the reduced 
lesion volume observed in ApoE–/–Tst–/– mice. These include a reduction in plasma 
cholesterol concentrations (section 5.3.6) and a trend for reduced SBP (section 5.3.5). 
Further investigation of the SBP phenotype should be performed using the more accurate 
intra-arterial catheter telemetry monitors to record blood pressure under unstressed 
conditions and to confirm or reject the trend seen with tail cuff measurements. Further 
investigation of the effect of Tst deletion on endothelial cell function should also be 
performed using myography or in vivo measurements such as invasive blood pressure 
recording in response to vasodilator and constrictor compounds. 2D histology, as previously 
discussed, should also be used as evidence of decreased ICAM1, or similar adhesion 
molecules, expression would certainly increase the interest in this phenotype. 
Two approaches could be taken to identify the mechanism(s) responsible for reduced lesion 
volume in ApoE–/–Tst–/– mice. The first is to normalise plasma cholesterol or SBP of ApoE–/– 
mice to those of ApoE–/–Tst–/– using pharmacological treatment. Previous work has used this 
approach and demonstrated that ezetimibe treatment can reduce plasma cholesterol levels 
and hydralazine can reduce SBP in mice (187). By giving the relevant compound to 
normalise cholesterol or SBP during western diet feeding and lesion development to the 
levels seen in ApoE–/–Tst–/– mice the effect of that risk factor on lesion size could be assessed. 
These experiments would help to determine whether the decrease in cholesterol or trend 
towards decreased SBP contribute to the smaller lesion size observed in ApoE–/–Tst–/– mice.  
A second approach would be the use of the newly developed Tst loxP mouse which would 
enable tissue specific knockout of Tst. By breeding the Tst loxP mouse first onto an ApoE–/– 
background and then with tissue-specific CRE expressing lines, deletion of Tst could be 
limited to one tissue of interest to investigate its effects. Deletion of Tst in the liver (albumin-
cre expression) or the endothelium (V cadherin–cre expression) or smooth muscle (SM22-
CRE expression) of the blood vessels would allow testing of the specific roles of Tst in these 
tissues. This primarily should answer the question of whether Tst deletion in the vessel is 
exclusively responsible for reduced atherosclerotic lesions in mice with global Tst deletion. 
In addition, tissue-specific knockouts could provide evidence of which tissues are linked to 
which phenotypes. For example, Tst deletion in the liver would test the role of hepatic TST 
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in regulating plasma cholesterol levels. Deletion of Tst in the smooth muscle or endothelial 
cells of the vessels may test which cellular location is responsible for the observed trend 
towards reduction in SBP (if this is confirmed using the techniques described above) and 
whether deletion of Tst in the endothelial cells results in improved vascular function. The 
effect of Tst on immune cell function has also not been considered in this work (2D 
histology may provide evidence of involvement in the future) but previous studies have 
shown that changes in immune cells can affect lesion development (287). Therefore, tissue 
specific knockout of Tst in immune cells could also be used to investigate this if warranted 
by future data. 
In conjunction with all of the experiments detailed above it would be valuable to include 
groups of control mice treated with exogenous H2S donor compounds such as NaHS or 
AP123. While previous data have already established that exogenous NaHS administration 
can decrease atherosclerotic lesion formation this has not been performed in these models 
using OPT for lesion and artery volume calculation. Comparison of H2S treated control mice 
with mice lacking Tst would test whether similar effects are observed. In combination with 
direct measurements of H2S concentration the addition of this group could provide strong 
evidence that the effects of Tst deletion are mediated through increased H2S concentrations 
and hence signalling. 
6.5 Conclusions 
Overall this work has confirmed its original hypothesis by clearly demonstrating that Tst is 
protective against the formation of atherosclerosis despite induction of metabolic 
dysfunction; specifically, glucose intolerance. Future work should focus on refining these 
findings using tissue-specific Tst knockout models to focus on the exact mechanisms behind 
these phenotypes. Based on the consistent alignment of findings in this work with the 
published effects of increased H2S signalling, a central hypothesis for this future work 
should be that increased H2S signalling is responsible for the phenotypes described. In a 
wider context, these studies provide further evidence for the involvement of H2S in 
cardiometabolic diseases including diabetes and atherosclerosis. Further to this the work has 
shown that inhibition of TST can be used for investigation of the effects of raised 
endogenous H2S in disease conditions. Future work could aim to develop compounds for 
TST inhibition and test them as novel compounds for the treatment of atherosclerosis (by 
aiming to inhibit development or progression of lesions), a major cause of cardiovascular 
disease and death worldwide. However, this is with the caveat that glucose homeostasis may 
be detrimentally affected, and so future work will need to evaluate the benefit and risk of any 
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inhibition. The ability to target TST inhibition to specific organs, e.g. endothelial cells and 
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Chromosome Primer name Primer sequence 
1 1-141133664 L1 AAGACAGCTACAGTTCTTATCGaTGT 
1 1-59847112 L CGTCTGGCTCATTCTGTGAC 
1 1-59847271 R TTCTTCATGCTGGATCTTTCAA 
2 2-70619835 L CCCTTTAATCCCAGCACTCA 
2 2-70619835 R ATAGGCACAGCTGCGAACTT 
3 3-95,734,715 L CAACCTGACTTCTGCGAACA 
3 3-95,734,962 R GCTGTGGAAGGGACAGAGAC 
3 3-18484710 L GAAAAGCAGCATGGAAATGG 
3 3-18484710 R CTCTGCAGGCAAGCTCTCTT 
4 4-101954274 L GGGGAAGCTCCTGGAAATAG 
4 4-101954274 R TCAGTGCCTAAGCCTGACAA 
4 4-116051393 L AACCAAGGACTTGCCTCAGA 
4 4-116051393 R GGCCAGGAAACCACATCTAA 
4 4-137777588 L1 CATCCTAAGGCATgCCCA 
4 4-140354038 L GCTGGAGGTGTGGAGGATAA 
4 4-140354038 R CTCCATGAGCTGAGGCTAGG 
5 5-90356490 L GCCAGAGAACCTCAGTCCAC 
5 5-90356490 R AATCCTCATGCACCATGACA 
5 5-96758095 L CGAGAATGGCATGAGTCCTT 
5 5-96758323 R GCACATTGGGATCCTTCTTG 
6 6-86478779 L CTCAGTTGCTTGTGGATGGA 
6 6-86478779 R GATCTGATGCCCTCTTCTGG 
7 7-120135075 L TCGGGATGACGATTTTCAAT 
7 7-120135261 R AAGGTCTTGAGCAGGAACGA 
7 7-3222538 L TATCCTGGTCGGCTTCATTC 
7 7-3222538 R TGCAAGAGCAGAAGCATACG 
7 7-63386662 L GATGGTGGCTTCTGGACTGT 
7 7-63386662 R TTGTGAAGCCAGAACCAAAG 
9 9-25674550 L AGGAGGAAGTCAAGGGGAAA 
9 9-25674550 R GCTTAGGTGCTCAGGTCTGG 
9 9-65127938 L1 GCCGGCGTGGAAGCATGcGC 
9 9-65127938 R1 CGTGGGGGCCCTGTGGCAATCA 
10 10-66700922 L1 CCATAAGCATCTGATGtCGAC 
11 11-104906390 L CCAGCTGATCGTGAGTTTACC 
11 11-104906390 R ACGTGAGCTTTCTTGGCTTC 
13 13-73465884 L1 CCGGCGGAAGGTCAGtACCG 
13 13-73465884 R1 GCCGCAGCTCCGCATCCTAT 
15 15-31106173 L GTGAGTGGGAGGTGTCCAGT 
15 15-31106173 R TAAAAGGCAACTCCCTGCAC 
15 15-11266138 L1 AACTGAAGATCAAGACCAGaTCCT 
16 16-35291630 L1 CTGCTGGCCTGCTCCGgGTT 
16 16-35291630 R1 CCACACGTGCCACCCTGGAT 
16 16-35291477 L TGACATGGCCCTCTCTCTCT 
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16 16-35291709 R CCGCTACAGGGAGCAAATAA 
17 17-60286367 L TGCTCAAATGAACACCCTGT 
17 17-60286367 R TCCTTCCTGGAACAGTTTGTG 
17 17-47537359 L1 GACTTGCCCTCCATGATcTT 
17 17-47400378 CTCAGCTCTTCCACGGACTT 
17 17-47400608 CTCCGGCATCTCTAGTTTGG 
X X-15697909 L GCAGAGTCTCCATTCACAAGC 
X X-15697909 R GAAACAGGGCCTCATTGTGT 
X X-134692902 L ACTGTAGACCAGGCCAATGC 
X X-134693152 R CCCAAGACCCTTCATCACTG 
 
Appendix table 1. Primer sequences for C57BL/6 N and J substrain genotyping. A 
complete list of the primers used for genotyping mice during backcrossing to the 6J genetic 
background. This genotyping was performed by Prof. Simon Horvat. 
